14. Literaturverzeichnis – Colorectal Cancer

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:, http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html

2. Kirkegaard, H., Johnsen, N. F., Christensen, J., Frederiksen, K., Overvad, K., Tjonneland, A., Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study, BMJ, 2010. 341: p. c5504., http://www.ncbi.nlm.nih.gov/pubmed/20978063

3. Halle, M., Schoenberg, M. H., Physical activity in the prevention and treatment of colorectal carcinoma, Dtsch Arztebl Int, 2009. 106(44): p. 722-7., http://www.ncbi.nlm.nih.gov/pubmed/19997551

4. Wolin, K. Y., Yan, Y., Colditz, G. A., Lee, I. M., Physical activity and colon cancer prevention: a meta-analysis, Br J Cancer, 2009. 100(4): p. 611-6., http://www.ncbi.nlm.nih.gov/pubmed/19209175

5. Friedenreich, C. M., Orenstein, M. R., Physical activity and cancer prevention: etiologic evidence and biological mechanisms, J Nutr, 2002. 132(11 Suppl): p. 3456S-3464S., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12421870, http://jn.nutrition.org/content/132/11/3456S.full.pdf

6. Wolin, K. Y., Yan, Y., Colditz, G. A., Physical activity and risk of colon adenoma: a meta-analysis, Br J Cancer, 2011. 104(5): p. 882-5., http://www.ncbi.nlm.nih.gov/pubmed/21304525

7. Wolin, K. Y., Lee, I. M., Colditz, G. A., Glynn, R. J., Fuchs, C., Giovannucci, E., Leisure-time physical activity patterns and risk of colon cancer in women, Int J Cancer, 2007. 121(12): p. 2776-81., http://www.ncbi.nlm.nih.gov/pubmed/17722094

8. Friedenreich, C., Norat, T., Steindorf, K., Boutron-Ruault, M. C., Pischon, T., Mazuir, M., et.al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition, Cancer Epidemiol Biomarkers Prev, 2006. 15(12): p. 2398-407., http://www.ncbi.nlm.nih.gov/pubmed/17164362

9. Lubin, F., Rozen, P., Arieli, B., Farbstein, M., Knaani, Y., Bat, L., et.al. Nutritional and lifestyle habits and water-fiber interaction in colorectal adenoma etiology, Cancer Epidemiol Biomarkers Prev, 1997. 6(2): p. 79-85., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9037557, http://cebp.aacrjournals.org/content/6/2/79.full.pdf

10. Giacosa, A., Franceschi, S., La Vecchia, C., Favero, A., Andreatta, R., Energy intake, overweight, physical exercise and colorectal cancer risk, Eur J Cancer Prev, 1999. 8 Suppl 1: p. S53-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10772419

11. Terry, M. B., Neugut, A. I., Bostick, R. M., Sandler, R. S., Haile, R. W., Jacobson, J. S., et.al. Risk factors for advanced colorectal adenomas: a pooled analysis, Cancer Epidemiol Biomarkers Prev, 2002. 11(7): p. 622-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12101109, http://cebp.aacrjournals.org/content/11/7/622.full.pdf

12. Lee, I. M., Physical activity and cancer prevention--data from epidemiologic studies, Med Sci Sports Exerc, 2003. 35(11): p. 1823-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14600545

13. Wei, E. K., Giovannucci, E., Wu, K., Rosner, B., Fuchs, C. S., Willett, W. C., et.al. Comparison of risk factors for colon and rectal cancer, Int J Cancer, 2004. 108(3): p. 433-42., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14648711, http://onlinelibrary.wiley.com/store/10.1002/ijc.11540/asset/11540_ftp.pdf?v=1&t=ik57p9sa&s=d9839afe4670a7de533f74cc0bbbd4e22fed258e

14. Martinez, M. E., Heddens, D., Earnest, D. L., Bogert, C. L., Roe, D., Einspahr, J., et.al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa, J Natl Cancer Inst, 1999. 91(11): p. 950-3., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10359547, http://jnci.oxfordjournals.org/content/91/11/950.full.pdf

15. Giovannucci, E., Modifiable risk factors for colon cancer, Gastroenterol Clin North Am, 2002. 31(4): p. 925-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12489270

16. Giovannucci, E., Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence, J Womens Health (Larchmt), 2003. 12(2): p. 173-82., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12737716, http://online.liebertpub.com/doi/abs/10.1089/154099903321576574

17. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371(9612): p. 569-78., http://www.ncbi.nlm.nih.gov/pubmed/18280327

18. Pischon, T., Lahmann, P. H., Boeing, H., Friedenreich, C., Norat, T., Tjonneland, A., et.al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC), J Natl Cancer Inst, 2006. 98(13): p. 920-31., http://www.ncbi.nlm.nih.gov/pubmed/16818856

19. Ning, Y., Wang, L., Giovannucci, E. L., A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies, Obes Rev, 2010. 11(1): p. 19-30., http://www.ncbi.nlm.nih.gov/pubmed/19538439

20. Terry, M. B., Neugut, A. I., Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox, Am J Epidemiol, 1998. 147(10): p. 903-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9596467, http://aje.oxfordjournals.org/content/147/10/903.full.pdf

21. Almendingen, K., Hofstad, B., Trygg, K., Hoff, G., Hussain, A., Vatn, M. H., Smoking and colorectal adenomas: a case-control study, Eur J Cancer Prev, 2000. 9(3): p. 193-203., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10954259

22. Chao, A., Thun, M. J., Jacobs, E. J., Henley, S. J., Rodriguez, C., Calle, E. E., Cigarette smoking and colorectal cancer mortality in the cancer prevention study II, J Natl Cancer Inst, 2000. 92(23): p. 1888-96., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11106680, http://jnci.oxfordjournals.org/content/92/23/1888.full.pdf

23. Giovannucci, E., An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer, Cancer Epidemiol Biomarkers Prev, 2001. 10(7): p. 725-31., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11440957, http://cebp.aacrjournals.org/content/10/7/725.full.pdf

24. Reid, M. E., Marshall, J. R., Roe, D., Lebowitz, M., Alberts, D., Battacharyya, A. K., et.al. Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas, Cancer Epidemiol Biomarkers Prev, 2003. 12(10): p. 1006-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14578135, http://cebp.aacrjournals.org/content/12/10/1006.full.pdf

25. Botteri, E., Iodice, S., Raimondi, S., Maisonneuve, P., Lowenfels, A. B., Cigarette smoking and adenomatous polyps: a meta-analysis, Gastroenterology, 2008. 134(2): p. 388-95., http://www.ncbi.nlm.nih.gov/pubmed/18242207

26. Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A. B., Maisonneuve, P., Smoking and colorectal cancer: a meta-analysis, JAMA, 2008. 300(23): p. 2765-78., http://www.ncbi.nlm.nih.gov/pubmed/19088354

27. Miller, P. E., Lesko, S. M., Muscat, J. E., Lazarus, P., Hartman, T. J., Dietary patterns and colorectal adenoma and cancer risk: a review of the epidemiological evidence, Nutr Cancer, 2010. 62(4): p. 413-24., http://www.ncbi.nlm.nih.gov/pubmed/20432162

28. Cottet, V., Bonithon-Kopp, C., Kronborg, O., Santos, L., Andreatta, R., Boutron-Ruault, M. C., et.al. Dietary patterns and the risk of colorectal adenoma recurrence in a European intervention trial, Eur J Cancer Prev, 2005. 14(1): p. 21-9., http://www.ncbi.nlm.nih.gov/pubmed/15677892

29. Mai, V., Kant, A. K., Flood, A., Lacey, J. V., Jr., Schairer, C., Schatzkin, A., Diet quality and subsequent cancer incidence and mortality in a prospective cohort of women, Int J Epidemiol, 2005. 34(1): p. 54-60., http://www.ncbi.nlm.nih.gov/pubmed/15649959

30. Sansbury, L. B., Wanke, K., Albert, P. S., Kahle, L., Schatzkin, A., Lanza, E., The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence, Am J Epidemiol, 2009. 170(5): p. 576-84., http://www.ncbi.nlm.nih.gov/pubmed/19643809

31. Wakai, K., Hirose, K., Matsuo, K., Ito, H., Kuriki, K., Suzuki, T., et.al. Dietary risk factors for colon and rectal cancers: a comparative case-control study, J Epidemiol, 2006. 16(3): p. 125-35., http://www.ncbi.nlm.nih.gov/pubmed/16710081

32. Beresford, S. A., Johnson, K. C., Ritenbaugh, C., Lasser, N. L., Snetselaar, L. G., Black, H. R., et.al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial, JAMA, 2006. 295(6): p. 643-54., http://www.ncbi.nlm.nih.gov/pubmed/16467233

33. Lanza, E., Yu, B., Murphy, G., Albert, P. S., Caan, B., Marshall, J. R., et.al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization, Cancer Epidemiol Biomarkers Prev, 2007. 16(9): p. 1745-52., http://www.ncbi.nlm.nih.gov/pubmed/17855692

34. Dahm, C. C., Keogh, R. H., Spencer, E. A., Greenwood, D. C., Key, T. J., Fentiman, I. S., et.al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries, J Natl Cancer Inst, 2010. 102(9): p. 614-26., http://www.ncbi.nlm.nih.gov/pubmed/20407088

35. Ishikawa, H., Akedo, I., Otani, T., Suzuki, T., Nakamura, T., Takeyama, I., et.al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors, Int J Cancer, 2005. 116(5): p. 762-7., http://www.ncbi.nlm.nih.gov/pubmed/15828052

36. Jacobs, E. T., Lanza, E., Alberts, D. S., Hsu, C. H., Jiang, R., Schatzkin, A., et.al. Fiber, sex, and colorectal adenoma: results of a pooled analysis, Am J Clin Nutr, 2006. 83(2): p. 343-9., http://www.ncbi.nlm.nih.gov/pubmed/16469993

37. Park, Y., Hunter, D. J., Spiegelman, D., Bergkvist, L., Berrino, F., van den Brandt, P. A., et.al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies, JAMA, 2005. 294(22): p. 2849-57., http://www.ncbi.nlm.nih.gov/pubmed/16352792

38. Robertson, D. J., Sandler, R. S., Haile, R., Tosteson, T. D., Greenberg, E. R., Grau, M., et.al. Fat, fiber, meat and the risk of colorectal adenomas, Am J Gastroenterol, 2005. 100(12): p. 2789-95., http://www.ncbi.nlm.nih.gov/pubmed/16393237

39. Austin, G. L., Galanko, J. A., Martin, C. F., Sandler, R. S., Moderate alcohol consumption protects against colorectal adenomas in smokers, Dig Dis Sci, 2008. 53(1): p. 116-22., http://www.ncbi.nlm.nih.gov/pubmed/17510802

40. Cho, E., Smith-Warner, S. A., Ritz, J., van den Brandt, P. A., Colditz, G. A., Folsom, A. R., et.al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies, Ann Intern Med, 2004. 140(8): p. 603-13., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15096331, http://annals.org/article.aspx?articleid=717373

41. Mizoue, T., Inoue, M., Wakai, K., Nagata, C., Shimazu, T., Tsuji, I., et.al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies, Am J Epidemiol, 2008. 167(12): p. 1397-406., http://www.ncbi.nlm.nih.gov/pubmed/18420544

42. Moskal, A., Norat, T., Ferrari, P., Riboli, E., Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies, Int J Cancer, 2007. 120(3): p. 664-71., http://www.ncbi.nlm.nih.gov/pubmed/17096321

43. Chao, A., Thun, M. J., Connell, C. J., McCullough, M. L., Jacobs, E. J., Flanders, W. D., et.al. Meat consumption and risk of colorectal cancer, JAMA, 2005. 293(2): p. 172-82., http://www.ncbi.nlm.nih.gov/pubmed/15644544

44. Larsson, S. C., Wolk, A., Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies, Int J Cancer, 2006. 119(11): p. 2657-64., http://www.ncbi.nlm.nih.gov/pubmed/16991129

45. Mathew, A., Sinha, R., Burt, R., Caan, B., Paskett, E., Iber, F., et.al. Meat intake and the recurrence of colorectal adenomas, Eur J Cancer Prev, 2004. 13(3): p. 159-64., http://www.ncbi.nlm.nih.gov/pubmed/15167213

46. Norat, T., Bingham, S., Ferrari, P., Slimani, N., Jenab, M., Mazuir, M., et.al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition, J Natl Cancer Inst, 2005. 97(12): p. 906-16., http://www.ncbi.nlm.nih.gov/pubmed/15956652

47. Sinha, R., Peters, U., Cross, A. J., Kulldorff, M., Weissfeld, J. L., Pinsky, P. F., et.al. Meat, meat cooking methods and preservation, and risk for colorectal adenoma, Cancer Res, 2005. 65(17): p. 8034-41., http://www.ncbi.nlm.nih.gov/pubmed/16140978

48. Geelen, A., Schouten, J. M., Kamphuis, C., Stam, B. E., Burema, J., Renkema, J. M., et.al. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies, Am J Epidemiol, 2007. 166(10): p. 1116-25., http://www.ncbi.nlm.nih.gov/pubmed/17823383

49. Sugawara, Y., Kuriyama, S., Kakizaki, M., Nagai, M., Ohmori-Matsuda, K., Sone, T., et.al. Fish consumption and the risk of colorectal cancer: the Ohsaki Cohort Study, Br J Cancer, 2009. 101(5): p. 849-54., http://www.ncbi.nlm.nih.gov/pubmed/19638981

50. Pot, G. K., Majsak-Newman, G., Geelen, A., Harvey, L. J., Nagengast, F. M., Witteman, B. J., et.al. Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial, Am J Clin Nutr, 2009. 90(2): p. 354-61., http://www.ncbi.nlm.nih.gov/pubmed/19553301

51. Je, Y., Liu, W., Giovannucci, E., Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies, Int J Cancer, 2009. 124(7): p. 1662-8., http://www.ncbi.nlm.nih.gov/pubmed/19115212

52. Sun, C. L., Yuan, J. M., Koh, W. P., Yu, M. C., Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies, Carcinogenesis, 2006. 27(7): p. 1301-9., http://www.ncbi.nlm.nih.gov/pubmed/16638787

53. Zhang, X., Albanes, D., Beeson, W. L., van den Brandt, P. A., Buring, J. E., Flood, A., et.al. Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies, J Natl Cancer Inst, 2010. 102(11): p. 771-83., http://www.ncbi.nlm.nih.gov/pubmed/20453203

54. Foschi, R., Pelucchi, C., Dal Maso, L., Rossi, M., Levi, F., Talamini, R., et.al. Citrus fruit and cancer risk in a network of case-control studies, Cancer Causes Control, 2010. 21(2): p. 237-42., http://www.ncbi.nlm.nih.gov/pubmed/19856118

55. Millen, A. E., Subar, A. F., Graubard, B. I., Peters, U., Hayes, R. B., Weissfeld, J. L., et.al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial, Am J Clin Nutr, 2007. 86(6): p. 1754-64., http://www.ncbi.nlm.nih.gov/pubmed/18065596

56. Koushik, A., Hunter, D. J., Spiegelman, D., Beeson, W. L., van den Brandt, P. A., Buring, J. E., et.al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies, J Natl Cancer Inst, 2007. 99(19): p. 1471-83., http://www.ncbi.nlm.nih.gov/pubmed/17895473

57. Limburg, P. J., Liu-Mares, W., Vierkant, R. A., Wang, A. H., Harnack, L., Flood, A. P., et.al. Prospective evaluation of trans-fatty acid intake and colorectal cancer risk in the Iowa Women's Health Study, Int J Cancer, 2008. 123(11): p. 2717-9., http://www.ncbi.nlm.nih.gov/pubmed/18767047

58. Alexander, D. D., Cushing, C. A., Lowe, K. A., Sceurman, B., Roberts, M. A., Meta-analysis of animal fat or animal protein intake and colorectal cancer, Am J Clin Nutr, 2009. 89(5): p. 1402-9., http://www.ncbi.nlm.nih.gov/pubmed/19261724

59. Galeone, C., Talamini, R., Levi, F., Pelucchi, C., Negri, E., Giacosa, A., et.al. Fried foods, olive oil and colorectal cancer, Ann Oncol, 2007. 18(1): p. 36-9., http://www.ncbi.nlm.nih.gov/pubmed/17018706

60. Nakamura, T., Ishikawa, H., Takeyama, I., Kawano, A., Ishiguro, S., Otani, T., et.al. Excessive fat restriction might promote the recurrence of colorectal tumors, Nutr Cancer, 2010. 62(2): p. 154-63., http://www.ncbi.nlm.nih.gov/pubmed/20099189

61. Larsson, S. C., Akesson, A., Bergkvist, L., Wolk, A., Dietary acrylamide intake and risk of colorectal cancer in a prospective cohort of men, Eur J Cancer, 2009. 45(4): p. 513-6., http://www.ncbi.nlm.nih.gov/pubmed/19121931

62. Hogervorst, J. G., Schouten, L. J., Konings, E. J., Goldbohm, R. A., van den Brandt, P. A., Dietary acrylamide intake is not associated with gastrointestinal cancer risk, J Nutr, 2008. 138(11): p. 2229-36., http://www.ncbi.nlm.nih.gov/pubmed/18936224

63. Mucci, L. A., Wilson, K. M., Acrylamide intake through diet and human cancer risk, J Agric Food Chem, 2008. 56(15): p. 6013-9., http://www.ncbi.nlm.nih.gov/pubmed/18624443

64. Mucci, L. A., Adami, H. O., Wolk, A., Prospective study of dietary acrylamide and risk of colorectal cancer among women, Int J Cancer, 2006. 118(1): p. 169-73., http://www.ncbi.nlm.nih.gov/pubmed/16003738

65. Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, JAMA, 2007. 297(8): p. 842-57., http://www.ncbi.nlm.nih.gov/pubmed/17327526

66. Weingarten, M. A., Zalmanovici, A., Yaphe, J., Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps, Cochrane Database Syst Rev, 2008. p. CD003548., http://www.ncbi.nlm.nih.gov/pubmed/18254022

67. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O'Sullivan, M. J., et.al. Calcium plus vitamin D supplementation and the risk of colorectal cancer, N Engl J Med, 2006. 354(7): p. 684-96., http://www.ncbi.nlm.nih.gov/pubmed/16481636

68. Sanjoaquin, M. A., Allen, N., Couto, E., Roddam, A. W., Key, T. J., Folate intake and colorectal cancer risk: a meta-analytical approach, Int J Cancer, 2005. 113(5): p. 825-8., http://www.ncbi.nlm.nih.gov/pubmed/15499620

69. Wu, K., Platz, E. A., Willett, W. C., Fuchs, C. S., Selhub, J., Rosner, B. A., et.al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma, Am J Clin Nutr, 2009. 90(6): p. 1623-31., http://www.ncbi.nlm.nih.gov/pubmed/19864409

70. Jaszewski, R., Misra, S., Tobi, M., Ullah, N., Naumoff, J. A., Kucuk, O., et.al. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial, World J Gastroenterol, 2008. 14(28): p. 4492-8., http://www.ncbi.nlm.nih.gov/pubmed/18680228

71. Cole, B. F., Baron, J. A., Sandler, R. S., Haile, R. W., Ahnen, D. J., Bresalier, R. S., et.al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial, JAMA, 2007. 297(21): p. 2351-9., http://www.ncbi.nlm.nih.gov/pubmed/17551129

72. Logan, R. F., Grainge, M. J., Shepherd, V. C., Armitage, N. C., Muir, K. R., Aspirin and folic acid for the prevention of recurrent colorectal adenomas, Gastroenterology, 2008. 134(1): p. 29-38., http://www.ncbi.nlm.nih.gov/pubmed/18022173

73. Grau, M. V., Baron, J. A., Sandler, R. S., Wallace, K., Haile, R. W., Church, T. R., et.al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial, J Natl Cancer Inst, 2007. 99(2): p. 129-36., http://www.ncbi.nlm.nih.gov/pubmed/17227996

74. Wallace, K., Baron, J. A., Cole, B. F., Sandler, R. S., Karagas, M. R., Beach, M. A., et.al. Effect of calcium supplementation on the risk of large bowel polyps, J Natl Cancer Inst, 2004. 96(12): p. 921-5., http://www.ncbi.nlm.nih.gov/pubmed/15199111

75. Hartman, T. J., Albert, P. S., Snyder, K., Slattery, M. L., Caan, B., Paskett, E., et.al. The association of calcium and vitamin D with risk of colorectal adenomas, J Nutr, 2005. 135(2): p. 252-9., http://www.ncbi.nlm.nih.gov/pubmed/15671222

76. Lin, J., Cook, N. R., Lee, I. M., Manson, J. E., Buring, J. E., Zhang, S. M., Total magnesium intake and colorectal cancer incidence in women, Cancer Epidemiol Biomarkers Prev, 2006. 15(10): p. 2006-9., http://www.ncbi.nlm.nih.gov/pubmed/17035414

77. Jacobs, E. T., Jiang, R., Alberts, D. S., Greenberg, E. R., Gunter, E. W., Karagas, M. R., et.al. Selenium and colorectal adenoma: results of a pooled analysis, J Natl Cancer Inst, 2004. 96(22): p. 1669-75., http://www.ncbi.nlm.nih.gov/pubmed/15547179

78. Peters, U., Chatterjee, N., Church, T. R., Mayo, C., Sturup, S., Foster, C. B., et.al. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program, Cancer Epidemiol Biomarkers Prev, 2006. 15(2): p. 315-20., http://www.ncbi.nlm.nih.gov/pubmed/16492922

79. Vinogradova, Y., Hippisley-Cox, J., Coupland, C., Logan, R. F., Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study, Gastroenterology, 2007. 133(2): p. 393-402., http://www.ncbi.nlm.nih.gov/pubmed/17681160

80. Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., et.al. Celecoxib for the prevention of sporadic colorectal adenomas, N Engl J Med, 2006. 355(9): p. 873-84., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16943400, http://www.nejm.org/doi/pdf/10.1056/NEJMoa061355

81. Arber, N., Eagle, C. J., Spicak, J., Racz, I., Dite, P., Hajer, J., et.al. Celecoxib for the prevention of colorectal adenomatous polyps, N Engl J Med, 2006. 355(9): p. 885-95., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16943401, http://www.nejm.org/doi/pdf/10.1056/NEJMoa061652

82. Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., et.al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas, Gastroenterology, 2006. 131(6): p. 1674-82., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17087947, http://www.gastrojournal.org/article/S0016-5085(06)01994-9/pdf

83. Bardou, M., Barkun, A., Martel, M., Effect of statin therapy on colorectal cancer, Gut, 2010. 59(11): p. 1572-85., http://www.ncbi.nlm.nih.gov/pubmed/20660702

84. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 2007. 146(5): p. 361-4., http://www.ncbi.nlm.nih.gov/pubmed/17339621

85. Flossmann, E., Rothwell, P. M., Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies, Lancet, 2007. 369(9573): p. 1603-13., http://www.ncbi.nlm.nih.gov/pubmed/17499602

86. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., Meade, T. W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, Lancet, 2011. 377(9759): p. 31-41., http://www.ncbi.nlm.nih.gov/pubmed/21144578

87. Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Curhan, G. C., Fuchs, C. S., Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer, JAMA, 2005. 294(8): p. 914-23., http://www.ncbi.nlm.nih.gov/pubmed/16118381

88. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force, Ann Intern Med, 2005. 142(10): p. 855-60., http://www.ncbi.nlm.nih.gov/pubmed/15897536

89. Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., Lamberts, Q., Long term hormone therapy for perimenopausal and postmenopausal women, Cochrane Database Syst Rev, 2009. p. CD004143., http://www.ncbi.nlm.nih.gov/pubmed/19370593

90. Alberts, D. S., Martinez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., et.al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence, J Natl Cancer Inst, 2005. 97(11): p. 846-53., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15928305, http://jnci.oxfordjournals.org/content/97/11/846.full.pdf

91. DGGG, Hormontherapie (HT) in der Peri- und Postmenopause, 2009.

92. Birkner, B. R., [Evidence-based prevention of colorectal carcinoma], Dtsch Med Wochenschr, 2003. 128(49): p. 2598-603., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14655077, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-45207

93. Winawer, S. J., Fletcher, R. H., Miller, L., Godlee, F., Stolar, M. H., Mulrow, C. D., et.al. Colorectal cancer screening: clinical guidelines and rationale, Gastroenterology, 1997. 112(2): p. 594-642., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9024315

94. Imperiale, T. F., Wagner, D. R., Lin, C. Y., Larkin, G. N., Rogge, J. D., Ransohoff, D. F., Results of screening colonoscopy among persons 40 to 49 years of age, N Engl J Med, 2002. 346(23): p. 1781-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12050337, http://www.nejm.org/doi/pdf/10.1056/NEJM200206063462304

95. Whitlock, E. P., Lin, J. S., Liles, E., Beil, T. L., Fu, R., Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 2008. 149(9): p. 638-58., http://www.ncbi.nlm.nih.gov/pubmed/18838718

96. Stevens, T., Burke, C. A., Colonoscopy screening in the elderly: when to stop?, Am J Gastroenterol, 2003. 98(8): p. 1881-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12907348

97. Kirchgatterer, A., Hubner, D., Aschl, G., Hinterreiter, M., Stadler, B., Knoflach, P., [Colonoscopy and sigmoidoscopy in patients aged eighty years or older], Z Gastroenterol, 2002. 40(12): p. 951-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12518261, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2002-36157

98. Pox, C. P., Altenhofen, L., Brenner, H., Theilmeier, A., Stillfried, D. V., Schmiegel, W., Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer, Gastroenterology, 2012., http://www.ncbi.nlm.nih.gov/pubmed/22446606

99. Zhang, B., Fattah, A., Nakama, H., Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening, Hepatogastroenterology, 2000. 47(32): p. 414-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10791202

100. Huppe, D., Hartmann, H., Felten, G., Kemen, M., Tannapfel, A., Gillessen, A., et.al. [Effectiveness of screening colonoscopy in a community-based study], Z Gastroenterol, 2008. 46(2): p. 193-200., http://www.ncbi.nlm.nih.gov/pubmed/18253898

101. Kahi, C. J., Imperiale, T. F., Juliar, B. E., Rex, D. K., Effect of screening colonoscopy on colorectal cancer incidence and mortality, Clin Gastroenterol Hepatol, 2009. 7(7): p. 770-5; quiz 711., http://www.ncbi.nlm.nih.gov/pubmed/19268269

102. Imperiale, T. F., Wagner, D. R., Lin, C. Y., Larkin, G. N., Rogge, J. D., Ransohoff, D. F., Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings, N Engl J Med, 2000. 343(3): p. 169-74., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10900275, http://www.nejm.org/doi/pdf/10.1056/NEJM200007203430302

103. Lieberman, D. A., Weiss, D. G., Bond, J. H., Ahnen, D. J., Garewal, H., Chejfec, G., Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380, N Engl J Med, 2000. 343(3): p. 162-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10900274, http://www.nejm.org/doi/pdf/10.1056/NEJM200007203430301

104. Atkin, WS., Cook, CF., Cuzick, J., Edwards, R., Northover, JM., Wardle, J., Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial, Lancet, 2002. 359(9314): p. 1291-300., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11965274, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08268-5/abstract

105. Muller, A. D., Sonnenberg, A., Protection by endoscopy against death from colorectal cancer. A case-control study among veterans, Arch Intern Med, 1995. 155(16): p. 1741-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7654107, http://archinte.jamanetwork.com/article.aspx?articleid=620926

106. Newcomb, P. A., Norfleet, R. G., Storer, B. E., Surawicz, T. S., Marcus, P. M., Screening sigmoidoscopy and colorectal cancer mortality, J Natl Cancer Inst, 1992. 84(20): p. 1572-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1404450

107. Selby, J. V., Friedman, G. D., Quesenberry, C. P., Jr., Weiss, N. S., A case-control study of screening sigmoidoscopy and mortality from colorectal cancer, N Engl J Med, 1992. 326(10): p. 653-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1736103, http://www.nejm.org/doi/pdf/10.1056/NEJM199203053261001

108. Singh, H., Nugent, Z., Mahmud, S. M., Demers, A. A., Bernstein, C. N., Predictors of colorectal cancer after negative colonoscopy: a population-based study, Am J Gastroenterol, 2010. 105(3): p. 663-73; quiz 674., http://www.ncbi.nlm.nih.gov/pubmed/19904239

109. Brenner, H., Hoffmeister, M., Arndt, V., Stegmaier, C., Altenhofen, L., Haug, U., Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study, J Natl Cancer Inst, 2010. 102(2): p. 89-95., http://www.ncbi.nlm.nih.gov/pubmed/20042716

110. Brenner, H., Chang-Claude, J., Seiler, C. M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study, Ann Intern Med, 2011. 154(1): p. 22-30., http://annals.org/aim/article/746683/protection-from-colorectal-cancer-after-colonoscopy-population-based-case-control

111. Sieg, A., Hachmoeller-Eisenbach, U., Eisenbach, T., Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists., Gastrointest Endosc, 2001. 53: p. 620-7.

112. Rex, D.K., Cutler, C.S., Lemmel, G.T., Rahmani, E.Y., Helper, D.J., Lehman, G.A., et.al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies, Gastroenterology, 1997. 112(1): p. 24-8.

113. Rex, D. K., Cummings, O. W., Helper, D. J., Nowak, T. V., McGill, J. M., Chiao, G. Z., et.al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment], Gastroenterology, 1996. 111(5): p. 1178-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8898630, http://www.gastrojournal.org/article/S0016-5085(96)00471-4/pdf

114. Brenner, H., Chang-Claude, J., Seiler, C. M., Hoffmeister, M., Long-term risk of colorectal cancer after negative colonoscopy, J Clin Oncol, 2011. 29(28): p. 3761-7., http://www.ncbi.nlm.nih.gov/pubmed/21876077

115. Elahi, A., Bendaly, J., Zheng, Z., Muscat, J. E., Richie, J. P., Jr., Schantz, S. P., et.al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk, Cancer, 2003. 98(4): p. 872-80., https://www.ncbi.nlm.nih.gov/pubmed/12910533

116. Bekanntmachungen: Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krebserkrankungen („Krebsfrüherkennungs-Richtlinien“)*, Dtsch Arztebl Int, 2002. 1(11): p. 518., http://www.aerzteblatt.de/int/article.asp?id=34420

117. Atkin, W. S., Edwards, R., Kralj-Hans, I., Wooldrage, K., Hart, A. R., Northover, J. M., et.al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial, Lancet, 2010. 375(9726): p. 1624-33., http://www.ncbi.nlm.nih.gov/pubmed/20430429

118. Muller, A. D., Sonnenberg, A., Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans, Ann Intern Med, 1995. 123(12): p. 904-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7486484, http://annals.org/article.aspx?articleid=709280

119. Newcomb, P. A., Storer, B. E., Morimoto, L. M., Templeton, A., Potter, J. D., Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence, J Natl Cancer Inst, 2003. 95(8): p. 622-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12697855, http://jnci.oxfordjournals.org/content/95/8/622.full.pdf

120. Schoen, R. E., Pinsky, P. F., Weissfeld, J. L., Bresalier, R. S., Church, T., Prorok, P., et.al. Results of repeat sigmoidoscopy 3 years after a negative examination, Jama, 2003. 290(1): p. 41-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12837710, http://jama.jamanetwork.com/article.aspx?articleid=196852

121. Burke, C. A., Elder, K., Lopez, R., Screening for colorectal cancer with flexible sigmoidoscopy: is a 5-yr interval appropriate? A comparison of the detection of neoplasia 3 yr versus 5 yr after a normal examination, Am J Gastroenterol, 2006. 101(6): p. 1329-32., http://www.ncbi.nlm.nih.gov/pubmed/16771957

122. Winawer, S. J., Flehinger, B. J., Schottenfeld, D., Miller, D. G., Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy, J Natl Cancer Inst, 1993. 85(16): p. 1311-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8340943, http://jnci.oxfordjournals.org/content/85/16/1311.full.pdf

123. Lieberman, D. A., Weiss, D. G., One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon, N Engl J Med, 2001. 345(8): p. 555-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11529208, http://www.nejm.org/doi/pdf/10.1056/NEJMoa010328

124. Gondal, G., Grotmol, T., Hofstad, B., Bretthauer, M., Eide, T. J., Hoff, G., The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years, Scand J Gastroenterol, 2003. 38(6): p. 635-42., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12825872

125. Kato, J., Morikawa, T., Kuriyama, M., Yamaji, Y., Wada, R., Mitsushima, T., et.al. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia, Clin Gastroenterol Hepatol, 2009. 7(12): p. 1341-6., http://www.ncbi.nlm.nih.gov/pubmed/19426835

126. Eliakim, R., Fireman, Z., Gralnek, I. M., Yassin, K., Waterman, M., Kopelman, Y., et.al. Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study, Endoscopy, 2006. 38(10): p. 963-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17058158, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2006-944832

127. Schoofs, N., Deviere, J., Van Gossum, A., PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study, Endoscopy, 2006. 38(10): p. 971-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17058159, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2006-944835

128. Van Gossum, A., Munoz-Navas, M., Fernandez-Urien, I., Carretero, C., Gay, G., Delvaux, M., et.al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer, N Engl J Med, 2009. 361(3): p. 264-70., http://www.ncbi.nlm.nih.gov/pubmed/19605831

129. Spada, C., Hassan, C., Marmo, R., Petruzziello, L., Riccioni, M. E., Zullo, A., et.al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps, Clin Gastroenterol Hepatol, 2010. 8(6): p. 516-22., http://www.ncbi.nlm.nih.gov/pubmed/20215066

130. Gay, G., Delvaux, M., Frederic, M., Fassler, I., Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening, Am J Gastroenterol, 2010. 105(5): p. 1076-86., http://www.ncbi.nlm.nih.gov/pubmed/19888198

131. Eliakim, R., Yassin, K., Niv, Y., Metzger, Y., Lachter, J., Gal, E., et.al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy, Endoscopy, 2009. 41(12): p. 1026-31., http://www.ncbi.nlm.nih.gov/pubmed/19967618

132. Spada, C., Hassan, C., Munoz-Navas, M., Neuhaus, H., Deviere, J., Fockens, P., et.al. Second-generation colon capsule endoscopy compared with colonoscopy, Gastrointest Endosc, 2011. 74(3): p. 581-589 e1., http://www.ncbi.nlm.nih.gov/pubmed/21601200

133. Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., et.al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N Engl J Med, 1993. 328(19): p. 1365-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8474513, http://www.nejm.org/doi/pdf/10.1056/NEJM199305133281901

134. Hol, L., van Leerdam, M. E., van Ballegooijen, M., van Vuuren, A. J., van Dekken, H., Reijerink, J. C., et.al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy, Gut, 2010. 59(1): p. 62-8., http://www.ncbi.nlm.nih.gov/pubmed/19671542

135. Zhu, M. M., Xu, X. T., Nie, F., Tong, J. L., Xiao, S. D., Ran, Z. H., Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis, J Dig Dis, 2010. 11(3): p. 148-60., http://www.ncbi.nlm.nih.gov/pubmed/20579218

136. van Rossum, L. G., van Rijn, A. F., Verbeek, A. L., van Oijen, M. G., Laheij, R. J., Fockens, P., et.al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis, Int J Cancer, 2011. 128(8): p. 1908-17., http://www.ncbi.nlm.nih.gov/pubmed/20589677

137. Hundt, S., Haug, U., Brenner, H., Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection, Ann Intern Med, 2009. 150(3): p. 162-9., http://www.ncbi.nlm.nih.gov/pubmed/19189905

138. Brenner, H., Haug, U., Hundt, S., Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests, Int J Cancer, 2010. 127(7): p. 1643-9., http://www.ncbi.nlm.nih.gov/pubmed/20049840

139. Haug, U., Kuntz, K. M., Knudsen, A. B., Hundt, S., Brenner, H., Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia, Br J Cancer, 2011. 104(11): p. 1779-85., http://www.ncbi.nlm.nih.gov/pubmed/21559011

140. Allison, J. E., Sakoda, L. C., Levin, T. R., Tucker, J. P., Tekawa, I. S., Cuff, T., et.al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics, J Natl Cancer Inst, 2007. 99(19): p. 1462-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17895475, http://jnci.oxfordjournals.org/content/99/19/1462.full.pdf

141. Park, D. I., Ryu, S., Kim, Y. H., Lee, S. H., Lee, C. K., Eun, C. S., et.al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening, Am J Gastroenterol, 2010. 105(9): p. 2017-25., http://www.ncbi.nlm.nih.gov/pubmed/20502450

142. Launoy, G. D., Bertrand, H. J., Berchi, C., Talbourdet, V. Y., Guizard, A. V., Bouvier, V. M., et.al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population, Int J Cancer, 2005. 115(3): p. 493-6., http://www.ncbi.nlm.nih.gov/pubmed/15700317

143. van Roon, A. H., Wilschut, J. A., Hol, L., van Ballegooijen, M., Reijerink, J. C., t Mannetje, H., et.al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance, Clin Gastroenterol Hepatol, 2011. 9(4): p. 333-9., http://www.ncbi.nlm.nih.gov/pubmed/21185397

144. Haug, U., Hundt, S., Brenner, H., Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests, Am J Gastroenterol, 2010. 105(3): p. 682-90., http://www.ncbi.nlm.nih.gov/pubmed/19953091

145. Doran, J., Hardcastle, J. D., Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing, Br J Surg, 1982. 69(12): p. 711-3., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7171971, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800691209/abstract

146. Ahlquist, D. A., McGill, D. B., Fleming, J. L., Schwartz, S., Wieand, H. S., Rubin, J., et.al. Patterns of occult bleeding in asymptomatic colorectal cancer, Cancer, 1989. 63(9): p. 1826-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2702590, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19900501)63:9<1826::AID-CNCR2820630928>3.0.CO;2-P/asset/2820630928_ftp.pdf?v=1&t=ik5145pu&s=bd11143eb9b9b88081f2892f6315fbe6cb0664cb

147. Macrae, F.A., St. John, D.J., Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas., Gastroenterology, 1982. 82: p. 891-8.

148. Greegor, D.H., Occult blood testing for detection of asymptomatic colon cancer., Cancer, 1971. 28: p. 131-4., http://onlinelibrary.wiley.com/store/10.1002/1097-0142(197107)28:1<131::AID-CNCR2820280125>3.0.CO;2-I/asset/2820280125_ftp.pdf?v=1&t=ik52llmb&s=924d09ddaeaf06a565a6016d3967619b4be1b1c3

149. Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., et.al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 1996. 348(9040): p. 1472-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8942775, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)03386-7/abstract

150. Kronborg, O., Fenger, C., Olsen, J., Jorgensen, O. D., Sondergaard, O., Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet, 1996. 348(9040): p. 1467-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8942774, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)03430-7/abstract

151. Hewitson, P., Glasziou, P., Irwig, L., Towler, B., Watson, E., Screening for colorectal cancer using the faecal occult blood test, Hemoccult, Cochrane Database Syst Rev, 2007. p. CD001216., http://www.ncbi.nlm.nih.gov/pubmed/17253456

152. Levin, B., Hess, K., Johnson, C., Screening for colorectal cancer. A comparison of 3 fecal occult blood tests, Arch Intern Med, 1997. 157(9): p. 970-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9140267, http://archinte.jamanetwork.com/article.aspx?articleid=623273

153. Gnauck, R., Macrae, F.A., Fleisher, M., How to perform the fecal occult blood test, CA Cancer J Clin, 1984. 34: p. 134-47., http://onlinelibrary.wiley.com/store/10.3322/canjclin.34.3.134/asset/134_ftp.pdf?v=1&t=ik52kxkw&s=c7efe54df86eb0e4a4eaf31d62cbaa32dd235b85

154. Jaffe, R. M., Kasten, B., Young, D. S., MacLowry, J. D., False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C), Ann Intern Med, 1975. 83(6): p. 824-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1200528, http://annals.org/article.aspx?articleid=689937

155. Macrae, F. A., St John, D. J., Caligiore, P., Taylor, L. S., Legge, J. W., Optimal dietary conditions for hemoccult testing, Gastroenterology, 1982. 82(5 Pt 1): p. 899-903., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7060911

156. Rozen, P., Knaani, J., Samuel, Z., Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test, Dig Dis Sci, 1999. 44(4): p. 756-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10219834

157. Pignone, M., Campbell, M. K., Carr, C., Phillips, C., Meta-analysis of dietary restriction during fecal occult blood testing, Eff Clin Pract, 2001. 4(4): p. 150-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11525101

158. van Rossum, L. G., van Rijn, A. F., Laheij, R. J., van Oijen, M. G., Fockens, P., van Krieken, H. H., et.al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population, Gastroenterology, 2008. 135(1): p. 82-90., http://www.ncbi.nlm.nih.gov/pubmed/18482589

159. Webendorfer, S., Messerer, P., Eberle, F., Zober, A., [Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company], Dtsch Med Wochenschr, 2004. 129(6): p. 239-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14750049, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-2004-817998.pdf

160. Mandel, J. S., Church, T. R., Bond, J. H., Ederer, F., Geisser, M. S., Mongin, S. J., et.al. The effect of fecal occult-blood screening on the incidence of colorectal cancer, N Engl J Med, 2000. 343(22): p. 1603-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11096167, http://www.nejm.org/doi/pdf/10.1056/NEJM200011303432203

161. Traverso, G., Shuber, A., Levin, B., Johnson, C., Olsson, L., Schoetz, D. J., Jr., et.al. Detection of APC mutations in fecal DNA from patients with colorectal tumors, N Engl J Med, 2002. 346(5): p. 311-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11821507, http://www.nejm.org/doi/pdf/10.1056/NEJMoa012294

162. Ahlquist, D. A., Skoletsky, J. E., Boynton, K. A., Harrington, J. J., Mahoney, D. W., Pierceall, W. E., et.al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel, Gastroenterology, 2000. 119(5): p. 1219-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11054379, http://www.gastrojournal.org/article/S0016-5085(00)89526-8/pdf

163. Dong, S. M., Traverso, G., Johnson, C., Geng, L., Favis, R., Boynton, K., et.al. Detecting colorectal cancer in stool with the use of multiple genetic targets, J Natl Cancer Inst, 2001. 93(11): p. 858-65., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11390535, http://jnci.oxfordjournals.org/content/93/11/858.full.pdf

164. Tagore, K. S., Lawson, M. J., Yucaitis, J. A., Gage, R., Orr, T., Shuber, A. P., et.al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia, Clin Colorectal Cancer, 2003. 3(1): p. 47-53., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12777192, http://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70467-4/abstract

165. Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., Ross, M. E., Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population, N Engl J Med, 2004. 351(26): p. 2704-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15616205, http://www.nejm.org/doi/pdf/10.1056/NEJMoa033403

166. Ahlquist, D. A., Sargent, D. J., Loprinzi, C. L., Levin, T. R., Rex, D. K., Ahnen, D. J., et.al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia, Ann Intern Med, 2008. 149(7): p. 441-50, W81., http://www.ncbi.nlm.nih.gov/pubmed/18838724

167. Haug, U., Hundt, S., Brenner, H., Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study, Br J Cancer, 2008. 99(1): p. 133-5., http://www.ncbi.nlm.nih.gov/pubmed/18542075

168. Moslein, G., Schneider, C., Theilmeier, A., Erckenbrecht, H., Normann, S., Hoffmann, B., et.al. [Analysis of the statistical value of various commercially available stool tests - a comparison of one stool sample in correlation to colonoscopy], Dtsch Med Wochenschr, 2010. 135(12): p. 557-62., http://www.ncbi.nlm.nih.gov/pubmed/20209426

169. de Haan, M. C., van Gelder, R. E., Graser, A., Bipat, S., Stoker, J., Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis, Eur Radiol, 2011. 21(8): p. 1747-63., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128257/pdf/330_2011_Article_2104.pdf

170. El-Maraghi, R. H., Kielar, A. Z., CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis, Acad Radiol, 2009. 16(5): p. 564-71., http://www.ncbi.nlm.nih.gov/pubmed/19345897

171. Pox, C. P., Schmiegel, W., Role of CT colonography in colorectal cancer screening: risks and benefits, Gut, 2010. 59(5): p. 692-700., http://www.ncbi.nlm.nih.gov/pubmed/20427403

172. Frazier, A. L., Colditz, G. A., Fuchs, C. S., Kuntz, K. M., Cost-effectiveness of screening for colorectal cancer in the general population, Jama, 2000. 284(15): p. 1954-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11035892, http://jama.jamanetwork.com/article.aspx?articleid=193186

173. Geul, K. W., Bosman, F. T., van Blankenstein, M., Grobbee, D. E., Wilson, J. H., Prevention of colorectal cancer. Costs and effectiveness of sigmoidoscopy, Scand J Gastroenterol Suppl, 1997. 223: p. 79-87., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9200311

174. Inadomi, J. M., Update on the cost-effectiveness of screening for colorectal neoplasia, Curr Opin Gastroenterol, 2003. 29: p. 44-50.

175. Khandker, R. K., Dulski, J. D., Kilpatrick, J. B., Ellis, R. P., Mitchell, J. B., Baine, W. B., A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults, Int J Technol Assess Health Care, 2000. 16(3): p. 799-810., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11028135

176. McGrath, J. S., Ponich, T. P., Gregor, J. C., Screening for colorectal cancer: the cost to find an advanced adenoma, Am J Gastroenterol, 2002. 97(11): p. 2902-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12425566

177. Norum, J., Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy, Ann Oncol, 1998. 9(6): p. 613-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9681074, http://annonc.oxfordjournals.org/content/9/6/613.full.pdf

178. Pignone, M., Saha, S., Hoerger, T., Mandelblatt, J., Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 2002. 137(2): p. 96-104., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12118964, http://annals.org/article.aspx?articleid=715436

179. Sonnenberg, A., Delco, F., Cost-effectiveness of a single colonoscopy in screening for colorectal cancer, Arch Intern Med, 2002. 162(2): p. 163-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11802749, http://archinte.jamanetwork.com/article.aspx?articleid=214713

180. Vijan, S., Hwang, E. W., Hofer, T. P., Hayward, R. A., Which colon cancer screening test? A comparison of costs, effectiveness, and compliance, Am J Med, 2001. 111(8): p. 593-601., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11755501, http://www.amjmed.com/article/S0002-9343(01)00977-9/abstract

181. Zauber, A. G., Lansdorp-Vogelaar, I., Knudsen, A. B., Wilschut, J., van Ballegooijen, M., Kuntz, K. M., Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force, Ann Intern Med, 2008. 149(9): p. 659-69., http://www.ncbi.nlm.nih.gov/pubmed/18838717

182. Lansdorp-Vogelaar, I., Knudsen, A. B., Brenner, H., Cost-effectiveness of colorectal cancer screening, Epidemiol Rev, 2011. 33(1): p. 88-100., http://www.ncbi.nlm.nih.gov/pubmed/21633092

183. Sung, J. J., Lau, J. Y., Young, G. P., Sano, Y., Chiu, H. M., Byeon, J. S., et.al. Asia Pacific consensus recommendations for colorectal cancer screening, Gut, 2008. 57(8): p. 1166-76., http://www.ncbi.nlm.nih.gov/pubmed/18628378

184. Jasperson, K. W., Tuohy, T. M., Neklason, D. W., Burt, R. W., Hereditary and familial colon cancer, Gastroenterology, 2010. 138(6): p. 2044-58., http://www.ncbi.nlm.nih.gov/pubmed/20420945

185. Andrieu, N., Launoy, G., Guillois, R., Ory-Paoletti, C., Gignoux, M., Familial relative risk of colorectal cancer: a population-based study, Eur J Cancer, 2003. 39(13): p. 1904-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12932670, http://www.ejcancer.com/article/S0959-8049(03)00420-9/abstract

186. Johns, L. E., Houlston, R. S., A systematic review and meta-analysis of familial colorectal cancer risk, Am J Gastroenterol, 2001. 96(10): p. 2992-3003., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11693338

187. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., et.al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med, 2000. 343(2): p. 78-85., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10891514, http://www.nejm.org/doi/pdf/10.1056/NEJM200007133430201

188. Slattery, M. L., Levin, T. R., Ma, K., Goldgar, D., Holubkov, R., Edwards, S., Family history and colorectal cancer: predictors of risk, Cancer Causes Control, 2003. 14(9): p. 879-87., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14682445

189. Winawer, S., Fletcher, R., Rex, D., Bond, J., Burt, R., Ferrucci, J., et.al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, Gastroenterology, 2003. 124(2): p. 544-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12557158, http://www.gastrojournal.org/article/S0016-5085(02)15895-1/pdf

190. Bonelli, L., Martines, H., Conio, M., Bruzzi, P., Aste, H., Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study, Int J Cancer, 1988. 41(4): p. 513-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3356486, http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910410407/abstract

191. Fuchs, C.S., Giovannucci, E.L., Colditz, G.A., Hunter, D.J., Speizer, F.E., Willett, W.C., A prospective study of family history and the risk of colorectal cancer, N Engl J Med, 1994. 331(25): p. 1669-74., http://www.nejm.org/doi/pdf/10.1056/NEJM199412223312501

192. Guillem, J.G., Bastar, A.L., Ng, J., Huhn, J.L., Cohen, A.M., Clustering of colorectal cancer in families of probands under 40 years of age, Dis Colon Rectum, 1996. 39(9): p. 1004-7.

193. Guillem, J.G., Forde, K.A., Treat, M.R., Neugut, A.I., O'Toole, K.M., Diamond, B.E., Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study, Dis Colon Rectum, 1992. 35(6): p. 523-9.

194. Kune, G.A., Kune, S., Watson, L.F., The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study, World J Surg, 1989. 13(1): p. 124-9.

195. Rozen, P., Fireman, Z., Figer, A., Legum, C., Ron, E., Lynch, H.T., Family history of colorectal cancer as a marker of potential malignancy within a screening programm, Cancer, 1987. 60(2): p. 248-54., http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19870715)60:2<248::AID-CNCR2820600223>3.0.CO;2-G/asset/2820600223_ftp.pdf?v=1&t=ik5892nf&s=00bb78e9114146c76b4808000d9b29f4b363283e

196. Sondergaard, J.O., Bulow, S., Lynge, E., Cancer incidence among parents of patients with colorectal cancer, Int J Cancer, 1991. 47(2): p. 202-6., http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910470207/abstract

197. St John, D.J., McDermott, F.T., Hopper, J.L., Debney, E.A., Johnson, W.R., Hughes, E.S., Cancer risk in relatives of patients with common colorectal cancer, Ann Int Med, 1993. 118(10): p. 785-90., http://annals.org/article.aspx?articleid=706371

198. Butterworth, A. S., Higgins, J. P., Pharoah, P., Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis, Eur J Cancer, 2006. 42(2): p. 216-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16338133, http://www.ejcancer.com/article/S0959-8049(05)00945-7/abstract

199. Hall, N. R., Bishop, D. T., Stephenson, B. M., Finan, P. J., Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk, Dis Colon Rectum, 1996. 39(7): p. 739-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8674364

200. Hunt, L.M., Rooney, P.S., Hardcastle, J.D., Armitage, N.C., Endoscopic screening of relatives of patients with colorectal cancer, Gut, 1998. 42(1): p. 71-5., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1726961/pdf/v042p00071.pdf

201. Winawer, S.J., Zauber, A.G., Gerdes, H., O'Brien, M.J., Gottlieb, L.S., Sternberg, S.S., et.al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup, N Engl J Med, 1996. 334(2): p. 82-7., http://www.nejm.org/doi/pdf/10.1056/NEJM199601113340204

202. Ahsan, H., Neugut, A. I., Garbowski, G. C., Jacobson, J. S., Forde, K. A., Treat, M. R., et.al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer, Ann Intern Med, 1998. 128(11): p. 900-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9634428, http://annals.org/article.aspx?articleid=711453

203. Nakama, H., Zhang, B., Fukazawa, K., Abdul Fattah, A. S., Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer, Eur J Cancer, 2000. 36(16): p. 2111-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11044649, http://www.ejcancer.com/article/S0959-8049(00)00293-8/abstract

204. Almendingen, K., Hofstad, B., Vatn, M. H., Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?, Gut, 2003. 52(5): p. 747-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12692063, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773641/pdf/gut05200747.pdf

205. Winawer, S. J., Zauber, A. G., Ho, M. N., O'Brien, M. J., Gottlieb, L. S., Sternberg, S. S., et.al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup, N Engl J Med, 1993. 329(27): p. 1977-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8247072, http://www.nejm.org/doi/pdf/10.1056/NEJM199312303292701

206. Citarda, F., Tomaselli, G., Capocaccia, R., Barcherini, S., Crespi, M., Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence, Gut, 2001. 48(6): p. 812-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11358901, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728339/pdf/v048p00812.pdf

207. Winawer, S.J., O'Brien, M.J., Waye, J.D., Kronborg, O., Bond, J., Fruhmorgen, P., et.al. Risk and surveillance of individuals with colorectal polyps. WHO Collaborating Centre for the Prevention of Colorectal Cancer, Bull World Health Organ, 1990. 68(6): p. 789-95., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2393163/pdf/bullwho00057-0099.pdf

208. Atkin, W. S., Morson, B. C., Cuzick, J., Long-term risk of colorectal cancer after excision of rectosigmoid adenomas, N Engl J Med, 1992. 326(10): p. 658-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1736104, http://www.nejm.org/doi/pdf/10.1056/NEJM199203053261002

209. Otchy, D.P., Ransohoff, D.F., Wolff, B.G., Weaver, A., Ilstrup, D., Carlson, H., et.al. Metachronous colon cancer in persons who have had a large adenomatous polyp, Am J Gastroenterol, 1996. 91(3): p. 448-54.

210. van Stolck, R.U., Beck, G.J., Baron, J.A., Haile, R., Summers, R., Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group, Gastroenterology, 1998. 115(1): p. 13-8.

211. Noshirwani, K.C., van Stolk, R.U., Rybicki, L.A., G.J., Beck, Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy., Gastrointest Endosc, 2000. 51: p. 433-7.

212. Aldridge, A. J., Simson, J. N., Histological assessment of colorectal adenomas by size. Are polyps less than 10 mm in size clinically important?, Eur J Surg, 2001. 167(10): p. 777-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11775731

213. Avidan, B., Sonnenberg, A., Schnell, T. G., Leya, J., Metz, A., Sontag, S. J., New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy, Am J Gastroenterol, 2002. 97(6): p. 1524-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12094877

214. Bertario, L., Russo, A., Sala, P., Pizzetti, P., Ballardini, G., Andreola, S., et.al. Predictors of metachronous colorectal neoplasms in sporadic adenoma patients, Int J Cancer, 2003. 105(1): p. 82-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12672034, http://onlinelibrary.wiley.com/store/10.1002/ijc.11036/asset/11036_ftp.pdf?v=1&t=ik51izoz&s=cdfb8364c2d4decd16f520102975ab5305a93026

215. Chen, C. D., Yen, M. F., Wang, W. M., Wong, J. M., Chen, T. H., A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy, Br J Cancer, 2003. 88(12): p. 1866-73., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12799628, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741116/pdf/88-6601007a.pdf

216. Bensen, S., Mott, L. A., Dain, B., Rothstein, R., Baron, J., The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group, Am J Gastroenterol, 1999. 94(1): p. 194-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9934755

217. Katalinic, A., Raspe, H., Waldmann, A., [Positive family history of colorectal cancer--use of a questionnaire], Z Gastroenterol, 2009. 47(11): p. 1125-31., http://www.ncbi.nlm.nih.gov/pubmed/19899019

218. Baron, J. A., Cole, B. F., Mott, L., Haile, R., Grau, M., Church, T. R., et.al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial, J Natl Cancer Inst, 2003. 95(10): p. 717-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12759389, http://jnci.oxfordjournals.org/content/95/10/717.full.pdf

219. Karnes, W.E., Epidemiology and etiology of sporadic colorectal adenocarcinoma, Current opinion in Gastroenterology, 1994. 10: p. 19-26.

220. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., et.al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer, N Engl J Med, 2003. 348(10): p. 883-90., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12621132, http://www.nejm.org/doi/pdf/10.1056/NEJMoa021633

221. Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., et.al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 2010. 376(9754): p. 1741-50., http://www.ncbi.nlm.nih.gov/pubmed/20970847

222. Burt, R. W., Screening of patients with a positive family history of colorectal cancer, Gastrointest Endosc Clin N Am, 1997. 7(1): p. 65-79., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8995113

223. Gilbert, J. M., Vaizey, C. J., Cassell, P. G., Holden, J., Feasibility study of colonoscopy as the primary screening investigation in relatives of patients with colorectal cancer, Ann R Coll Surg Engl, 2001. 83(6): p. 415-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11777138, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503678/pdf/annrcse01634-0055.pdf

224. Syrigos, K. N., Charalampopoulos, A., Ho, J. L., Zbar, A., Murday, V. A., Leicester, R. J., Colonoscopy in asymptomatic individuals with a family history of colorectal cancer, Ann Surg Oncol, 2002. 9(5): p. 439-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12052753

225. Bradshaw, N., Holloway, S., Penman, I., Dunlop, M. G., Porteous, M. E., Colonoscopy surveillance of individuals at risk of familial colorectal cancer, Gut, 2003. 52(12): p. 1748-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14633955, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773898/pdf/gut05201748.pdf

226. Brenner, H., Hoffmeister, M., Haug, U., Family history and age at initiation of colorectal cancer screening, Am J Gastroenterol, 2008. 103(9): p. 2326-31., http://www.ncbi.nlm.nih.gov/pubmed/18702651

227. Waldmann, A., Raspe, H., Katalinic, A., [Colon cancer risk in persons at familial or hereditary risk aged < 55 years], Z Gastroenterol, 2009. 47(10): p. 1052-8., http://www.ncbi.nlm.nih.gov/pubmed/19809955

228. Levin, B., Lieberman, D. A., McFarland, B., Andrews, K. S., Brooks, D., Bond, J., et.al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology, Gastroenterology, 2008. 134(5): p. 1570-95., http://www.ncbi.nlm.nih.gov/pubmed/18384785

229. Engel, C., Rahner, N., Schulmann, K., Holinski-Feder, E., Goecke, T. O., Schackert, H. K., et.al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer, Clin Gastroenterol Hepatol, 2010. 8(2): p. 174-82., http://www.ncbi.nlm.nih.gov/pubmed/19835992

230. Dove-Edwin, I., Sasieni, P., Adams, J., Thomas, H. J., Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study, BMJ, 2005. 331(7524): p. 1047., http://www.ncbi.nlm.nih.gov/pubmed/16243849

231. Vasen, H. F., Mecklin, J. P., Khan, P. M., Lynch, H. T., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC), Dis Colon Rectum, 1991. 34(5): p. 424-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2022152

232. Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Jass, J. R., Khan, P. M., et.al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines, J Natl Cancer Inst, 1997. 89(23): p. 1758-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9392616, http://jnci.oxfordjournals.org/content/89/23/1758.full.pdf

233. Schulmann, K., Engel, C., Propping, P., Schmiegel, W., Small bowel cancer risk in Lynch syndrome, Gut, 2008. 57(11): p. 1629-30., http://www.ncbi.nlm.nih.gov/pubmed/18941010

234. ten Kate, G. L., Kleibeuker, J. H., Nagengast, F. M., Craanen, M., Cats, A., Menko, F. H., et.al. Is surveillance of the small bowel indicated for Lynch syndrome families?, Gut, 2007. 56(9): p. 1198-201., http://www.ncbi.nlm.nih.gov/pubmed/17409122

235. Schulmann, K., Brasch, F. E., Kunstmann, E., Engel, C., Pagenstecher, C., Vogelsang, H., et.al. HNPCC-associated small bowel cancer: clinical and molecular characteristics, Gastroenterology, 2005. 128(3): p. 590-9., http://www.ncbi.nlm.nih.gov/pubmed/15765394

236. van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., et.al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers, J Med Genet, 2010. 47(7): p. 464-70., http://www.ncbi.nlm.nih.gov/pubmed/20591884

237. Kastrinos, F., Mukherjee, B., Tayob, N., Wang, F., Sparr, J., Raymond, V. M., et.al. Risk of pancreatic cancer in families with Lynch syndrome, JAMA, 2009. 302(16): p. 1790-5., http://www.ncbi.nlm.nih.gov/pubmed/19861671

238. Korner, H., Soreide, K., Stokkeland, P. J., Soreide, J. A., Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance, J Gastrointest Surg, 2005. 9(3): p. 320-8., http://www.ncbi.nlm.nih.gov/pubmed/15749591

239. Vasen, H. F., Stormorken, A., Menko, F. H., Nagengast, F. M., Kleibeuker, J. H., Griffioen, G., et.al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families, J Clin Oncol, 2001. 19(20): p. 4074-80., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11600610, http://jco.ascopubs.org/content/19/20/4074.long

240. Aarnio, M., Mecklin, J. P., Aaltonen, L. A., Nystrom-Lahti, M., Jarvinen, H. J., Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome, Int J Cancer, 1995. 64(6): p. 430-3., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8550246, http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910640613/abstract

241. Vasen, H. F., Sanders, E. A., Taal, B. G., Nagengast, F. M., Griffioen, G., Menko, F. H., et.al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC), Int J Cancer, 1996. 65(4): p. 422-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8621220, http://onlinelibrary.wiley.com/store/10.1002/(SICI)1097-0215(19960208)65:4<422::AID-IJC4>3.0.CO;2-Z/asset/4_ftp.pdf?v=1&t=ik58o9b4&s=8618fc8160c4d89e7659fa137d063007f96d0656

242. Kruse, R., Rutten, A., Lamberti, C., Hosseiny-Malayeri, H. R., Wang, Y., Ruelfs, C., et.al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria, Am J Hum Genet, 1998. 63(1): p. 63-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9634524, http://ac.els-cdn.com/S0002929707607666/1-s2.0-S0002929707607666-main.pdf?_tid=c2c0f6b2-c986-11e5-989a-00000aacb35d&acdnat=1454401813_c8c362a656871e2bb905c3fe99f1edbe

243. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et.al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, 2004. 96(4): p. 261-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14970275, http://jnci.oxfordjournals.org/content/96/4/261.full.pdf

244. Shia, J., Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry, J Mol Diagn, 2008. 10(4): p. 293-300., http://www.ncbi.nlm.nih.gov/pubmed/18556767

245. Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., et.al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res, 2004. 10(1 Pt 1): p. 191-5., http://www.ncbi.nlm.nih.gov/pubmed/14734469

246. Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., et.al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing, J Med Genet, 2004. 41(9): p. 664-8., http://www.ncbi.nlm.nih.gov/pubmed/15342696

247. McGivern, A., Wynter, C. V., Whitehall, V. L., Kambara, T., Spring, K. J., Walsh, M. D., et.al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer, Fam Cancer, 2004. 3(2): p. 101-7., http://www.ncbi.nlm.nih.gov/pubmed/15340260

248. Levine, A. J., Win, A. K., Buchanan, D. D., Jenkins, M. A., Baron, J. A., Young, J. P., et.al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry, Cancer Prev Res (Phila), 2012. 5(2): p. 328-35., http://www.ncbi.nlm.nih.gov/pubmed/22144422

249. Foulkes, W. D., A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome, QJM, 1995. 88(12): p. 853-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8593545, http://qjmed.oxfordjournals.org/content/88/12/853.long

250. Lynch, H. T., Smyrk, T., McGinn, T., Lanspa, S., Cavalieri, J., Lynch, J., et.al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP, Cancer, 1995. 76(12): p. 2427-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8625067, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19951215)76:12<2427::AID-CNCR2820761205>3.0.CO;2-B/asset/2820761205_ftp.pdf?v=1&t=ik55kafs&s=d50efac1ea4650f49b3dababd6de00b0482b7557

251. Lynch, H. T., Smyrk, T. C., Classification of familial adenomatous polyposis: a diagnostic nightmare, Am J Hum Genet, 1998. 62(6): p. 1288-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9585618, http://ac.els-cdn.com/S0002929707627694/1-s2.0-S0002929707627694-main.pdf?_tid=4898638c-c988-11e5-a803-00000aab0f26&acdnat=1454402467_ef46819bd1e4a848e8b04041cf8d3e27

252. Soravia, C., Berk, T., Madlensky, L., Mitri, A., Cheng, H., Gallinger, S., et.al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli., Am J Hum Genet, 1998. 62: p. 1290-1301., http://ac.els-cdn.com/S0002929707627700/1-s2.0-S0002929707627700-main.pdf?_tid=9e2251fe-c993-11e5-b030-00000aacb361&acdnat=1454407335_64a7b8447a188306740ffd43bf318885

253. Hernegger, G. S., Moore, H. G., Guillem, J. G., Attenuated familial adenomatous polyposis: an evolving and poorly understood entity, Dis Colon Rectum, 2002. 45(1): p. 127-34; discussion 134-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11786778

254. Knudsen, A. L., Bisgaard, M. L., Bulow, S., Attenuated familial adenomatous polyposis (AFAP). A review of the literature, Fam Cancer, 2003. 2(1): p. 43-55., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14574166

255. Al-Tassan, N., Chmiel, N. H., Maynard, J., Fleming, N., Livingston, A. L., Williams, G. T., et.al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors, Nat Genet, 2002. 30(2): p. 227-32., http://www.ncbi.nlm.nih.gov/pubmed/11818965

256. Cao, Y., Pieretti, M., Marshall, J., Khattar, N. H., Chen, B., Kam-Morgan, L., et.al. Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature, Am J Gastroenterol, 2002. 97(7): p. 1822-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12135043

257. Aretz, S., The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes, Dtsch Arztebl Int, 2010. 107(10): p. 163-73., http://www.ncbi.nlm.nih.gov/pubmed/20358032

258. Aretz, S., Genuardi, M., Hes, F. J., Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis.Eur J Hum Genet., 2012.

259. Sampson, J. R., Jones, N., MUTYH-associated polyposis, Best Pract Res Clin Gastroenterol, 2009. 23(2): p. 209-18., http://www.ncbi.nlm.nih.gov/pubmed/19414147

260. Morreau, H., Riddel, R., Aretz, S., MUTYH-associated polyposis., in WHO Classification of Tumours of the Digestive System, Bosman, F.T.Carneiro, F.Hruban, R.H. and Theise, N.D., Editors. 2010, IARC/ WHO Press: Lyon. 3: p. 156-159.

261. Aretz, S., Uhlhaas, S., Goergens, H., Siberg, K., Vogel, M., Pagenstecher, C., et.al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype, Int J Cancer, 2006. 119(4): p. 807-14., http://www.ncbi.nlm.nih.gov/pubmed/16557584

262. Lubbe, S. J., Di Bernardo, M. C., Chandler, I. P., Houlston, R. S., Clinical implications of the colorectal cancer risk associated with MUTYH mutation, J Clin Oncol, 2009. 27(24): p. 3975-80., http://www.ncbi.nlm.nih.gov/pubmed/19620482

263. Cleary, S. P., Cotterchio, M., Jenkins, M. A., Kim, H., Bristow, R., Green, R., et.al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study, Gastroenterology, 2009. 136(4): p. 1251-60., http://www.ncbi.nlm.nih.gov/pubmed/19245865

264. Boparai, K. S., Dekker, E., Van Eeden, S., Polak, M. M., Bartelsman, J. F., Mathus-Vliegen, E. M., et.al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis, Gastroenterology, 2008. 135(6): p. 2014-8., http://www.ncbi.nlm.nih.gov/pubmed/19013464

265. Vogt, S., Jones, N., Christian, D., Engel, C., Nielsen, M., Kaufmann, A., et.al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis, Gastroenterology, 2009. 137(6): p. 1976-85 e1-10., http://www.ncbi.nlm.nih.gov/pubmed/19732775

266. Papadopoulos, N., Lindblom, A., Molecular basis of HNPCC: mutations of MMR genes., Hum Mut, 1997. 10: p. 89-99., http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1098-1004(1997)10:2%3C89::AID-HUMU1%3E3.0.CO;2-H/abstract?wol1URL=/doi/10.1002/(SICI)1098-1004(1997)10:2%3C89::AID-HUMU1%3E3.0.CO;2-H/abstract®ionCode=DE-NW&identityKey=1a157281-943f-4140-8aef-5a4303331978, http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1098-1004(1997)10:2%3C89::AID-HUMU1%3E3.0.CO;2-H/abstract?wol1URL=/doi/10.1002/(SICI)1098-1004(1997)10:2%3C89::AID-HUMU1%3E3.0.CO;2-H/abstract&wol1URL=/doi/10.1002/(SICI)1098-1004(1997)10:2%3C89::AID-HUMU1%3E3.0.CO&2-H/abstract®ionCode=DE-NW&identityKey=1a157281-943f-4140-8aef-5a4303331978

267. Kuiper, R. P., Vissers, L. E., Venkatachalam, R., Bodmer, D., Hoenselaar, E., Goossens, M., et.al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome, Hum Mutat, 2011. 32(4): p. 407-14., http://www.ncbi.nlm.nih.gov/pubmed/21309036

268. Jarvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., Peltomaki, P., et.al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer, Gastroenterology, 2000. 118(5): p. 829-34., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10784581

269. de Vos tot Nederveen Cappel, W. H., Nagengast, F. M., Griffioen, G., Menko, F. H., Taal, B. G., Kleibeuker, J. H., et.al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families, Dis Colon Rectum, 2002. 45(12): p. 1588-94., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12473880

270. Edelstein, D. L., Axilbund, J., Baxter, M., Hylind, L. M., Romans, K., Griffin, C. A., et.al. Rapid development of colorectal neoplasia in patients with Lynch syndrome, Clin Gastroenterol Hepatol, 2011. 9(4): p. 340-3., http://www.ncbi.nlm.nih.gov/pubmed/21070872

271. Renkonen-Sinisalo, L., Aarnio, M., Mecklin, J. P., Jarvinen, H. J., Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer, Cancer Detect Prev, 2000. 24(2): p. 137-42., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10917133

272. Huneburg, R., Lammert, F., Rabe, C., Rahner, N., Kahl, P., Buttner, R., et.al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening, Endoscopy, 2009. 41(4): p. 316-22., http://www.ncbi.nlm.nih.gov/pubmed/19340735

273. Stoffel, E. M., Turgeon, D. K., Stockwell, D. H., Zhao, L., Normolle, D. P., Tuck, M. K., et.al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer), Cancer Prev Res (Phila), 2008. 1(6): p. 470-5., http://www.ncbi.nlm.nih.gov/pubmed/19138994

274. Hurlstone, D. P., Brown, S., Cross, S. S., Shorthouse, A. J., Sanders, D. S., High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: a comparative prospective analysis, Gut, 2005. 54(11): p. 1585-9., http://www.ncbi.nlm.nih.gov/pubmed/15964906

275. Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., et.al. Cancer risk in mutation carriers of DNA-mismatch-repair genes, Int J Cancer, 1999. 81(2): p. 214-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10188721, http://onlinelibrary.wiley.com/store/10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L/asset/8_ftp.pdf?v=1&t=ik512orz&s=6de1d9c4242eaa77352818b1bf5b4bc6c613b830

276. Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et.al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma, Cancer, 2002. 94(6): p. 1708-12., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11920532, http://onlinelibrary.wiley.com/store/10.1002/cncr.10380/asset/10380_ftp.pdf?v=1&t=ik52cjjr&s=d47538683c10bb8f5aa6094ecc41ddabb64632fe

277. Rijcken, F. E., Mourits, M. J., Kleibeuker, J. H., Hollema, H., van der Zee, A. G., Gynecologic screening in hereditary nonpolyposis colorectal cancer, Gynecol Oncol, 2003. 91(1): p. 74-80., http://www.ncbi.nlm.nih.gov/pubmed/14529665

278. Renkonen-Sinisalo, L., Butzow, R., Leminen, A., Lehtovirta, P., Mecklin, J. P., Jarvinen, H. J., Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome, Int J Cancer, 2007. 120(4): p. 821-4., http://www.ncbi.nlm.nih.gov/pubmed/17096354

279. Vasen, H. F., Moslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., et.al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer), J Med Genet, 2007. 44(6): p. 353-62., http://www.ncbi.nlm.nih.gov/pubmed/17327285

280. Goecke, T., Schulmann, K., Engel, C., Holinski-Feder, E., Pagenstecher, C., Schackert, H. K., et.al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium, J Clin Oncol, 2006. 24(26): p. 4285-92., http://www.ncbi.nlm.nih.gov/pubmed/16908935

281. Burn, J., Bishop, D. T., Mecklin, J. P., Macrae, F., Moslein, G., Olschwang, S., et.al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome, N Engl J Med, 2008. 359(24): p. 2567-78., http://www.ncbi.nlm.nih.gov/pubmed/19073976

282. Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., et.al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial, Lancet, 2011. 378(9809): p. 2081-7., http://www.ncbi.nlm.nih.gov/pubmed/22036019

283. Natarajan, N., Watson, P., Silva-Lopez, E., Lynch, H. T., Comparison of extended colectomy and limited resection in patients with Lynch syndrome, Dis Colon Rectum, 2010. 53(1): p. 77-82., http://www.ncbi.nlm.nih.gov/pubmed/20010355

284. Kalady, M. F., McGannon, E., Vogel, J. D., Manilich, E., Fazio, V. W., Church, J. M., Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria, Ann Surg, 2010. 252(3): p. 507-11; discussion 511-3., http://www.ncbi.nlm.nih.gov/pubmed/20739851

285. Parry, S., Win, A. K., Parry, B., Macrae, F. A., Gurrin, L. C., Church, J. M., et.al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery, Gut, 2011. 60(7): p. 950-7., http://www.ncbi.nlm.nih.gov/pubmed/21193451

286. Stupart, D. A., Goldberg, P. A., Baigrie, R. J., Algar, U., Ramesar, R., Surgery for colonic cancer in HNPCC: total vs segmental colectomy, Colorectal Dis, 2011. 13(12): p. 1395-9., http://www.ncbi.nlm.nih.gov/pubmed/20969713

287. Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et.al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome, N Engl J Med, 2006. 354(3): p. 261-9., http://www.ncbi.nlm.nih.gov/pubmed/16421367

288. Church, J. M., McGannon, E., Burke, C., Clark, B., Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?, Dis Colon Rectum, 2002. 45(7): p. 887-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12130875

289. King, J. E., Dozois, R. R., Lindor, N. M., Ahlquist, D. A., Care of patients and their families with familial adenomatous polyposis, Mayo Clin Proc, 2000. 75(1): p. 57-67., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10630758, http://www.mayoclinicproceedings.org/article/S0025-6196(11)64256-0/abstract

290. Bertario, L., Presciuttini, S., Sala, P., Rossetti, C., Pietroiusti, M., Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee, Semin Surg Oncol, 1994. 10(3): p. 225-34., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8085100

291. Galle, T. S., Juel, K., Bulow, S., Causes of death in familial adenomatous polyposis, Scand J Gastroenterol, 1999. 34(8): p. 808-12., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10499482

292. Heiskanen, I., Luostarinen, T., Jarvinen, H. J., Impact of screening examinations on survival in familial adenomatous polyposis, Scand J Gastroenterol, 2000. 35(12): p. 1284-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11199368

293. Vasen, H. F., van Duijvendijk, P., Buskens, E., Bulow, C., Bjork, J., Jarvinen, H. J., et.al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients, Gut, 2001. 49(2): p. 231-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11454800, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728380/pdf/v049p00231.pdf

294. Bulow, S., Results of national registration of familial adenomatous polyposis, Gut, 2003. 52(5): p. 742-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12692062, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773626/pdf/gut05200742.pdf

295. Ficari, F., Cama, A., Valanzano, R., Curia, M. C., Palmirotta, R., Aceto, G., et.al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis, Br J Cancer, 2000. 82(2): p. 348-53., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10646887, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363293/pdf/82-6690925a.pdf

296. Bulow, S., Clinical features in familial polyposis coli. Results of the Danish Polyposis Register, Dis Colon Rectum, 1986. 29(2): p. 102-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3943418

297. De Cosse, J. J., Bulow, S., Neale, K., Jarvinen, H., Alm, T., Hultcrantz, R., et.al. Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group, Br J Surg, 1992. 79(12): p. 1372-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1336702, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800791245/abstract

298. Nyam, D. C., Brillant, P. T., Dozois, R. R., Kelly, K. A., Pemberton, J. H., Wolff, B. G., Ileal pouch-anal canal anastomosis for familial adenomatous polyposis: early and late results, Ann Surg, 1997. 226(4): p. 514-9; discussion 519-21., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9351719, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1191071/pdf/annsurg00020-0132.pdf

299. Parc, Y. R., Moslein, G., Dozois, R. R., Pemberton, J. H., Wolff, B. G., King, J. E., Familial adenomatous polyposis: results after ileal pouch-anal anastomosis in teenagers, Dis Colon Rectum, 2000. 43(7): p. 893-8; discussion 898-902., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10910233

300. Van Duijvendijk, P., Slors, J. F., Taat, C. W., Oosterveld, P., Sprangers, M. A., Obertop, H., et.al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis, Br J Surg, 2000. 87(5): p. 590-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10792315, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.2000.01442.x/abstract

301. Church, J., Burke, C., McGannon, E., Pastean, O., Clark, B., Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options, Dis Colon Rectum, 2003. 46(9): p. 1175-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12972960

302. Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., Delatycki, M. B., The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis, Fam Cancer, 2010. 9(1): p. 27-35., http://www.ncbi.nlm.nih.gov/pubmed/19760114

303. Douma, K. F., Aaronson, N. K., Vasen, H. F., Bleiker, E. M., Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature, Psychooncology, 2008. 17(8): p. 737-45., http://www.ncbi.nlm.nih.gov/pubmed/18613296

304. Will, O. C., Man, R. F., Phillips, R. K., Tomlinson, I. P., Clark, S. K., Familial adenomatous polyposis and the small bowel: a loco-regional review and current management strategies, Pathol Res Pract, 2008. 204(7): p. 449-58., http://www.ncbi.nlm.nih.gov/pubmed/18538945

305. Spigelman, A. D., Williams, C. B., Talbot, I. C., Domizio, P., Phillips, R. K., Upper gastrointestinal cancer in patients with familial adenomatous polyposis, Lancet, 1989. 2(8666): p. 783-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2571019, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(89)90840-4/abstract

306. Douma, K. F., Aaronson, N. K., Vasen, H. F., Gerritsma, M. A., Gundy, C. M., Janssen, E. P., et.al. Psychological distress and use of psychosocial support in familial adenomatous polyposis, Psychooncology, 2010. 19(3): p. 289-98., http://www.ncbi.nlm.nih.gov/pubmed/19382100

307. Burke, C. A., Beck, G. J., Church, J. M., van Stolk, R. U., The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program, Gastrointest Endosc, 1999. 49(3 Pt 1): p. 358-64., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10049420

308. Matsumoto, T., Iida, M., Nakamura, S., Hizawa, K., Yao, T., Tsuneyoshi, M., et.al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance, Am J Gastroenterol, 2000. 95(6): p. 1557-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10894596

309. Moozar, K. L., Madlensky, L., Berk, T., Gallinger, S., Slow progression of periampullary neoplasia in familial adenomatous polyposis, J Gastrointest Surg, 2002. 6(6): p. 831-7; discussion 837., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12504221

310. Saurin, J. C., Ligneau, B., Ponchon, T., Lepretre, J., Chavaillon, A., Napoleon, B., et.al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis, Gastrointest Endosc, 2002. 55(3): p. 342-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11868006, http://www.giejournal.org/article/S0016-5107(02)43810-2/abstract

311. Saurin, J. C., Gutknecht, C., Napoleon, B., Chavaillon, A., Ecochard, R., Scoazec, J. Y., et.al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease, J Clin Oncol, 2004. 22(3): p. 493-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14752072, http://jco.ascopubs.org/content/22/3/493.full.pdf

312. Vasen, H.F., Bülow, S., Myrhøj, T., Mathus-Vliegen, L., Griffioen, G., Buskens, E., et.al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis., Gut, 1997. 40: p. 716-9., http://gut.bmj.com/content/40/6/716.full.pdf

313. Bulow, S., Bjork, J., Christensen, I. J., Fausa, O., Jarvinen, H., Moesgaard, F., et.al. Duodenal adenomatosis in familial adenomatous polyposis, Gut, 2004. 53(3): p. 381-6., http://www.ncbi.nlm.nih.gov/pubmed/14960520

314. Kadmon, M., Tandara, A., Herfarth, C., Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register, Int J Colorectal Dis, 2001. 16(2): p. 63-75., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11355321

315. Norton, I. D., Gostout, C. J., Baron, T. H., Geller, A., Petersen, B. T., Wiersema, M. J., Safety and outcome of endoscopic snare excision of the major duodenal papilla, Gastrointest Endosc, 2002. 56(2): p. 239-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12145603

316. Kalady, M. F., Clary, B. M., Tyler, D. S., Pappas, T. N., Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis, J Gastrointest Surg, 2002. 6(1): p. 82-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11986022

317. Parc, Y., Mabrut, J. Y., Shields, C., Surgical management of the duodenal manifestations of familial adenomatous polyposis, Br J Surg, 2011. 98(4): p. 480-4., http://www.ncbi.nlm.nih.gov/pubmed/21656714

318. de Vos tot Nederveen Cappel, W. H., Jarvinen, H. J., Bjork, J., Berk, T., Griffioen, G., Vasen, H. F., Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis, Br J Surg, 2003. 90(6): p. 705-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12808618, http://onlinelibrary.wiley.com/doi/10.1002/bjs.4094/abstract

319. Heiskanen, I., Kellokumpu, I., Jarvinen, H., Management of duodenal adenomas in 98 patients with familial adenomatous polyposis, Endoscopy, 1999. 31(6): p. 412-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10494676, https://www.thieme-connect.com/DOI/DOI?10.1055/s-1999-41

320. Norton, I. D., Geller, A., Petersen, B. T., Sorbi, D., Gostout, C. J., Endoscopic surveillance and ablative therapy for periampullary adenomas, Am J Gastroenterol, 2001. 96(1): p. 101-6., http://www.ncbi.nlm.nih.gov/pubmed/11197237

321. Bleau, B. L., Gostout, C. J., Endoscopic treatment of ampullary adenomas in familial adenomatous polyposis, J Clin Gastroenterol, 1996. 22(3): p. 237-41., http://www.ncbi.nlm.nih.gov/pubmed/8724267

322. Soravia, C., Berk, T., McLeod, R. S., Cohen, Z., Desmoid disease in patients with familial adenomatous polyposis, Dis Colon Rectum, 2000. 43(3): p. 363-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10733118

323. Bertario, L., Russo, A., Sala, P., Varesco, L., Giarola, M., Mondini, P., et.al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis, J Clin Oncol, 2003. 21(9): p. 1698-707., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12721244, http://jco.ascopubs.org/content/21/9/1698.long

324. Friedl, W., Caspari, R., Sengteller, M., Uhlhaas, S., Lamberti, C., Jungck, M., et.al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families, Gut, 2001. 48(4): p. 515-21., http://www.ncbi.nlm.nih.gov/pubmed/11247896

325. Janinis, J., Patriki, M., Vini, L., Aravantinos, G., Whelan, J. S., The pharmacological treatment of aggressive fibromatosis: a systematic review, Ann Oncol, 2003. 14(2): p. 181-90., http://www.ncbi.nlm.nih.gov/pubmed/12562642

326. Tonelli, F., Ficari, F., Valanzano, R., Brandi, M. L., Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene, Tumori, 2003. 89(4): p. 391-6., http://www.ncbi.nlm.nih.gov/pubmed/14606641

327. Gega, M., Yanagi, H., Yoshikawa, R., Noda, M., Ikeuchi, H., Tsukamoto, K., et.al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis, J Clin Oncol, 2006. 24(1): p. 102-5., http://www.ncbi.nlm.nih.gov/pubmed/16382119

328. Skapek, S. X., Ferguson, W. S., Granowetter, L., Devidas, M., Perez-Atayde, A. R., Dehner, L. P., et.al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial, J Clin Oncol, 2007. 25(5): p. 501-6., http://www.ncbi.nlm.nih.gov/pubmed/17290057

329. Latchford, A. R., Sturt, N. J., Neale, K., Rogers, P. A., Phillips, R. K., A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis, Br J Surg, 2006. 93(10): p. 1258-64., http://www.ncbi.nlm.nih.gov/pubmed/16952208

330. Möslein, G., Current ideas in desmoid tumours: invited commentary, Fam Cancer, 2006. 5: p. 287-288.

331. Clark, S. K., Phillips, R. K., Desmoids in familial adenomatous polyposis, Br J Surg, 1996. 83(11): p. 1494-504., http://www.ncbi.nlm.nih.gov/pubmed/9014661

332. Huang, K., Fu, H., Shi, Y. Q., Zhou, Y., Du, C. Y., Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution, J Surg Oncol, 2009. 100(7): p. 563-9., http://www.ncbi.nlm.nih.gov/pubmed/19722232

333. Salas, S., Dufresne, A., Bui, B., Blay, J. Y., Terrier, P., Ranchere-Vince, D., et.al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation, J Clin Oncol, 2011. 29(26): p. 3553-8., http://www.ncbi.nlm.nih.gov/pubmed/21844500

334. Nieuwenhuis, M. H., Mathus-Vliegen, E. M., Baeten, C. G., Nagengast, F. M., van der Bijl, J., van Dalsen, A. D., et.al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients, Br J Cancer, 2011. 104(1): p. 37-42., http://www.ncbi.nlm.nih.gov/pubmed/21063417

335. Bulow, C., Bulow, S., Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group, Int J Colorectal Dis, 1997. 12(4): p. 240-2., http://www.ncbi.nlm.nih.gov/pubmed/9272455

336. Jarrar, A. M., Milas, M., Mitchell, J., Laguardia, L., O'Malley, M., Berber, E., et.al. Screening for thyroid cancer in patients with familial adenomatous polyposis, Ann Surg, 2011. 253(3): p. 515-21., http://www.ncbi.nlm.nih.gov/pubmed/21173694

337. Martayan, A., Sanchez-Mete, L., Baldelli, R., Falvo, E., Barnabei, A., Conti, L., et.al. Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation, J Endocrinol Invest, 2010. 33(9): p. 603-6., http://www.ncbi.nlm.nih.gov/pubmed/20935450

338. Herraiz, M., Barbesino, G., Faquin, W., Chan-Smutko, G., Patel, D., Shannon, K. M., et.al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations, Clin Gastroenterol Hepatol, 2007. 5(3): p. 367-73., http://www.ncbi.nlm.nih.gov/pubmed/17258512

339. Bell, B., Mazzaferri, E. L., Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature, Dig Dis Sci, 1993. 38(1): p. 185-90., http://www.ncbi.nlm.nih.gov/pubmed/8420756

340. Perrier, N. D., van Heerden, J. A., Goellner, J. R., Williams, E. D., Gharib, H., Marchesa, P., et.al. Thyroid cancer in patients with familial adenomatous polyposis, World J Surg, 1998. 22(7): p. 738-42; discussion 743., http://www.ncbi.nlm.nih.gov/pubmed/9606291

341. Hughes, L. J., Michels, V. V., Risk of hepatoblastoma in familial adenomatous polyposis, Am J Med Genet, 1992. 43(6): p. 1023-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1329510, http://onlinelibrary.wiley.com/doi/10.1002/ajmg.1320430621/abstract

342. Thomas, D., Pritchard, J., Davidson, R., McKiernan, P., Grundy, R. G., de Ville de Goyet, J., Familial hepatoblastoma and APC gene mutations: renewed call for molecular research, Eur J Cancer, 2003. 39(15): p. 2200-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14522379, http://www.ejcancer.com/article/S0959-8049(03)00618-X/abstract

343. Aretz, S., Koch, A., Uhlhaas, S., Friedl, W., Propping, P., von Schweinitz, D., et.al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?, Pediatr Blood Cancer, 2006. 47(6): p. 811-8., http://www.ncbi.nlm.nih.gov/pubmed/16317745

344. Vasen, H. F., Moslein, G., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., et.al. Guidelines for the clinical management of familial adenomatous polyposis (FAP), Gut, 2008. 57(5): p. 704-13., http://www.ncbi.nlm.nih.gov/pubmed/18194984

345. Waddell, W. R., Loughry, R. W., Sulindac for polyposis of the colon, J Surg Oncol, 1983. 24(1): p. 83-7., http://www.ncbi.nlm.nih.gov/pubmed/6887943

346. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., et.al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis, Gastroenterology, 1991. 101(3): p. 635-9., http://www.ncbi.nlm.nih.gov/pubmed/1650315

347. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., et.al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis, N Engl J Med, 1993. 328(18): p. 1313-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8385741, http://www.nejm.org/doi/pdf/10.1056/NEJM199305063281805

348. Cruz-Correa, M., Hylind, L. M., Romans, K. E., Booker, S. V., Giardiello, F. M., Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study, Gastroenterology, 2002. 122(3): p. 641-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11874996, http://www.gastrojournal.org/article/S0016-5085(02)83373-X/pdf

349. Winde, G., Schmid, K.W., Schlegel, W., Fischer, R., Osswald, H., Bunte, H., Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months., Dis Colon Rectum, 1995. 38(8): p. 813-30.

350. Giardiello, F. M., Yang, V. W., Hylind, L. M., Krush, A. J., Petersen, G. M., Trimbath, J. D., et.al. Primary chemoprevention of familial adenomatous polyposis with sulindac, N Engl J Med, 2002. 346(14): p. 1054-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11932472, http://www.nejm.org/doi/pdf/10.1056/NEJMoa012015

351. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., et.al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 2000. 342(26): p. 1946-52., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10874062, http://www.nejm.org/doi/pdf/10.1056/NEJM200006293422603

352. Phillips, R. K., Wallace, M. H., Lynch, P. M., Hawk, E., Gordon, G. B., Saunders, B. P., et.al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis, Gut, 2002. 50(6): p. 857-60., http://www.ncbi.nlm.nih.gov/pubmed/12010890

353. Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., et.al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis, Circulation, 2008. 117(16): p. 2104-13., http://www.ncbi.nlm.nih.gov/pubmed/18378608

354. Matsuo, S., Eguchi, S., Azuma, T., Hidaka, M., Yamaguchi, S., Hayashi, T., et.al. Attenuated familial adenomatous polyposis associated with advanced rectal cancer in a 16-year-old boy: report of a case, Surg Today, 2001. 31(11): p. 1020-3., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11766074

355. Leggett, B. A., Young, J. P., Biden, K., Buttenshaw, R. L., Knight, N., Cowen, A. E., Severe upper gastrointestinal polyposis associated with sparse colonic polyposis in a familial adenomatous polyposis family with an APC mutation at codon 1520, Gut, 1997. 41(4): p. 518-21., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9391252, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891546/pdf/v041p00518.pdf

356. Zwick, A., Munir, M., Ryan, C. K., Gian, J., Burt, R. W., Leppert, M., et.al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli, Gastroenterology, 1997. 113(2): p. 659-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9247488, http://www.gastrojournal.org/article/S0016-5085(97)00393-4/pdf

357. Hofgartner, W. T., Thorp, M., Ramus, M. W., Delorefice, G., Chey, W. Y., Ryan, C. K., et.al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis, Am J Gastroenterol, 1999. 94(8): p. 2275-81., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10445562

358. Jones, N., Vogt, S., Nielsen, M., Christian, D., Wark, P. A., Eccles, D., et.al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH, Gastroenterology, 2009. 137(2): p. 489-94, 494 e1; quiz 725-6., http://www.ncbi.nlm.nih.gov/pubmed/19394335

359. Farrington, S. M., Tenesa, A., Barnetson, R., Wiltshire, A., Prendergast, J., Porteous, M., et.al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects, Am J Hum Genet, 2005. 77(1): p. 112-9., http://www.ncbi.nlm.nih.gov/pubmed/15931596

360. Nielsen, M., Joerink-van de Beld, M. C., Jones, N., Vogt, S., Tops, C. M., Vasen, H. F., et.al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis, Gastroenterology, 2009. 136(2): p. 471-6., http://www.ncbi.nlm.nih.gov/pubmed/19032956

361. Nascimbeni, R., Pucciarelli, S., Di Lorenzo, D., Urso, E., Casella, C., Agostini, M., et.al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis, Dis Colon Rectum, 2010. 53(12): p. 1670-5., http://www.ncbi.nlm.nih.gov/pubmed/21178863

362. Nielsen, M., Poley, J. W., Verhoef, S., van Puijenbroek, M., Weiss, M. M., Burger, G. T., et.al. Duodenal carcinoma in MUTYH-associated polyposis, J Clin Pathol, 2006. 59(11): p. 1212-5., http://www.ncbi.nlm.nih.gov/pubmed/16943222

363. Zbuk, K. M., Eng, C., Hamartomatous polyposis syndromes, Nat Clin Pract Gastroenterol Hepatol, 2007. 4(9): p. 492-502., http://www.ncbi.nlm.nih.gov/pubmed/17768394

364. Aretz, S., Stienen, D., Uhlhaas, S., Loff, S., Back, W., Pagenstecher, C., et.al. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome, Hum Mutat, 2005. 26(6): p. 513-9., http://www.ncbi.nlm.nih.gov/pubmed/16287113

365. Hinds, R., Philp, C., Hyer, W., Fell, J. M., Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening, J Pediatr Gastroenterol Nutr, 2004. 39(2): p. 219-20., http://www.ncbi.nlm.nih.gov/pubmed/15269641

366. Reid, J. D., Intestinal carcinoma in the Peutz-Jeghers syndrome, Jama, 1974. 229(7): p. 833-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=4407824, http://jama.jamanetwork.com/article.aspx?articleid=356230

367. Burdick, D., Prior, J. T., Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 27-year follow-up, Cancer, 1982. 50(10): p. 2139-46., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7127254, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19821115)50:10<2139::AID-CNCR2820501028>3.0.CO;2-K/asset/2820501028_ftp.pdf?v=1&t=ik51tlv8&s=e00a359ed1efe1c7b8d60f9f033c6346fa2aef23

368. Giardiello, F.M., Welsh, S.B., Hamilton, S.R., Ofehaus, G.J., Gittelsohn, A.M., Booker, S.V., et.al. Increased risk of cancer in the Peutz-Jeghers syndrome, N Engl J Med, 1987. 316(24): p. 1511-4.

369. Foley, T. R., McGarrity, T. J., Abt, A. B., Peutz-Jeghers syndrome: a clinicopathologic survey of the "Harrisburg family" with a 49-year follow-up, Gastroenterology, 1988. 95(6): p. 1535-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3181678

370. Spigelman, A. D., Murday, V., Phillips, R. K., Cancer and the Peutz-Jeghers syndrome, Gut, 1989. 30(11): p. 1588-90., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2599445, http://gut.bmj.com/content/30/11/1588.full.pdf

371. Hizawa, K., Iida, M., Matsumoto, T., Kohrogi, N., Yao, T., Fujishima, M., Neoplastic transformation arising in Peutz-Jeghers polyposis., Dis Colon Rectum, 1993. 36: p. 953-57.

372. Boardman, L. A., Thibodeau, S. N., Schaid, D. J., Lindor, N. M., McDonnell, S. K., Burgart, L. J., et.al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome, Ann Intern Med, 1998. 128(11): p. 896-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9634427, http://annals.org/article.aspx?articleid=711451

373. Mehenni, H., Resta, N., Park, J. G., Miyaki, M., Guanti, G., Costanza, M. C., Cancer risks in LKB1 germline mutation carriers, Gut, 2006. 55(7): p. 984-90., http://www.ncbi.nlm.nih.gov/pubmed/16407375

374. Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., et.al. Very high risk of cancer in familial Peutz-Jeghers syndrome, Gastroenterology, 2000. 119(6): p. 1447-53., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11113065, http://www.gastrojournal.org/article/S0016-5085(00)78005-X/pdf

375. Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J., et.al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome, Clin Cancer Res, 2006. 12(10): p. 3209-15., http://www.ncbi.nlm.nih.gov/pubmed/16707622

376. Sweet, K., Willis, J., Zhou, X. P., Gallione, C., Sawada, T., Alhopuro, P., et.al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis, JAMA, 2005. 294(19): p. 2465-73., http://www.ncbi.nlm.nih.gov/pubmed/16287957

377. Aretz, S., Stienen, D., Uhlhaas, S., Stolte, M., Entius, M. M., Loff, S., et.al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome, J Med Genet, 2007. 44(11): p. 702-9., http://www.ncbi.nlm.nih.gov/pubmed/17873119

378. Gallione, C. J., Repetto, G. M., Legius, E., Rustgi, A. K., Schelley, S. L., Tejpar, S., et.al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4), Lancet, 2004. 363(9412): p. 852-9., http://www.ncbi.nlm.nih.gov/pubmed/15031030

379. Watanabe, A., Nagashima, H., Motoi, M., Ogawa, K., Familial juvenile polyposis of the stomach, Gastroenterology, 1979. 77(1): p. 148-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=447014

380. Jass, J. R., Williams, C. B., Bussey, H. J., Morson, B. C., Juvenile polyposis--a precancerous condition, Histopathology, 1988. 13(6): p. 619-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2853131, http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.1988.tb02093.x/abstract

381. Sassatelli, R., Bertoni, G., Serra, L., Bedogni, G., Ponz de Leon, M., Generalized juvenile polyposis with mixed pattern and gastric cancer, Gastroenterology, 1993. 104(3): p. 910-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8440442

382. Coburn, M. C., Pricolo, V. E., DeLuca, F. G., Bland, K. I., Malignant potential in intestinal juvenile polyposis syndromes, Ann Surg Oncol, 1995. 2(5): p. 386-91., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7496832

383. Desai, D. C., Neale, K. F., Talbot, I. C., Hodgson, S. V., Phillips, R. K., Juvenile polyposis, Br J Surg, 1995. 82(1): p. 14-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7881943, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800820106/abstract

384. Delnatte, C., Sanlaville, D., Mougenot, J. F., Vermeesch, J. R., Houdayer, C., Blois, M. C., et.al. Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes, Am J Hum Genet, 2006. 78(6): p. 1066-74., http://www.ncbi.nlm.nih.gov/pubmed/16685657

385. Hobert, J. A., Eng, C., PTEN hamartoma tumor syndrome: an overview, Genet Med, 2009. 11(10): p. 687-94., http://www.ncbi.nlm.nih.gov/pubmed/19668082

386. Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., Eng, C., Lifetime cancer risks in individuals with germline PTEN mutations, Clin Cancer Res, 2012. 18(2): p. 400-7., http://www.ncbi.nlm.nih.gov/pubmed/22252256

387. Orloff, M. S., Eng, C., Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome, Oncogene, 2008. 27(41): p. 5387-97., http://www.ncbi.nlm.nih.gov/pubmed/18794875

388. Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F., et.al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome, Hum Mol Genet, 1999. 8(8): p. 1461-72., http://www.ncbi.nlm.nih.gov/pubmed/10400993

389. Jeevaratnam, P., Cottier, D. S., Browett, P. J., Van De Water, N. S., Pokos, V., Jass, J. R., Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome, J Pathol, 1996. 179(1): p. 20-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8691339, http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-9896(199605)179:1<20::AID-PATH538>3.0.CO;2-C/abstract

390. Leggett, B. A., Devereaux, B., Biden, K., Searle, J., Young, J., Jass, J., Hyperplastic polyposis: association with colorectal cancer, Am J Surg Pathol, 2001. 25(2): p. 177-84., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11176066

391. Renaut, A. J., Douglas, P. R., Newstead, G. L., Hyperplastic polyposis of the colon and rectum, Colorectal Dis, 2002. 4(3): p. 213-215., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12780620

392. Jaeger, E. E., Woodford-Richens, K. L., Lockett, M., Rowan, A. J., Sawyer, E. J., Heinimann, K., et.al. An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome, Am J Hum Genet, 2003. 72(5): p. 1261-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12696020, http://ac.els-cdn.com/S0002929707606521/1-s2.0-S0002929707606521-main.pdf?_tid=d4fc4a2e-c97d-11e5-9346-00000aacb361&acdnat=1454397978_8d142bbf133c93bbb1ffee68c4985e3b

393. Rozen, P., Samuel, Z., Brazowski, E., A prospective study of the clinical, genetic, screening, and pathologic features of a family with hereditary mixed polyposis syndrome, Am J Gastroenterol, 2003. 98(10): p. 2317-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14572586

394. Beggs, A. D., Latchford, A. R., Vasen, H. F., Moslein, G., Alonso, A., Aretz, S., et.al. Peutz-Jeghers syndrome: a systematic review and recommendations for management, Gut, 2010. 59(7): p. 975-86., http://www.ncbi.nlm.nih.gov/pubmed/20581245

395. Dignass, A., Preiss, J. C., Aust, D. E., Autschbach, F., Ballauff, A., Barretton, G., et.al. [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011], Z Gastroenterol, 2011. 49(9): p. 1276-341., http://www.ncbi.nlm.nih.gov/pubmed/21866493

396. Collins, P. D., Mpofu, C., Watson, A. J., Rhodes, J. M., Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease, Cochrane Database Syst Rev, 2006. p. CD000279., http://www.ncbi.nlm.nih.gov/pubmed/16625534

397. Rutter, M. D., Saunders, B. P., Wilkinson, K. H., Rumbles, S., Schofield, G., Kamm, M. A., et.al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis, Gastroenterology, 2006. 130(4): p. 1030-8., http://www.ncbi.nlm.nih.gov/pubmed/16618396

398. Lim, C. H., Dixon, M. F., Vail, A., Forman, D., Lynch, D. A., Axon, A. T., Ten year follow up of ulcerative colitis patients with and without low grade dysplasia, Gut, 2003. 52(8): p. 1127-32., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12865270, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773763/pdf/gut05201127.pdf

399. Connell, W. R., Lennard-Jones, J. E., Williams, C. B., Talbot, I. C., Price, A. B., Wilkinson, K. H., Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis, Gastroenterology, 1994. 107(4): p. 934-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7926483

400. Claessen, M. M., Lutgens, M. W., van Buuren, H. R., Oldenburg, B., Stokkers, P. C., van der Woude, C. J., et.al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis, Inflamm Bowel Dis, 2009. 15(9): p. 1331-6., http://www.ncbi.nlm.nih.gov/pubmed/19229982

401. Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., Blackstone, M. O., Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis, Gastrointest Endosc, 2002. 56(1): p. 48-54., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12085034, http://www.giejournal.org/article/S0016-5107(02)00006-8/abstract

402. Scarpa, M., van Koperen, P. J., Ubbink, D. T., Hommes, D. W., Ten Kate, F. J., Bemelman, W. A., Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis, Br J Surg, 2007. 94(5): p. 534-45., http://www.ncbi.nlm.nih.gov/pubmed/17443850

403. Lutgens, M. W., Vleggaar, F. P., Schipper, M. E., Stokkers, P. C., van der Woude, C. J., Hommes, D. W., et.al. High frequency of early colorectal cancer in inflammatory bowel disease, Gut, 2008. 57(9): p. 1246-51., http://www.ncbi.nlm.nih.gov/pubmed/18337322

404. Hoffmann, J. C., Preiss, J. C., Autschbach, F., Buhr, H. J., Hauser, W., Herrlinger, K., et.al. [Clinical practice guideline on diagnosis and treatment of Crohn's disease], Z Gastroenterol, 2008. 46(9): p. 1094-146., http://www.ncbi.nlm.nih.gov/pubmed/18810679

405. Boroff, E. S., Gurudu, S. R., Hentz, J. G., Leighton, J. A., Ramirez, F. C., Polyp and adenoma detection rates in the proximal and distal colon, Am J Gastroenterol, 2013. 108(6): p. 993-9.

406. Dodou, D., de Winter, J. C., The relationship between distal and proximal colonic neoplasia: a meta-analysis, J Gen Intern Med, 2012. 27(3): p. 361-70., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286557/pdf/11606_2011_Article_1919.pdf

407. Lin, O. S., Gerson, L. B., Soon, M. S., Schembre, D. B., Kozarek, R. A., Risk of proximal colon neoplasia with distal hyperplastic polyps: a meta-analysis, Arch Intern Med, 2005. 165(4): p. 382-90., http://archinte.jamanetwork.com/pdfaccess.ashx?url=/data/journals/intemed/12024/ira40053.pdf

408. Arora, A., Singh, P., Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield, Gastrointest Endosc, 2004. 60(3): p. 408-13., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15332032, http://www.giejournal.org/article/S0016-5107(04)01715-8/abstract

409. Karajeh, M. A., Sanders, D. S., Hurlstone, D. P., Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients, Endoscopy, 2006. 38(3): p. 226-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16528647, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-921209

410. Jafri, S. M., Monkemuller, K., Lukens, F. J., Endoscopy in the elderly: a review of the efficacy and safety of colonoscopy, esophagogastroduodenoscopy, and endoscopic retrograde cholangiopancreatography, J Clin Gastroenterol, 2010. 44(3): p. 161-6.

411. Travis, A. C., Pievsky, D., Saltzman, J. R., Endoscopy in the elderly, Am J Gastroenterol, 2012. 107(10): p. 1495-501; quiz 1494, 1502.

412. Khan, S., Ahmed, J., Lim, M., Owais, A., McNaught, C., Mainprize, K., et.al. Colonoscopy in the octogenarian population: diagnostic and survival outcomes from a large series of patients, Surgeon, 2011. 9(4): p. 195-9., http://www.thesurgeon.net/article/S1479-666X(10)00218-0/fulltext

413. Lim, Y. J., Hong, S. J., What is the best strategy for successful bowel preparation under special conditions?, World J Gastroenterol, 2014. 20(11): p. 2741-5., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961988/pdf/WJG-20-2741.pdf

414. Lin, O. S., Performing colonoscopy in elderly and very elderly patients: Risks, costs and benefits, World J Gastrointest Endosc, 2014. 6(6): p. 220-6., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055990/pdf/WJGE-6-220.pdf

415. Lin, O. S., Kozarek, R. A., Schembre, D. B., Ayub, K., Gluck, M., Drennan, F., et.al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy, JAMA, 2006. 295(20): p. 2357-65., http://jama.jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/5025/joc60059.pdf

416. Yano, H., Iishi, H., Tatsuta, M., Sakai, N., Narahara, H., Omori, M., Oxygen desaturation during sedation for colonoscopy in elderly patients, Hepatogastroenterology, 1998. 45(24): p. 2138-41.

417. Schreuders, E. H., Ruco, A., Rabeneck, L., Schoen, R. E., Sung, J. J., Young, G. P., et.al. Colorectal cancer screening: a global overview of existing programmes, Gut, 2015. 64(10): p. 1637-49., http://gut.bmj.com/content/gutjnl/64/10/1637.full.pdf

418. Kiesslich, R., Fritsch, J., Holtmann, M., Koehler, H. H., Stolte, M., Kanzler, S., et.al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis, Gastroenterology, 2003. 124(4): p. 880-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12671882, http://www.gastrojournal.org/article/S0016-5085(03)00060-X/pdf

419. Freire, P., Figueiredo, P., Cardoso, R., Donato, M. M., Ferreira, M., Mendes, S., et.al. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial, Inflamm Bowel Dis, 2014. 20(11): p. 2038-45.

420. Mooiweer, E., van der Meulen-de Jong, A. E., Ponsioen, C. Y., Fidder, H. H., Siersema, P. D., Dekker, E., et.al. Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study, Am J Gastroenterol, 2015. 110(7): p. 1014-21.

421. Wu, L., Li, P., Wu, J., Cao, Y., Gao, F., The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials, Colorectal Dis, 2012. 14(4): p. 416-20.

422. Iannone, A., Ruospo, M., Wong, G., Principi, M., Barone, M., Strippoli, G. F., et.al. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials, Clin Gastroenterol Hepatol, 2016. 15: p. 1684 - 1697.

423. Rahmi, G., Lecomte, T., Malka, D., Maniere, T., Le Rhun, M., Guimbaud, R., et.al. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study, Am J Gastroenterol, 2015. 110(2): p. 288-98.

424. Lecomte, T., Cellier, C., Meatchi, T., Barbier, J. P., Cugnenc, P. H., Jian, R., et.al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome, Clin Gastroenterol Hepatol, 2005. 3(9): p. 897-902., http://www.cghjournal.org/article/S1542-3565(05)00403-9/pdf

425. Dinesen, L., Chua, T. J., Kaffes, A. J., Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection, Gastrointest Endosc, 2012. 75(3): p. 604-11., http://www.giejournal.org/article/S0016-5107(11)02306-6/fulltext

426. Omata, F., Ohde, S., Deshpande, G. A., Kobayashi, D., Masuda, K., Fukui, T., Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis, Scand J Gastroenterol, 2014. 49(2): p. 222-37.

427. Sabbagh, L. C., Reveiz, L., Aponte, D., de Aguiar, S., Narrow-band imaging does not improve detection of colorectal polyps when compared to conventional colonoscopy: a randomized controlled trial and meta-analysis of published studies, BMC Gastroenterol, 2011. 11: p. 100., http://www.biomedcentral.com/content/pdf/1471-230X-11-100.pdf

428. Kudo, S., Rubio, C. A., Teixeira, C. R., Kashida, H., Kogure, E., Pit pattern in colorectal neoplasia: endoscopic magnifying view, Endoscopy, 2001. 33(4): p. 367-73., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11315901, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2004-826104

429. Brooker, J. C., Saunders, B. P., Shah, S. G., Thapar, C. J., Thomas, H. J., Atkin, W. S., et.al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial, Gastrointest Endosc, 2002. 56(3): p. 333-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12196768

430. Eisen, G. M., Kim, C. Y., Fleischer, D. E., Kozarek, R. A., Carr-Locke, D. L., Li, T. C., et.al. High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study, Gastrointest Endosc, 2002. 55(6): p. 687-94., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11979251, http://www.giejournal.org/article/S0016-5107(02)24117-6/abstract

431. Tsuda, S., Veress, B., Toth, E., Fork, F. T., Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study, Gut, 2002. 51(4): p. 550-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12235079, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773398/pdf/gut05100550.pdf

432. Chung, S. J., Kim, D., Song, J. H., Kang, H. Y., Chung, G. E., Choi, J., et.al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study, Gut, 2014. 63(5): p. 785-91., http://gut.bmj.com/content/63/5/785.long

433. Hoffman, A., Loth, L., Rey, J. W., Rahman, F., Goetz, M., Hansen, T., et.al. High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: A randomized trial, Dig Liver Dis, 2014. 46(11): p. 991-6., http://ac.els-cdn.com/S1590865814005969/1-s2.0-S1590865814005969-main.pdf?_tid=8b27bda6-e383-11e4-a78a-00000aab0f27&acdnat=1429111664_6b49b4a9c8ad7bd163c5ac89611294d7

434. Hoffman, A., Sar, F., Goetz, M., Tresch, A., Mudter, J., Biesterfeld, S., et.al. High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial, Endoscopy, 2010. 42(10): p. 827-33., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1255713

435. Hong, S. N., Choe, W. H., Lee, J. H., Kim, S. I., Kim, J. H., Lee, T. Y., et.al. Prospective, randomized, back-to-back trial evaluating the usefulness of i-SCAN in screening colonoscopy, Gastrointest Endosc, 2012. 75(5): p. 1011-1021 e2., http://www.giejournal.org/article/S0016-5107(11)02499-0/fulltext

436. Kudo, S., Kashida, H., Tamura, T., Kogure, E., Imai, Y., Yamano, H., et.al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer, World J Surg, 2000. 24(9): p. 1081-90., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11036286

437. Kiesslich, R., von Bergh, M., Hahn, M., Hermann, G., Jung, M., Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon, Endoscopy, 2001. 33(12): p. 1001-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11740641, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2001-18932

438. He, Q., Li, J. D., An, S. L., Liu, S. D., Xiao, B., Zhang, Y. L., et.al. Cap-assisted colonoscopy versus conventional colonoscopy: systematic review and meta-analysis, Int J Colorectal Dis, 2013. 28(2): p. 279-81., http://link.springer.com/article/10.1007%2Fs00384-012-1466-y

439. Morgan, J. L., Thomas, K., Braungart, S., Nelson, R. L., Transparent cap colonoscopy versus standard colonoscopy: a systematic review and meta-analysis, Tech Coloproctol, 2013. 17(4): p. 353-60., http://link.springer.com/article/10.1007%2Fs10151-013-0974-2

440. Ng, S. C., Tsoi, K. K., Hirai, H. W., Lee, Y. T., Wu, J. C., Sung, J. J., et.al. The efficacy of cap-assisted colonoscopy in polyp detection and cecal intubation: a meta-analysis of randomized controlled trials, Am J Gastroenterol, 2012. 107(8): p. 1165-73.

441. Westwood, D. A., Alexakis, N., Connor, S. J., Transparent cap-assisted colonoscopy versus standard adult colonoscopy: a systematic review and meta-analysis, Dis Colon Rectum, 2012. 55(2): p. 218-25.

442. Biecker, E., Floer, M., Heinecke, A., Strobel, P., Bohme, R., Schepke, M., et.al. Novel Endocuff-assisted Colonoscopy Significantly Increases the Polyp Detection Rate: A Randomized Controlled Trial, J Clin Gastroenterol, 2014.

443. Floer, M., Biecker, E., Fitzlaff, R., Roming, H., Ameis, D., Heinecke, A., et.al. Higher adenoma detection rates with endocuff-assisted colonoscopy - a randomized controlled multicenter trial, PLoS One, 2014. 9(12): p. e114267., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255000/pdf/pone.0114267.pdf

444. van Doorn, S. C., van der Vlugt, M., Depla, A., Wientjes, C. A., Mallant-Hent, R. C., Siersema, P. D., et.al. Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial, Gut, 2015.

445. Ngu WS, Bevan R, Tsiamoulos Z, Bassett P, Hoare Z, Rutter M,Totton N, Lee TJ, Ramadas A, Silcock J, Painter J, Neilson LJ, Saunders BP, Rees CJ, Improved adenoma detection with endocuff vision - a multicentre randomised controlled trial, UEGW late breaking abstract, 2016.

446. Halpern, Z., Gross, S. A., Gralnek, I. M., Shpak, B., Pochapin, M., Hoffman, A., et.al. Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study, Endoscopy, 2015. 47(4): p. 301., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0034-1391894

447. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002, Gastrointest Endosc, 2003. 58(6 Suppl): p. S3-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14652541, http://www.giejournal.org/article/S0016-5107(03)02159-X/abstract

448. Abu Dayyeh, B. K., Thosani, N., Konda, V., Wallace, M. B., Rex, D. K., Chauhan, S. S., et.al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps, Gastrointest Endosc, 2015. 81(3): p. 502.e1-502.e16., http://www.giejournal.org/article/S0016-5107(14)02592-9/pdf

449. Hewett, D. G., Kaltenbach, T., Sano, Y., Tanaka, S., Saunders, B. P., Ponchon, T., et.al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging, Gastroenterology, 2012. 143(3): p. 599-607 e1., http://www.gastrojournal.org/article/S0016-5085(12)00687-7/pdf

450. Ignjatovic, A., East, J. E., Subramanian, V., Suzuki, N., Guenther, T., Palmer, N., et.al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial, Am J Gastroenterol, 2012. 107(6): p. 885-90.

451. Hassan, C., Repici, A., Zullo, A., Kanakadandi, V., Sharma, P., Colonic polyps: are we ready to resect and discard?, Gastrointest Endosc Clin N Am, 2013. 23(3): p. 663-78., http://www.sciencedirect.com/science/article/pii/S1052515713000238

452. Hassan, C., Pickhardt, P. J., Rex, D. K., A resect and discard strategy would improve cost-effectiveness of colorectal cancer screening, Clin Gastroenterol Hepatol, 2010. 8(10): p. 865-9, 869 e1-3., http://www.cghjournal.org/article/S1542-3565(10)00543-4/pdf

453. Kessler, W. R., Imperiale, T. F., Klein, R. W., Wielage, R. C., Rex, D. K., A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps, Endoscopy, 2011. 43(8): p. 683-91., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1256381

454. Denzer, U., Beilenhoff, U., Eickhoff, A., Faiss, S., Huttl, P., Smitten, S. I., et.al. [S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021-022], Z Gastroenterol, 2015. 53(12): p. E1-e227., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0041-109598.pdf

455. Kiesslich, R., Burg, J., Vieth, M., Gnaendiger, J., Enders, M., Delaney, P., et.al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo, Gastroenterology, 2004. 127(3): p. 706-13., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15362025, http://www.gastrojournal.org/article/S0016-5085(04)01182-5/pdf

456. Javeri, K., Williams, T. R., Bonnett, J. W., An overview of the method, application, and various findings of computed tomographic colonography in patients after incomplete colonoscopy, Curr Probl Diagn Radiol, 2010. 39(6): p. 262-74., http://www.cpdrjournal.com/article/S0363-0188(09)00077-2/fulltext

457. Copel, L., Sosna, J., Kruskal, J. B., Raptopoulos, V., Farrell, R. J., Morrin, M. M., CT colonography in 546 patients with incomplete colonoscopy, Radiology, 2007. 244(2): p. 471-8.

458. Neri, E., Giusti, P., Battolla, L., Vagli, P., Boraschi, P., Lencioni, R., et.al. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy, Radiology, 2002. 223(3): p. 615-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12034925

459. Morrin, M. M., Farrell, R. J., Raptopoulos, V., McGee, J. B., Bleday, R., Kruskal, J. B., Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions, Dis Colon Rectum, 2000. 43(3): p. 303-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10733110

460. Pickhardt, P. J., Hassan, C., Halligan, S., Marmo, R., Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis, Radiology, 2011. 259(2): p. 393-405., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079122/pdf/101887.pdf

461. Gondal, G., Grotmol, T., Hofstad, B., Bretthauer, M., Eide, T. J., Hoff, G., Biopsy of colorectal polyps is not adequate for grading of neoplasia, Endoscopy, 2005. 37(12): p. 1193-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16329016, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-921031

462. Nivatvongs, S., Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies, Dis Colon Rectum, 1986. 29(12): p. 825-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3491746

463. Reiertsen, O., Skjoto, J., Jacobsen, C. D., Rosseland, A. R., Complications of fiberoptic gastrointestinal endoscopy--five years' experience in a central hospital, Endoscopy, 1987. 19(1): p. 1-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3493897, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1013011

464. Waye, J. D., Lewis, B. S., Yessayan, S., Colonoscopy: a prospective report of complications, J Clin Gastroenterol, 1992. 15(4): p. 347-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1294644

465. Waye, J. D., Kahn, O., Auerbach, M. E., Complications of colonoscopy and flexible sigmoidoscopy, Gastrointest Endosc Clin N Am, 1996. 6(2): p. 343-77., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8673332

466. Hsieh, Y. H., Lin, H. J., Tseng, G. Y., Perng, C. L., Li, A. F., Chang, F. Y., et.al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study, Hepatogastroenterology, 2001. 48(41): p. 1379-82., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11677969

467. Heitman, S. J., Tate, D. J., Bourke, M. J., Optimizing Resection of Large Colorectal Polyps, Curr Treat Options Gastroenterol, 2017.

468. Imai, K., Hotta, K., Yamaguchi, Y., Tanaka, M., Kakushima, N., Takizawa, K., et.al. Should laterally spreading tumors granular type be resected en bloc in endoscopic resections?, Surg Endosc, 2014. 28(7): p. 2167-73., http://link.springer.com/article/10.1007%2Fs00464-014-3449-2

469. Oka, S., Tanaka, S., Kanao, H., Oba, S., Chayama, K., Therapeutic strategy for colorectal laterally spreading tumor, Dig Endosc, 2009. 21 Suppl 1: p. S43-6., http://onlinelibrary.wiley.com/doi/10.1111/j.1443-1661.2009.00869.x/abstract

470. Saito, Y., Fujii, T., Kondo, H., Mukai, H., Yokota, T., Kozu, T., et.al. Endoscopic treatment for laterally spreading tumors in the colon, Endoscopy, 2001. 33(8): p. 682-6., https://www.thieme-connect.com/DOI/DOI?10.1055/s-2001-16213

471. Saito, Y., Sakamoto, T., Fukunaga, S., Nakajima, T., Kiriyama, S., Matsuda, T., Endoscopic submucosal dissection (ESD) for colorectal tumors, Dig Endosc, 2009. 21 Suppl 1: p. S7-12., http://onlinelibrary.wiley.com/doi/10.1111/j.1443-1661.2009.00870.x/abstract

472. Moss, A., Bourke, M. J., Williams, S. J., Hourigan, L. F., Brown, G., Tam, W., et.al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia, Gastroenterology, 2011. 140(7): p. 1909-18., http://www.gastrojournal.org/article/S0016-5085(11)00274-5/pdf

473. Rotondano, G., Bianco, M. A., Buffoli, F., Gizzi, G., Tessari, F., Cipolletta, L., The Cooperative Italian FLIN Study Group: prevalence and clinico-pathological features of colorectal laterally spreading tumors, Endoscopy, 2011. 43(10): p. 856-61., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1256639

474. Ishiguro, A., Uno, Y., Ishiguro, Y., Munakata, A., Morita, T., Correlation of lifting versus non-lifting and microscopic depth of invasion in early colorectal cancer, Gastrointest Endosc, 1999. 50(3): p. 329-33., http://www.giejournal.org/article/S0016-5107(99)00446-0/fulltext

475. Uno, Y., Munakata, A., The non-lifting sign of invasive colon cancer, Gastrointest Endosc, 1994. 40(4): p. 485-9., http://www.giejournal.org/article/S0016-5107(94)70216-0/fulltext

476. Kobayashi, N., Saito, Y., Sano, Y., Uragami, N., Michita, T., Nasu, J., et.al. Determining the treatment strategy for colorectal neoplastic lesions: endoscopic assessment or the non-lifting sign for diagnosing invasion depth?, Endoscopy, 2007. 39(8): p. 701-5., https://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-966587

477. Voloyiannis, T., Snyder, M. J., Bailey, R. R., Pidala, M., Management of the difficult colon polyp referred for resection: resect or rescope?, Dis Colon Rectum, 2008. 51(3): p. 292-5., http://link.springer.com/article/10.1007/s10350-007-9175-2

478. Aziz Aadam, A., Wani, S., Kahi, C., Kaltenbach, T., Oh, Y., Edmundowicz, S., et.al. Physician assessment and management of complex colon polyps: a multicenter video-based survey study, Am J Gastroenterol, 2014. 109(9): p. 1312-24.

479. Lipof, T., Bartus, C., Sardella, W., Johnson, K., Vignati, P., Cohen, J., Preoperative colonoscopy decreases the need for laparoscopic management of colonic polyps, Dis Colon Rectum, 2005. 48(5): p. 1076-80., http://link.springer.com/article/10.1007/s10350-004-0908-1

480. Church, J. M., Avoiding surgery in patients with colorectal polyps, Dis Colon Rectum, 2003. 46(11): p. 1513-6.

481. Buchner, A. M., Guarner-Argente, C., Ginsberg, G. G., Outcomes of EMR of defiant colorectal lesions directed to an endoscopy referral center, Gastrointest Endosc, 2012. 76(2): p. 255-63., http://www.giejournal.org/article/S0016-5107(12)00226-X/fulltext

482. Friedland, S., Banerjee, S., Kochar, R., Chen, A., Shelton, A., Outcomes of repeat colonoscopy in patients with polyps referred for surgery without biopsy-proven cancer, Gastrointest Endosc, 2014. 79(1): p. 101-7., http://www.giejournal.org/article/S0016-5107(13)02099-3/fulltext

483. Efthymiou, M., Taylor, A. C., Desmond, P. V., Allen, P. B., Chen, R. Y., Biopsy forceps is inadequate for the resection of diminutive polyps, Endoscopy, 2011. 43(4): p. 312-6., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1256086

484. Deenadayalu, V. P., Rex, D. K., Colon polyp retrieval after cold snaring, Gastrointest Endosc, 2005. 62(2): p. 253-6., http://www.giejournal.org/article/S0016-5107(05)00376-7/fulltext

485. Repici, A., Hassan, C., Vitetta, E., Ferrara, E., Manes, G., Gullotti, G., et.al. Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study, Endoscopy, 2012. 44(1): p. 27-31., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0031-1291387

486. Tappero, G., Gaia, E., De Giuli, P., Martini, S., Gubetta, L., Emanuelli, G., Cold snare excision of small colorectal polyps, Gastrointest Endosc, 1992. 38(3): p. 310-3., http://www.giejournal.org/article/S0016-5107(92)70422-2/pdf

487. Kim, J. S., Lee, B. I., Choi, H., Jun, S. Y., Park, E. S., Park, J. M., et.al. Cold snare polypectomy versus cold forceps polypectomy for diminutive and small colorectal polyps: a randomized controlled trial, Gastrointest Endosc, 2015. 81(3): p. 741-7., http://www.giejournal.org/article/S0016-5107(14)02504-8/fulltext

488. Lee, C. K., Shim, J. J., Jang, J. Y., Cold snare polypectomy vs. Cold forceps polypectomy using double-biopsy technique for removal of diminutive colorectal polyps: a prospective randomized study, Am J Gastroenterol, 2013. 108(10): p. 1593-600.

489. Moss, A., Williams, S. J., Hourigan, L. F., Brown, G., Tam, W., Singh, R., et.al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study, Gut, 2015. 64(1): p. 57-65., http://gut.bmj.com/content/64/1/57.long

490. Knabe, M., Pohl, J., Gerges, C., Ell, C., Neuhaus, H., Schumacher, B., Standardized long-term follow-up after endoscopic resection of large, nonpedunculated colorectal lesions: a prospective two-center study, Am J Gastroenterol, 2014. 109(2): p. 183-9.

491. Seidel, J., Farber, E., Baumbach, R., Cordruwisch, W., Bohmler, U., Feyerabend, B., et.al. Complication and local recurrence rate after endoscopic resection of large high-risk colorectal adenomas of >/=3 cm in size, Int J Colorectal Dis, 2016. 31(3): p. 603-11., http://link.springer.com/article/10.1007%2Fs00384-015-2498-x

492. Cipolletta, L., Rotondano, G., Bianco, M. A., Buffoli, F., Gizzi, G., Tessari, F., Endoscopic resection for superficial colorectal neoplasia in Italy: a prospective multicentre study, Dig Liver Dis, 2014. 46(2): p. 146-51., http://www.dldjournalonline.com/article/S1590-8658(13)00592-6/fulltext

493. Heresbach, D., Kornhauser, R., Seyrig, J. A., Coumaros, D., Claviere, C., Bury, A., et.al. A national survey of endoscopic mucosal resection for superficial gastrointestinal neoplasia, Endoscopy, 2010. 42(10): p. 806-13., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1255715

494. Woodward, T. A., Heckman, M. G., Cleveland, P., De Melo, S., Raimondo, M., Wallace, M., Predictors of complete endoscopic mucosal resection of flat and depressed gastrointestinal neoplasia of the colon, Am J Gastroenterol, 2012. 107(5): p. 650-4.

495. Repici, A., Hassan, C., De Paula Pessoa, D., Pagano, N., Arezzo, A., Zullo, A., et.al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review, Endoscopy, 2012. 44(2): p. 137-50., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0031-1291448

496. Kim, Y. J., Kim, E. S., Cho, K. B., Park, K. S., Jang, B. K., Chung, W. J., et.al. Comparison of clinical outcomes among different endoscopic resection methods for treating colorectal neoplasia, Dig Dis Sci, 2013. 58(6): p. 1727-36., http://link.springer.com/article/10.1007%2Fs10620-013-2560-x

497. Kobayashi, N., Yoshitake, N., Hirahara, Y., Konishi, J., Saito, Y., Matsuda, T., et.al. Matched case-control study comparing endoscopic submucosal dissection and endoscopic mucosal resection for colorectal tumors, J Gastroenterol Hepatol, 2012. 27(4): p. 728-33., http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2011.06942.x/abstract

498. Saito, Y., Fukuzawa, M., Matsuda, T., Fukunaga, S., Sakamoto, T., Uraoka, T., et.al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection, Surg Endosc, 2010. 24(2): p. 343-52., http://link.springer.com/article/10.1007%2Fs00464-009-0562-8

499. Tajika, M., Niwa, Y., Bhatia, V., Kondo, S., Tanaka, T., Mizuno, N., et.al. Comparison of endoscopic submucosal dissection and endoscopic mucosal resection for large colorectal tumors, Eur J Gastroenterol Hepatol, 2011. 23(11): p. 1042-9.

500. Terasaki, M., Tanaka, S., Oka, S., Nakadoi, K., Takata, S., Kanao, H., et.al. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm, J Gastroenterol Hepatol, 2012. 27(4): p. 734-40., http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2011.06977.x/abstract

501. Fujiya, M., Tanaka, K., Dokoshi, T., Tominaga, M., Ueno, N., Inaba, Y., et.al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection, Gastrointest Endosc, 2015. 81(3): p. 583-95., http://www.giejournal.org/article/S0016-5107(14)01983-X/fulltext

502. Wang, J., Zhang, X. H., Ge, J., Yang, C. M., Liu, J. Y., Zhao, S. L., Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: a meta-analysis, World J Gastroenterol, 2014. 20(25): p. 8282-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081704/pdf/WJG-20-8282.pdf

503. Sauer, M., Hildenbrand, R., Oyama, T., Sido, B., Yahagi, N., Dumoulin, F. L., Endoscopic submucosal dissection for flat or sessile colorectal neoplasia > 20 mm: A European single-center series of 182 cases, Endosc Int Open, 2016. 4(8): p. E895-900., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0042-111204.pdf

504. Probst, A., Golger, D., Anthuber, M., Markl, B., Messmann, H., Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center, Endoscopy, 2012. 44(7): p. 660-7., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1309403

505. Rahmi, G., Hotayt, B., Chaussade, S., Lepilliez, V., Giovannini, M., Coumaros, D., et.al. Endoscopic submucosal dissection for superficial rectal tumors: prospective evaluation in France, Endoscopy, 2014. 46(8): p. 670-6., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0034-1365810

506. Repici, A., Hassan, C., Pagano, N., Rando, G., Romeo, F., Spaggiari, P., et.al. High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm, Gastrointest Endosc, 2013. 77(1): p. 96-101., http://www.giejournal.org/article/S0016-5107(12)02657-0/fulltext

507. Probst, A., Ebigbo, A., Markl, B., Schaller, T., Anthuber, M., Fleischmann, C., et.al. Endoscopic submucosal dissection for early rectal neoplasia: experience from a European center, Endoscopy, 2017. 49(3): p. 222-232., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0042-118449

508. Schmidt, A. Damm, M. Gubier, C. Caca, K. Bauerfeind, P., Endoskopische Vollwandresektion im unteren GI-Trakt mit dem FTRD-System: eine retrospektive Studie, Zeitschrift für Gastroenterologie, 2014. 52: p. 52 - 56.

509. Fisher, D. A., Maple, J. T., Ben-Menachem, T., Cash, B. D., Decker, G. A., Early, D. S., et.al. Complications of colonoscopy, Gastrointest Endosc, 2011. 74(4): p. 745-52., http://www.giejournal.org/article/S0016-5107(11)01965-1/pdf

510. Niv, Y., Hazazi, R., Levi, Z., Fraser, G., Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis, Dig Dis Sci, 2008. 53(12): p. 3049-54., http://link.springer.com/article/10.1007%2Fs10620-008-0286-y

511. Adler, A., Lieberman, D., Aminalai, A., Aschenbeck, J., Drossel, R., Mayr, M., et.al. Data quality of the German screening colonoscopy registry, Endoscopy, 2013. 45(10): p. 813-8., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0033-1344583

512. Bokemeyer, B., Bock, H., Huppe, D., Duffelmeyer, M., Rambow, A., Tacke, W., et.al. Screening colonoscopy for colorectal cancer prevention: results from a German online registry on 269000 cases, Eur J Gastroenterol Hepatol, 2009. 21(6): p. 650-5.

513. Crispin, A., Birkner, B., Munte, A., Nusko, G., Mansmann, U., Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies, Endoscopy, 2009. 41(12): p. 1018-25., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1215214

514. Eckardt, V. F., Kanzler, G., Schmitt, T., Eckardt, A. J., Bernhard, G., Complications and adverse effects of colonoscopy with selective sedation, Gastrointest Endosc, 1999. 49(5): p. 560-5., http://www.giejournal.org/article/S0016-5107(99)70382-2/fulltext

515. Pox, C. P., Altenhofen, L., Brenner, H., Theilmeier, A., Von Stillfried, D., Schmiegel, W., Efficacy of a nationwide screening colonoscopy program for colorectal cancer, Gastroenterology, 2012. 142(7): p. 1460-7 e2., http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf

516. Bowles, C. J., Leicester, R., Romaya, C., Swarbrick, E., Williams, C. B., Epstein, O., A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow?, Gut, 2004. 53(2): p. 277-83., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774946/pdf/gut05300277.pdf

517. Kang, H. Y., Kang, H. W., Kim, S. G., Kim, J. S., Park, K. J., Jung, H. C., et.al. Incidence and management of colonoscopic perforations in Korea, Digestion, 2008. 78(4): p. 218-23., http://www.karger.com/Article/Abstract/190811

518. Ko, C. W., Riffle, S., Michaels, L., Morris, C., Holub, J., Shapiro, J. A., et.al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon, Clin Gastroenterol Hepatol, 2010. 8(2): p. 166-73., http://www.cghjournal.org/article/S1542-3565(09)01042-8/pdf

519. Nelson, D. B., McQuaid, K. R., Bond, J. H., Lieberman, D. A., Weiss, D. G., Johnston, T. K., Procedural success and complications of large-scale screening colonoscopy, Gastrointest Endosc, 2002. 55(3): p. 307-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11868001, http://www.giejournal.org/article/S0016-5107(02)22076-3/abstract

520. Niv, Y., Gershtansky, Y., Kenett, R. S., Tal, Y., Birkenfeld, S., Complications in colonoscopy: analysis of 7-year physician-reported adverse events, Eur J Gastroenterol Hepatol, 2011. 23(6): p. 492-8.

521. Rabeneck, L., Paszat, L. F., Hilsden, R. J., Saskin, R., Leddin, D., Grunfeld, E., et.al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice, Gastroenterology, 2008. 135(6): p. 1899-1906, 1906 e1., http://www.gastrojournal.org/article/S0016-5085(08)01673-9/pdf

522. Singh, H., Penfold, R. B., DeCoster, C., Kaita, L., Proulx, C., Taylor, G., et.al. Colonoscopy and its complications across a Canadian regional health authority, Gastrointest Endosc, 2009. 69(3 Pt 2): p. 665-71., http://www.giejournal.org/article/S0016-5107(08)02634-5/fulltext

523. Warren, J. L., Klabunde, C. N., Mariotto, A. B., Meekins, A., Topor, M., Brown, M. L., et.al. Adverse events after outpatient colonoscopy in the Medicare population, Ann Intern Med, 2009. 150(12): p. 849-57, W152., http://annals.org/pdfaccess.ashx?url=/data/journals/aim/20184/0000605-200906160-00008.pdf

524. Zubarik, R., Fleischer, D. E., Mastropietro, C., Lopez, J., Carroll, J., Benjamin, S., et.al. Prospective analysis of complications 30 days after outpatient colonoscopy, Gastrointest Endosc, 1999. 50(3): p. 322-8., http://ac.els-cdn.com/S001651079900423X/1-s2.0-S001651079900423X-main.pdf?_tid=7207401e-e377-11e4-a5f0-00000aacb35f&acdnat=1429106468_a243aafbb31f50727da9ee2a1a38e0ad

525. Zubarik, R., Ganguly, E., Benway, D., Ferrentino, N., Moses, P., Vecchio, J., Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy, Am J Gastroenterol, 2002. 97(12): p. 3056-61.

526. Heldwein, W., Dollhopf, M., Rosch, T., Meining, A., Schmidtsdorff, G., Hasford, J., et.al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies, Endoscopy, 2005. 37(11): p. 1116-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16281142, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-870512

527. Chetty, R., Traditional serrated adenoma (TSA): morphological questions, queries and quandaries, J Clin Pathol, 2016. 69(1): p. 6-11., http://jcp.bmj.com/content/jclinpath/69/1/6.full.pdf

528. Gibson, J. A., Odze, R. D., Pathology of premalignant colorectal neoplasia, Dig Endosc, 2016. 28(3): p. 312-23., http://onlinelibrary.wiley.com/store/10.1111/den.12633/asset/den12633.pdf?v=1&t=izxtpxow&s=c822f385e1e982b74cbe3a2d7cc1243d7b186309

529. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D., WHO Classification of Tumours of the Digestive System, 2010. 4 ed. World Health Organisation, 2010:

530. Gao, Q., Tsoi, K. K., Hirai, H. W., Wong, M. C., Chan, F. K., Wu, J. C., et.al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis, Am J Gastroenterol, 2015. 110(4): p. 501-9; quiz 510.

531. Holme, O., Bretthauer, M., Eide, T. J., Loberg, E. M., Grzyb, K., Loberg, M., et.al. Long-term risk of colorectal cancer in individuals with serrated polyps, Gut, 2015. 64(6): p. 929-36., http://gut.bmj.com/content/64/6/929.long

532. Erichsen, R., Baron, J. A., Hamilton-Dutoit, S. J., Snover, D. C., Torlakovic, E. E., Pedersen, L., et.al. Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps, Gastroenterology, 2016. 150(4): p. 895-902 e5., http://www.gastrojournal.org/article/S0016-5085(15)01732-1/abstract

533. Hassan, C., Repici, A., Zullo, A., Sharma, P., New paradigms for colonoscopic management of diminutive colorectal polyps: predict, resect, and discard or do not resect?, Clin Endosc, 2013. 46(2): p. 130-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630306/pdf/ce-46-130.pdf

534. Baretton, G. B., Tannapfel, A., Schmitt, W., [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification], Pathologe, 2011. 32(4): p. 289-96., http://link.springer.com/article/10.1007%2Fs00292-011-1436-0

535. Wada, H., Shiozawa, M., Katayama, K., Okamoto, N., Miyagi, Y., Rino, Y., et.al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer, J Gastroenterol, 2015. 50(7): p. 727-34.

536. Kawachi, H., Eishi, Y., Ueno, H., Nemoto, T., Fujimori, T., Iwashita, A., et.al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study, Mod Pathol, 2015. 28(6): p. 872-9., http://www.nature.com/modpathol/journal/v28/n6/pdf/modpathol201536a.pdf

537. Mou, S., Soetikno, R., Shimoda, T., Rouse, R., Kaltenbach, T., Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis, Surg Endosc, 2013. 27(8): p. 2692-703., http://link.springer.com/article/10.1007%2Fs00464-013-2835-5

538. Beaton, C., Twine, C. P., Williams, G. L., Radcliffe, A. G., Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer, Colorectal Dis, 2013. 15(7): p. 788-97., http://onlinelibrary.wiley.com/store/10.1111/codi.12129/asset/codi12129.pdf?v=1&t=j277wpxr&s=a351d25bda0126abbb37c9c0317fefeb930045ac

539. Bosch, S. L., Teerenstra, S., de Wilt, J. H., Cunningham, C., Nagtegaal, I. D., Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions, Endoscopy, 2013. 45(10): p. 827-34., https://www.thieme-connect.com/DOI/DOI?10.1055/s-0033-1344238

540. Choi, J. Y., Jung, S. A., Shim, K. N., Cho, W. Y., Keum, B., Byeon, J. S., et.al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma, J Korean Med Sci, 2015. 30(4): p. 398-406.

541. Ueno, H., Mochizuki, H., Hashiguchi, Y., Shimazaki, H., Aida, S., Hase, K., et.al. Risk factors for an adverse outcome in early invasive colorectal carcinoma, Gastroenterology, 2004. 127(2): p. 385-94., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15300569, http://www.gastrojournal.org/article/S0016-5085(04)00717-6/pdf

542. Hassan, C., Zullo, A., Risio, M., Rossini, F. P., Morini, S., Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis, Dis Colon Rectum, 2005. 48(8): p. 1588-96., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15937622

543. Blackstock, W., Russo, S. M., Suh, W. W., Cosman, B. C., Herman, J., Mohiuddin, M., et.al. ACR Appropriateness Criteria: local excision in early-stage rectal cancer, Curr Probl Cancer, 2010. 34(3): p. 193-200., http://www.cpcancer.com/article/S0147-0272(10)00046-2/fulltext

544. Russo, S., Blackstock, A. W., Herman, J. M., Abdel-Wahab, M., Azad, N., Das, P., et.al. ACR Appropriateness Criteria(R) Local Excision in Early Stage Rectal Cancer, Am J Clin Oncol, 2015. 38(5): p. 520-5.

545. Kikuchi, R., Takano, M., Takagi, K., Fujimoto, N., Nozaki, R., Fujiyoshi, T., et.al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines, Dis Colon Rectum, 1995. 38(12): p. 1286-95., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7497841

546. Di Gregorio, C., Bonetti, L. R., de Gaetani, C., Pedroni, M., Kaleci, S., Ponz de Leon, M., Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature, Intern Emerg Med, 2014. 9(2): p. 151-60., http://link.springer.com/article/10.1007%2Fs11739-012-0772-2

547. Fischer, J., Dobbs, B., Dixon, L., Eglinton, T. W., Wakeman, C. J., Frizelle, F. A., Management of malignant colorectal polyps in New Zealand, ANZ J Surg, 2016., http://onlinelibrary.wiley.com/doi/10.1111/ans.13502/abstract

548. Wu, X. R., Liang, J., Church, J. M., Management of sessile malignant polyps: is colonoscopic polypectomy enough?, Surg Endosc, 2015. 29(10): p. 2947-52., http://link.springer.com/article/10.1007%2Fs00464-014-4027-3

549. Hassan, C., Gaglia, P., Zullo, A., Scaccianoce, G., Piglionica, D., Rossini, F. P., et.al. Endoscopic follow-up after colorectal cancer resection: an Italian multicentre study, Dig Liver Dis, 2006. 38(1): p. 45-50., http://www.dldjournalonline.com/article/S1590-8658(05)00376-2/fulltext

550. Seitz, U., Bohnacker, S., Seewald, S., Thonke, F., Brand, B., Braiutigam, T., et.al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature, Dis Colon Rectum, 2004. 47(11): p. 1789-96; discussion 1796-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15622570

551. Meining, A., von Delius, S., Eames, T. M., Popp, B., Seib, H. J., Schmitt, W., Risk factors for unfavorable outcomes after endoscopic removal of submucosal invasive colorectal tumors, Clin Gastroenterol Hepatol, 2011. 9(7): p. 590-4.

552. Nascimbeni, R., Burgart, L. J., Nivatvongs, S., Larson, D. R., Risk of lymph node metastasis in T1 carcinoma of the colon and rectum, Dis Colon Rectum, 2002. 45(2): p. 200-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11852333

553. Ramirez, M., Schierling, S., Papaconstantinou, H. T., Thomas, J. S., Management of the malignant polyp, Clin Colon Rectal Surg, 2008. 21(4): p. 286-90., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780260/pdf/ccrs21286.pdf

554. Matsuda, T., Fukuzawa, M., Uraoka, T., Nishi, M., Yamaguchi, Y., Kobayashi, N., et.al. Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study, Cancer Sci, 2011. 102(9): p. 1693-7.

555. Kitajima, K., Fujimori, T., Fujii, S., Takeda, J., Ohkura, Y., Kawamata, H., et.al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study, J Gastroenterol, 2004. 39(6): p. 534-43., http://link.springer.com/article/10.1007%2Fs00535-004-1339-4

556. Suh, J. H., Han, K. S., Kim, B. C., Hong, C. W., Sohn, D. K., Chang, H. J., et.al. Predictors for lymph node metastasis in T1 colorectal cancer, Endoscopy, 2012. 44(6): p. 590-5.

557. Okabe, S., Shia, J., Nash, G., Wong, W. D., Guillem, J. G., Weiser, M. R., et.al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum, J Gastrointest Surg, 2004. 8(8): p. 1032-9; discussion 1039-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15585391

558. Nakadoi, K., Tanaka, S., Kanao, H., Terasaki, M., Takata, S., Oka, S., et.al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection, J Gastroenterol Hepatol, 2012. 27(6): p. 1057-62.

559. Ikematsu, H., Yoda, Y., Matsuda, T., Yamaguchi, Y., Hotta, K., Kobayashi, N., et.al. Long-term outcomes after resection for submucosal invasive colorectal cancers, Gastroenterology, 2013. 144(3): p. 551-9; quiz e14.

560. Cooper, G. S., Xu, F., Barnholtz Sloan, J. S., Koroukian, S. M., Schluchter, M. D., Management of malignant colonic polyps: a population-based analysis of colonoscopic polypectomy versus surgery, Cancer, 2012. 118(3): p. 651-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193545/pdf/nihms-302827.pdf

561. Provenzale, D., Garrett, J.W., Condon, S.E., Sandler, R.S., Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps., Ann Intern Med, 1990. 113: p. 760-3., http://annals.org/article.aspx?articleid=704240

562. Rex, D.K., Smith, J.J., Ulbright, T.M., Lehman, G.A., Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects., Gastroenterology, 1992. 102: p. 317-9.

563. Sciallero, S., Costantini, M., Bertinelli, E., Castiglione, G., Onofri, P., Aste, H., et.al. Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas, Gastrointest Endosc, 1997. 46(2): p. 124-30., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9283861

564. Koide, N., Saito, Y., Fujii, T., Kondo, H., Saito, D., Shimoda, T., A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up, Endoscopy, 2002. 34(6): p. 499-502., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12048637, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2002-32008

565. Martinez, M. E., Baron, J. A., Lieberman, D. A., Schatzkin, A., Lanza, E., Winawer, S. J., et.al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy, Gastroenterology, 2009. 136(3): p. 832-41., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685417/pdf/nihms467134.pdf

566. Cottet, V., Jooste, V., Fournel, I., Bouvier, A. M., Faivre, J., Bonithon-Kopp, C., Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study, Gut, 2012. 61(8): p. 1180-6., http://gut.bmj.com/content/61/8/1180.long

567. Loberg, M., Kalager, M., Holme, O., Hoff, G., Adami, H. O., Bretthauer, M., Long-term colorectal-cancer mortality after adenoma removal, N Engl J Med, 2014. 371(9): p. 799-807., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315870

568. Winawer, S. J., Zauber, A. G., O'Brien, M. J., Ho, M. N., Gottlieb, L., Sternberg, S. S., et.al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup, N Engl J Med, 1993. 328(13): p. 901-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8446136, http://www.nejm.org/doi/pdf/10.1056/NEJM199304013281301

569. Higaki, S., Hashimoto, S., Harada, K., Nohara, H., Saito, Y., Gondo, T., et.al. Long-term follow-up of large flat colorectal tumors resected endoscopically, Endoscopy, 2003. 35(10): p. 845-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14551863, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-42622

570. Regula, J., Wronska, E., Polkowski, M., Nasierowska-Guttmejer, A., Pachlewski, J., Rupinski, M., et.al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study, Endoscopy, 2003. 35(3): p. 212-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12584639, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-37254

571. Seitz, U., Bohnacker, S., Seewald, S., Thonke, F., Soehendra, N., Long-term results of endoscopic removal of large colorectal adenomas, Endoscopy, 2003. 35(8): p. S41-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12929053, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-41535

572. Hurlstone, D. P., Sanders, D. S., Cross, S. S., George, R., Shorthouse, A. J., Brown, S., A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery, Colorectal Dis, 2005. 7(4): p. 339-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15932555, http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1318.2005.00813.x/abstract

573. Boix, J., Lorenzo-Zuniga, V., Moreno de Vega, V., Ananos, F. E., Domenech, E., Ojanguren, I., et.al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?, Dig Dis Sci, 2007. 52(3): p. 840-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17253129, http://link.springer.com/article/10.1007%2Fs10620-006-9617-z

574. Pereyra, L., Zamora, R., Gomez, E. J., Fischer, C., Panigadi, G. N., Gonzalez, R., et.al. Risk of Metachronous Advanced Neoplastic Lesions in Patients with Sporadic Sessile Serrated Adenomas Undergoing Colonoscopic Surveillance, Am J Gastroenterol, 2016. 111(6): p. 871-8.

575. Macaron, C., Vu, H. T., Lopez, R., Pai, R. K., Burke, C. A., Risk of Metachronous Polyps in Individuals With Serrated Polyps, Dis Colon Rectum, 2015. 58(8): p. 762-8.

576. Lieberman, D. A., Holub, J., Eisen, G., Kraemer, D., Morris, C. D., Utilization of colonoscopy in the United States: results from a national consortium, Gastrointest Endosc, 2005. 62(6): p. 875-83., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16301030, http://www.giejournal.org/article/S0016-5107(05)02300-X/abstract

577. Pabby, A., Schoen, R. E., Weissfeld, J. L., Burt, R., Kikendall, J. W., Lance, P., et.al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial, Gastrointest Endosc, 2005. 61(3): p. 385-91., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15758908, http://www.giejournal.org/article/S0016-5107(04)02765-8/abstract

578. Robertson, D. J., Greenberg, E. R., Beach, M., Sandler, R. S., Ahnen, D., Haile, R. W., et.al. Colorectal cancer in patients under close colonoscopic surveillance, Gastroenterology, 2005. 129(1): p. 34-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16012932, http://www.gastrojournal.org/article/S0016-5085(05)00882-6/pdf

579. Sawhney, M. S., Farrar, W. D., Gudiseva, S., Nelson, D. B., Lederle, F. A., Rector, T. S., et.al. Microsatellite instability in interval colon cancers, Gastroenterology, 2006. 131(6): p. 1700-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17087932, http://www.gastrojournal.org/article/S0016-5085(06)02256-6/pdf

580. Bressler, B., Paszat, L. F., Vinden, C., Li, C., He, J., Rabeneck, L., Colonoscopic miss rates for right-sided colon cancer: a population-based analysis, Gastroenterology, 2004. 127(2): p. 452-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15300577, http://www.gastrojournal.org/article/S0016-5085(04)00924-2/pdf

581. Pickhardt, P. J., Choi, J. R., Hwang, I., Butler, J. A., Puckett, M. L., Hildebrandt, H. A., et.al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults, N Engl J Med, 2003. 349(23): p. 2191-200., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14657426, http://www.nejm.org/doi/pdf/10.1056/NEJMoa031618

582. Vemulapalli, K. C., Rex, D. K., Risk of advanced lesions at first follow-up colonoscopy in high-risk groups as defined by the United Kingdom post-polypectomy surveillance guideline: data from a single U.S. center, Gastrointest Endosc, 2014. 80(2): p. 299-306.

583. Park, H. W., Han, S., Lee, J. Y., Chang, H. S., Choe, J., Choi, Y., et.al. Probability of high-risk colorectal neoplasm recurrence based on the results of two previous colonoscopies, Dig Dis Sci, 2015. 60(1): p. 226-33.

584. Suh, K. H., Koo, J. S., Hyun, J. J., Choi, J., Han, J. S., Kim, S. Y., et.al. Risk of adenomas with high-risk characteristics based on two previous colonoscopy, J Gastroenterol Hepatol, 2014. 29(12): p. 1985-90.

585. Laiyemo, A. O., Pinsky, P. F., Marcus, P. M., Lanza, E., Cross, A. J., Schatzkin, A., et.al. Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial, Clin Gastroenterol Hepatol, 2009. 7(5): p. 562-7; quiz 497.

586. Robertson, DJ, Estimated Risk of Advanced and Multiple Adenomas Based On the Results of Two Prior Colonoscopies, Ann Intern Med, 2009. July:

587. Robertson, D. J., Lieberman, D. A., Winawer, S. J., Ahnen, D. J., Baron, J. A., Schatzkin, A., et.al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis, Gut, 2014. 63(6): p. 949-56., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383397/pdf/nihms527879.pdf

588. Ferlitsch, M., Moss, A., Hassan, C., Bhandari, P., Dumonceau, J. M., Paspatis, G., et.al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline, Endoscopy, 2017. 49(3): p. 270-297., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-102569.pdf

589. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., et.al. A randomized trial of aspirin to prevent colorectal adenomas, N Engl J Med, 2003. 348(10): p. 891-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12621133, http://www.nejm.org/doi/pdf/10.1056/NEJMoa021735

590. Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., et.al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial, Gastroenterology, 2003. 125(2): p. 328-36., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12891533, http://www.gastrojournal.org/article/S0016-5085(03)00887-4/pdf

591. Weingarten, M. A., Zalmanovici, A., Yaphe, J., Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps, Cochrane Database Syst Rev, 2005. p. CD003548., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16034903, http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003548.pub3/abstract

592. Imperiale, T. F., Aspirin and the prevention of colorectal cancer, N Engl J Med, 2003. 348(10): p. 879-80., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12621130

593. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et.al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 2005. 352(11): p. 1092-102., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15713943, http://www.nejm.org/doi/pdf/10.1056/NEJMoa050493

594. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., et.al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 2005. 352(11): p. 1071-80., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15713944, http://www.nejm.org/doi/pdf/10.1056/NEJMoa050405

595. Psaty, B. M., Potter, J. D., Risks and benefits of celecoxib to prevent recurrent adenomas, N Engl J Med, 2006. 355(9): p. 950-2., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16943408

596. Fielding, L. P., Arsenault, P. A., Chapuis, P. H., Dent, O., Gathright, B., Hardcastle, J. D., et.al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT), J Gastroenterol Hepatol, 1991. 6(4): p. 325-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1912440, http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.1991.tb00867.x/abstract

597. Soreide, O., Norstein, J., Fielding, L.P., Silen, W., International standardization and documentation of the treatment of rectal cancer., in Rectal cancer surgery. Optimisation - standardization - documentation., Soreide, O. and Norstein, J., Editors. 1997, Springer: Berlin Heidelberg New York. p. 405-45.

598. UICC, TNM Classification of Malignant TumoursJohn Wiley & Sons, 2002.

599. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer, Jama, 1990. 264(11): p. 1444-50., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2202842, http://jama.jamanetwork.com/article.aspx?articleid=383259

600. Nelson, H., Petrelli, N., Carlin, A., Couture, J., Fleshman, J., Guillem, J., et.al. Guidelines 2000 for colon and rectal cancer surgery, J Natl Cancer Inst, 2001. 93(8): p. 583-96., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11309435, http://jnci.oxfordjournals.org/content/93/8/583.full.pdf

601. Pilipshen, S. J., Heilweil, M., Quan, S. H., Sternberg, S. S., Enker, W. E., Patterns of pelvic recurrence following definitive resections of rectal cancer, Cancer, 1984. 53(6): p. 1354-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6692324, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J/asset/2820530623_ftp.pdf?v=1&t=ik581dpu&s=0065343d161161c51387053d673106b8ee47c2d1

602. Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., Cunningham, D., MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?, Br J Cancer, 2006. 94(3): p. 351-7., http://www.ncbi.nlm.nih.gov/pubmed/16465171

603. Segelman, J., Singnomklao, T., Hellborg, H., Martling, A., Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer, Colorectal Dis, 2009. 11(7): p. 768-74., http://www.ncbi.nlm.nih.gov/pubmed/18662241

604. Barillari, P., Ramacciato, G., De Angelis, R., Gozzo, P., Indinnimeo, M., Valabrega, S., et.al. Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms, Acta Chir Scand, 1990. 156(2): p. 163-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2330795

605. Faivre, J., [Endoscopic monitoring after excision of colorectal cancer], J Chir (Paris), 1997. 134(7-8): p. 283-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9772990

606. Chen, H. S., Sheen-Chen, S. M., Synchronous and "early" metachronous colorectal adenocarcinoma: analysis of prognosis and current trends, Dis Colon Rectum, 2000. 43(8): p. 1093-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10950007

607. Floriani, I., Torri, V., Rulli, E., Garavaglia, D., Compagnoni, A., Salvolini, L., et.al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis, J Magn Reson Imaging, 2010. 31(1): p. 19-31., http://www.ncbi.nlm.nih.gov/pubmed/20027569

608. Rafaelsen, S. R., Jakobsen, A., Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis, Colorectal Dis, 2011. 13(4): p. 420-5., http://www.ncbi.nlm.nih.gov/pubmed/20412096

609. Quaia, E., D'Onofrio, M., Palumbo, A., Rossi, S., Bruni, S., Cova, M., Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence, Eur Radiol, 2006. 16(7): p. 1599-609., http://www.ncbi.nlm.nih.gov/pubmed/16552507

610. Niekel, M. C., Bipat, S., Stoker, J., Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment, Radiology, 2010. 257(3): p. 674-84., http://www.ncbi.nlm.nih.gov/pubmed/20829538

611. Mainenti, P. P., Mancini, M., Mainolfi, C., Camera, L., Maurea, S., Manchia, A., et.al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents, Abdom Imaging, 2010. 35(5): p. 511-21., http://www.ncbi.nlm.nih.gov/pubmed/19562412

612. McAndrew, M. R., Saba, A. K., Efficacy of routine preoperative computed tomography scans in colon cancer, Am Surg, 1999. 65(3): p. 205-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10075291

613. Barton, J. B., Langdale, L. A., Cummins, J. S., Stelzner, M., Lynge, D. C., Mock, C. N., et.al. The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer, Am J Surg, 2002. 183(5): p. 499-503., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12034380, http://www.americanjournalofsurgery.com/article/S0002-9610(02)00841-3/abstract

614. Dighe, S., Purkayastha, S., Swift, I., Tekkis, P. P., Darzi, A., A'Hern, R., et.al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis, Clin Radiol, 2010. 65(9): p. 708-19., http://www.ncbi.nlm.nih.gov/pubmed/20696298

615. Abdel-Nabi, H., Doerr, R. J., Lamonica, D. M., Cronin, V. R., Galantowicz, P. J., Carbone, G. M., et.al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings, Radiology, 1998. 206(3): p. 755-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9494497

616. Akiyoshi, T., Oya, M., Fujimoto, Y., Kuroyanagi, H., Ueno, M., Yamaguchi, T., et.al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer, Colorectal Dis, 2009. 11(5): p. 464-9., http://www.ncbi.nlm.nih.gov/pubmed/18637927

617. Furukawa, H., Ikuma, H., Seki, A., Yokoe, K., Yuen, S., Aramaki, T., et.al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer, Gut, 2006. 55(7): p. 1007-11., http://www.ncbi.nlm.nih.gov/pubmed/16361308

618. Kam, M. H., Wong, D. C., Siu, S., Stevenson, A. R., Lai, J., Phillips, G. E., Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer, Br J Surg, 2010. 97(2): p. 266-8., http://www.ncbi.nlm.nih.gov/pubmed/20035542

619. Kinner, S., Antoch, G., Bockisch, A., Veit-Haibach, P., Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging, Abdom Imaging, 2007. 32(5): p. 606-12., http://www.ncbi.nlm.nih.gov/pubmed/17387540

620. Llamas-Elvira, J. M., Rodriguez-Fernandez, A., Gutierrez-Sainz, J., Gomez-Rio, M., Bellon-Guardia, M., Ramos-Font, C., et.al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer, Eur J Nucl Med Mol Imaging, 2007. 34(6): p. 859-67., http://www.ncbi.nlm.nih.gov/pubmed/17195075

621. Ono, K., Ochiai, R., Yoshida, T., Kitagawa, M., Omagari, J., Kobayashi, H., et.al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases, J Magn Reson Imaging, 2009. 29(2): p. 336-40., http://www.ncbi.nlm.nih.gov/pubmed/19161185

622. Tateishi, U., Maeda, T., Morimoto, T., Miyake, M., Arai, Y., Kim, E. E., Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer, Eur J Nucl Med Mol Imaging, 2007. 34(10): p. 1627-34., http://www.ncbi.nlm.nih.gov/pubmed/17530248

623. Veit-Haibach, P., Kuehle, C. A., Beyer, T., Stergar, H., Kuehl, H., Schmidt, J., et.al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography, JAMA, 2006. 296(21): p. 2590-600., http://www.ncbi.nlm.nih.gov/pubmed/17148724

624. Bassi, M. C., Turri, L., Sacchetti, G., Loi, G., Cannillo, B., La Mattina, P., et.al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer, Int J Radiat Oncol Biol Phys, 2008. 70(5): p. 1423-6., http://www.ncbi.nlm.nih.gov/pubmed/17931795

625. Davey, K., Heriot, A. G., Mackay, J., Drummond, E., Hogg, A., Ngan, S., et.al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer, Dis Colon Rectum, 2008. 51(7): p. 997-1003., http://www.ncbi.nlm.nih.gov/pubmed/18461399

626. Gearhart, S. L., Frassica, D., Rosen, R., Choti, M., Schulick, R., Wahl, R., Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer, Ann Surg Oncol, 2006. 13(3): p. 397-404., http://www.ncbi.nlm.nih.gov/pubmed/16485158

627. Nagata, K., Ota, Y., Okawa, T., Endo, S., Kudo, S. E., PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer, Dis Colon Rectum, 2008. 51(6): p. 882-90., http://www.ncbi.nlm.nih.gov/pubmed/18330647

628. Park, I. J., Kim, H. C., Yu, C. S., Ryu, M. H., Chang, H. M., Kim, J. H., et.al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma, Eur J Surg Oncol, 2006. 32(9): p. 941-7., http://www.ncbi.nlm.nih.gov/pubmed/16843635

629. Paskeviciute, B., Bolling, T., Brinkmann, M., Rudykina, G., Ernst, I., Stegger, L., et.al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer, Strahlenther Onkol, 2009. 185(4): p. 260-5., http://www.ncbi.nlm.nih.gov/pubmed/19370430

630. Kantorova, I., Lipska, L., Belohlavek, O., Visokai, V., Trubac, M., Schneiderova, M., Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making, J Nucl Med, 2003. 44(11): p. 1784-8., http://www.ncbi.nlm.nih.gov/pubmed/14602860

631. Ruers, T. J., Wiering, B., van der Sijp, J. R., Roumen, R. M., de Jong, K. P., Comans, E. F., et.al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study, J Nucl Med, 2009. 50(7): p. 1036-41., http://www.ncbi.nlm.nih.gov/pubmed/19525451

632. Moulton, C. A., An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM)., J Clin Oncol, 2011. p. abstr 3520.

633. Glazer, E. S., Beaty, K., Abdalla, E. K., Vauthey, J. N., Curley, S. A., Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases, Arch Surg, 2010. 145(4): p. 340-5; discussion 345., http://www.ncbi.nlm.nih.gov/pubmed/20404283

634. Lubezky, N., Metser, U., Geva, R., Nakache, R., Shmueli, E., Klausner, J. M., et.al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings, J Gastrointest Surg, 2007. 11(4): p. 472-8., http://www.ncbi.nlm.nih.gov/pubmed/17436132

635. Spatz, J., Holl, G., Sciuk, J., Anthuber, M., Arnholdt, H. M., Markl, B., Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound, Int J Colorectal Dis, 2011. 26(2): p. 165-71., http://www.ncbi.nlm.nih.gov/pubmed/20960208

636. IQWIG, Positronenemissionstomographie (PET und PET/CT) bei rezidivierendem kolorektalen Karzinom - Vorbericht (vorläufige Nutzenbewertung), 2011.

637. Patel, S., McCall, M., Ohinmaa, A., Bigam, D., Dryden, D. M., Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review, Ann Surg, 2011. 253(4): p. 666-71., http://www.ncbi.nlm.nih.gov/pubmed/21475005

638. Taylor R.A., S. J. Tuorto, T. J. Akhurst, F. Yuman, Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score., 2007 Gastrointestinal Cancers Symposium, Abstract No: 240, 2007.

639. Adie, S., Yip, C., Chu, F., Morris, D. L., Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?, ANZ J Surg, 2009. 79(5): p. 358-61., http://www.ncbi.nlm.nih.gov/pubmed/19566517

640. Levy, M., Visokai, V., Lipska, L., Topolcan, O., Tumor markers in staging and prognosis of colorectal carcinoma, Neoplasma, 2008. 55(2): p. 138-42., http://www.ncbi.nlm.nih.gov/pubmed/18237252

641. Lewis, M. R., Euscher, E. D., Deavers, M. T., Silva, E. G., Malpica, A., Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall, Gynecol Oncol, 2007. 105(2): p. 395-8., http://www.ncbi.nlm.nih.gov/pubmed/17335881

642. Chen, C. C., Yang, S. H., Lin, J. K., Lin, T. C., Chen, W. S., Jiang, J. K., et.al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?, J Surg Res, 2005. 124(2): p. 169-74., http://www.ncbi.nlm.nih.gov/pubmed/15820244

643. Merkel, S., Mansmann, U., Siassi, M., Papadopoulos, T., Hohenberger, W., Hermanek, P., The prognostic inhomogeneity in pT3 rectal carcinomas, Int J Colorectal Dis, 2001. 16(5): p. 298-304., http://www.ncbi.nlm.nih.gov/pubmed/11686527

644. Nagtegaal, I. D., Quirke, P., What is the role for the circumferential margin in the modern treatment of rectal cancer?, J Clin Oncol, 2008. 26(2): p. 303-12.

645. Bipat, S., Glas, A. S., Slors, F. J., Zwinderman, A. H., Bossuyt, P. M., Stoker, J., Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis, Radiology, 2004. 232(3): p. 773-83., http://www.ncbi.nlm.nih.gov/pubmed/15273331

646. Puli, S. R., Reddy, J. B., Bechtold, M. L., Choudhary, A., Antillon, M. R., Brugge, W. R., Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review, Ann Surg Oncol, 2009. 16(5): p. 1255-65., http://www.ncbi.nlm.nih.gov/pubmed/19219506

647. Ahmetoglu, A., Cansu, A., Baki, D., Kul, S., Cobanoglu, U., Alhan, E., et.al. MDCT with multiplanar reconstruction in the preoperative local staging of rectal tumor, Abdom Imaging, 2011. 36(1): p. 31-7., http://www.ncbi.nlm.nih.gov/pubmed/19949791

648. Kim, C. K., Kim, S. H., Chun, H. K., Lee, W. Y., Yun, S. H., Song, S. Y., et.al. Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging, Eur Radiol, 2006. 16(5): p. 972-80., http://www.ncbi.nlm.nih.gov/pubmed/16416276

649. Kim, Y. W., Kim, N. K., Min, B. S., Kim, H., Pyo, J., Kim, M. J., et.al. A prospective comparison study for predicting circumferential resection margin between preoperative MRI and whole mount sections in mid-rectal cancer: significance of different scan planes, Eur J Surg Oncol, 2008. 34(6): p. 648-54., http://www.ncbi.nlm.nih.gov/pubmed/17574368

650. Kim, Y. W., Cha, S. W., Pyo, J., Kim, N. K., Min, B. S., Kim, M. J., et.al. Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study, World J Surg, 2009. 33(9): p. 1952-60., http://www.ncbi.nlm.nih.gov/pubmed/19603224

651. Matsuoka, H., Nakamura, A., Sugiyama, M., Hachiya, J., Atomi, Y., Masaki, T., MRI diagnosis of mesorectal lymph node metastasis in patients with rectal carcinoma. what is the optimal criterion?, Anticancer Res, 2004. 24(6): p. 4097-101., http://www.ncbi.nlm.nih.gov/pubmed/15736458

652. Wolberink, S. V., Beets-Tan, R. G., de Haas-Kock, D. F., van de Jagt, E. J., Span, M. M., Wiggers, T., Multislice CT as a primary screening tool for the prediction of an involved mesorectal fascia and distant metastases in primary rectal cancer: a multicenter study, Dis Colon Rectum, 2009. 52(5): p. 928-34., http://www.ncbi.nlm.nih.gov/pubmed/19502858

653. Purkayastha, S., Athanasiou, T., Tekkis, P. P., Constantinides, V., Teare, J., Darzi, A. W., Magnetic resonance colonography vs computed tomography colonography for the diagnosis of colorectal cancer: an indirect comparison, Colorectal Dis, 2007. 9(2): p. 100-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17223933, http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1318.2006.01126.x/abstract

654. Zirngibl, H., Husemann, B., Hermanek, P., Intraoperative spillage of tumor cells in surgery for rectal cancer, Dis Colon Rectum, 1990. 33(7): p. 610-4., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2361432

655. Cahill, R. A., Leroy, J., Marescaux, J., Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature, BMC Surg, 2008. 8: p. 17., http://www.ncbi.nlm.nih.gov/pubmed/18816403

656. Wiese, D., Sirop, S., Yestrepsky, B., Ghanem, M., Bassily, N., Ng, P., et.al. Ultrastaging of sentinel lymph nodes (SLNs) vs. non-SLNs in colorectal cancer--do we need both?, Am J Surg, 2010. 199(3): p. 354-8; discussion 358., http://www.ncbi.nlm.nih.gov/pubmed/20226909

657. Torzilli, G., Del Fabbro, D., Palmisano, A., Donadon, M., Bianchi, P., Roncalli, M., et.al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases, J Gastrointest Surg, 2005. 9(8): p. 1148-53; discussion 1153-4., http://www.ncbi.nlm.nih.gov/pubmed/16269386

658. Goligher, J.C., Incidence and pathology of carcinoma of the colon and rectum, in Surgery of the anus, rectum and colon., 1984, Balliére Tindall: London. p. S. 445.

659. Toyota, S., Ohta, H., Anazawa, S., Rationale for extent of lymph node dissection for right colon cancer, Dis Colon Rectum, 1995. 38(7): p. 705-11., http://www.ncbi.nlm.nih.gov/pubmed/7607029

660. Tan, K. Y., Kawamura, Y. J., Mizokami, K., Sasaki, J., Tsujinaka, S., Maeda, T., et.al. Distribution of the first metastatic lymph node in colon cancer and its clinical significance, Colorectal Dis, 2010. 12(1): p. 44-7., http://www.ncbi.nlm.nih.gov/pubmed/19438890

661. Lan, Y. T., Lin, J. K., Jiang, J. K., Chang, S. C., Liang, W. Y., Yang, S. H., Significance of lymph node retrieval from the terminal ileum for patients with cecal and ascending colonic cancers, Ann Surg Oncol, 2011. 18(1): p. 146-52., http://www.ncbi.nlm.nih.gov/pubmed/20734151

662. Chang, G. J., Rodriguez-Bigas, M. A., Skibber, J. M., Moyer, V. A., Lymph node evaluation and survival after curative resection of colon cancer: systematic review, J Natl Cancer Inst, 2007. 99(6): p. 433-41., http://www.ncbi.nlm.nih.gov/pubmed/17374833

663. Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., et.al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089, J Clin Oncol, 2003. 21(15): p. 2912-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12885809, http://jco.ascopubs.org/content/21/15/2912.long

664. Van Damme, J-P., Vascular anatomy in abdominal surgeryThieme, 1990.

665. Kanemitsu, Y., Hirai, T., Komori, K., Kato, T., Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery, Br J Surg, 2006. 93(5): p. 609-15., http://www.ncbi.nlm.nih.gov/pubmed/16607682

666. Chin, C. C., Wang, J. Y., Changchien, C. R., Huang, W. S., Tang, R., Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor, Int J Colorectal Dis, 2010. 25(7): p. 817-22., http://www.ncbi.nlm.nih.gov/pubmed/20135321

667. Hohenberger, W., Weber, K., Matzel, K., Papadopoulos, T., Merkel, S., Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome, Colorectal Dis, 2009. 11(4): p. 354-64; discussion 364-5., http://www.ncbi.nlm.nih.gov/pubmed/19016817

668. West, N. P., Anderin, C., Smith, K. J., Holm, T., Quirke, P., Multicentre experience with extralevator abdominoperineal excision for low rectal cancer, Br J Surg, 2010. 97(4): p. 588-99., http://www.ncbi.nlm.nih.gov/pubmed/20186891

669. Bertelsen, C. A., Bols, B., Ingholm, P., Jansen, J.E., Neuenschwander, A.U., Vilandt, J., Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision?, Colorectal Dis, 2011. 13(10): p. 1123-1129.

670. (NICE), National Institute for Clinical Excellence, Radiofrequency ablation for the treatment of colorectal metastases in the liver., 2011.

671. Kim, K. H., Yoon, Y. S., Yu, C. S., Kim, T. W., Kim, H. J., Kim, P. N., et.al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases, J Korean Surg Soc, 2011. 81(1): p. 25-34., http://www.ncbi.nlm.nih.gov/pubmed/22066097

672. Mulier, S., Ni, Y., Jamart, J., Michel, L., Marchal, G., Ruers, T., Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?, Ann Surg Oncol, 2008. 15(1): p. 144-57., http://www.ncbi.nlm.nih.gov/pubmed/17906898

673. (NICE), National Institute for Clinical Excellence, Selective internal radiation therapy for colorectal metastases in the liver., 2011.

674. Townsend, A., Price, T., Karapetis, C., Selective internal radiation therapy for liver metastases from colorectal cancer, Cochrane Database Syst Rev, 2009. p. CD007045., http://www.ncbi.nlm.nih.gov/pubmed/19821394

675. Christophi, C., Nikfarjam, M., Malcontenti-Wilson, C., Muralidharan, V., Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy, World J Surg, 2004. 28(10): p. 987-94., http://www.ncbi.nlm.nih.gov/pubmed/15573253

676. Wietzke-Braun, P., Schindler, C., Raddatz, D., Braun, F., Armbrust, T., Nolte, W., et.al. Quality of life and outcome of ultrasound-guided laser interstitial thermo-therapy for non-resectable liver metastases of colorectal cancer, Eur J Gastroenterol Hepatol, 2004. 16(4): p. 389-95., http://www.ncbi.nlm.nih.gov/pubmed/15028971

677. Abcarian, H., Pearl, R. K., Simple technique for high ligation of the inferior mesenteric artery and vein, Dis Colon Rectum, 1991. 34(12): p. 1138., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1959468

678. Buunen, M., Lange, M. M., Ditzel, M., Kleinrensink, G. J., van de Velde, C. J., Lange, J. F., Level of arterial ligation in total mesorectal excision (TME): an anatomical study, Int J Colorectal Dis, 2009. 24(11): p. 1317-20., http://www.ncbi.nlm.nih.gov/pubmed/19609537

679. Pezim, M. E., Nicholls, R. J., Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer, Ann Surg, 1984. 200(6): p. 729-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6508403, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1250590/pdf/annsurg00118-0057.pdf

680. Surtees, P., Ritchie, J. K., Phillips, R. K., High versus low ligation of the inferior mesenteric artery in rectal cancer, Br J Surg, 1990. 77(6): p. 618-21., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2383724, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800770607/abstract

681. Slanetz, C. A., Jr., Grimson, R., Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer, Dis Colon Rectum, 1997. 40(10): p. 1205-18; discussion 1218-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9336116

682. Lange, M. M., Buunen, M., van de Velde, C. J., Lange, J. F., Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review, Dis Colon Rectum, 2008. 51(7): p. 1139-45., http://www.ncbi.nlm.nih.gov/pubmed/18483828

683. Heald, R. J., Husband, E. M., Ryall, R. D., The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?, Br J Surg, 1982. 69(10): p. 613-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6751457, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800691019/abstract

684. Bokey, E. L., Ojerskog, B., Chapuis, P. H., Dent, O. F., Newland, R. C., Sinclair, G., Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection, Br J Surg, 1999. 86(9): p. 1164-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10504371, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1999.01216.x/abstract

685. Hermanek, P. jun., Multiviszerale Resektion beim kolorektalen Karzinom. Erfahrungen der SGKRK-Studie., Langenbecks Arch Surg, 1992. Kongressband: p. 95-100.

686. Havenga, K., Enker, W. E., McDermott, K., Cohen, A. M., Minsky, B. D., Guillem, J., Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum, J Am Coll Surg, 1996. 182(6): p. 495-502., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8646349

687. Enker, W. E., Havenga, K., Polyak, T., Thaler, H., Cranor, M., Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer, World J Surg, 1997. 21(7): p. 715-20., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9276702

688. Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., Nicholls, R. J., et.al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis, Lancet Oncol, 2009. 10(11): p. 1053-62., http://www.ncbi.nlm.nih.gov/pubmed/19767239

689. Gohl, J., Hohenberger, W., Merkel, S., Lymph node dissection in rectal carcinoma: TME and what else?, Onkologie, 2009. 32(1-2): p. 57-61., http://www.ncbi.nlm.nih.gov/pubmed/19209023

690. Mortenson, M. M., Khatri, V. P., Bennett, J. J., Petrelli, N. J., Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal, Surg Oncol Clin N Am, 2007. 16(1): p. 177-97., http://www.ncbi.nlm.nih.gov/pubmed/17336243

691. Koch, M., Kienle, P., Antolovic, D., Buchler, M. W., Weitz, J., Is the lateral lymph node compartment relevant?, Recent Results Cancer Res, 2005. 165: p. 40-5., http://www.ncbi.nlm.nih.gov/pubmed/15865019

692. Scott, N., Jackson, P., al-Jaberi, T., Dixon, M. F., Quirke, P., Finan, P. J., Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer, Br J Surg, 1995. 82(8): p. 1031-3., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7648142, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800820808/abstract

693. Reynolds, J. V., Joyce, W. P., Dolan, J., Sheahan, K., Hyland, J. M., Pathological evidence in support of total mesorectal excision in the management of rectal cancer, Br J Surg, 1996. 83(8): p. 1112-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8869320, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800830826/abstract

694. Hida, J., Yasutomi, M., Maruyama, T., Fujimoto, K., Uchida, T., Okuno, K., Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision, J Am Coll Surg, 1997. 184(6): p. 584-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9179114

695. Zaheer, S., Pemberton, J. H., Farouk, R., Dozois, R. R., Wolff, B. G., Ilstrup, D., Surgical treatment of adenocarcinoma of the rectum, Ann Surg, 1998. 227(6): p. 800-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9637543, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1191380/pdf/annsurg00016-0034.pdf

696. Leong, A. F., Selective total mesorectal excision for rectal cancer, Dis Colon Rectum, 2000. 43(9): p. 1237-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11005489

697. Heald, R. J., Karanjia, N. D., Results of radical surgery for rectal cancer, World J Surg, 1992. 16(5): p. 848-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1462619

698. Enker, W. E., Total mesorectal excision--the new golden standard of surgery for rectal cancer, Ann Med, 1997. 29(2): p. 127-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9187227

699. Lazorthes, F., Voigt, J. J., Roques, J., Chiotasso, P., Chevreau, P., Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement, Surg Gynecol Obstet, 1990. 170(1): p. 45-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2294629

700. Kwok, S. P., Lau, W. Y., Leung, K. L., Liew, C. T., Li, A. K., Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma, Br J Surg, 1996. 83(7): p. 969-72., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8813789, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800830726/abstract

701. Andreola, S., Leo, E., Belli, F., Lavarino, C., Bufalino, R., Tomasic, G., et.al. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis, Dis Colon Rectum, 1997. 40(1): p. 25-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9102256

702. Goldstein, N. S., Soman, A., Sacksner, J., Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage, Am J Clin Pathol, 1999. 111(3): p. 349-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10078110

703. Kiran, R. P., Lian, L., Lavery, I. C., Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy?, Dis Colon Rectum, 2011. 54(2): p. 157-63., http://www.ncbi.nlm.nih.gov/pubmed/21228662

704. Rutkowski, A., Bujko, K., Nowacki, M. P., Chmielik, E., Nasierowska-Guttmejer, A., Wojnar, A., Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe?, Ann Surg Oncol, 2008. 15(11): p. 3124-31., http://www.ncbi.nlm.nih.gov/pubmed/18766404

705. Brown, C. J., Fenech, D. S., McLeod, R. S., Reconstructive techniques after rectal resection for rectal cancer, Cochrane Database Syst Rev, 2008. p. CD006040., http://www.ncbi.nlm.nih.gov/pubmed/18425933

706. Fazio, V. W., Zutshi, M., Remzi, F. H., Parc, Y., Ruppert, R., Furst, A., et.al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers, Ann Surg, 2007. 246(3): p. 481-8; discussion 488-90., http://www.ncbi.nlm.nih.gov/pubmed/17717452

707. Liao, C., Gao, F., Cao, Y., Tan, A., Li, X., Wu, D., Meta-analysis of the colon J-pouch vs transverse coloplasty pouch after anterior resection for rectal cancer, Colorectal Dis, 2010. 12(7): p. 624-31., http://www.ncbi.nlm.nih.gov/pubmed/19555386

708. Hida, J., Yasutomi, M., Fujimoto, K., Okuno, K., Ieda, S., Machidera, N., et.al. Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size, Dis Colon Rectum, 1996. 39(9): p. 986-91., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8797646

709. Siddiqui, M. R., Sajid, M. S., Woods, W. G., Cheek, E., Baig, M. K., A meta-analysis comparing side to end with colonic J-pouch formation after anterior resection for rectal cancer, Tech Coloproctol, 2010. 14(2): p. 113-23., http://www.ncbi.nlm.nih.gov/pubmed/20422436

710. Hohenberger, W., Lahmer, G., Fietkau, R., Croner, R. S., Merkel, S., Gohl, J., et.al. [Neoadjuvant radiochemotherapy for rectal cancer], Chirurg, 2009. 80(4): p. 294-302., http://www.ncbi.nlm.nih.gov/pubmed/19350306

711. Artioukh, D. Y., Controversial aspects of rectal cancer surgery following preoperative chemoradiation, Colorectal Dis, 2010. 12 Suppl 2: p. 25-9., http://www.ncbi.nlm.nih.gov/pubmed/20618364

712. Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Jr., Silva e Sousa, A. H., Jr., et.al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 2004. 240(4): p. 711-7; discussion 717-8., http://www.ncbi.nlm.nih.gov/pubmed/15383798

713. Tekkis, P. P., Heriot, A. G., Smith, J., Thompson, M. R., Finan, P., Stamatakis, J. D., Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer, Colorectal Dis, 2005. 7(4): p. 369-74., http://www.ncbi.nlm.nih.gov/pubmed/15932561

714. Nagtegaal, I. D., van de Velde, C. J., Marijnen, C. A., van Krieken, J. H., Quirke, P., Low rectal cancer: a call for a change of approach in abdominoperineal resection, J Clin Oncol, 2005. 23(36): p. 9257-64., http://www.ncbi.nlm.nih.gov/pubmed/16361623

715. Nisar, P. J., Scott, H. J., Myocutaneous flap reconstruction of the pelvis after abdominoperineal excision, Colorectal Dis, 2009. 11(8): p. 806-16., http://www.ncbi.nlm.nih.gov/pubmed/19055518

716. Montedori, A., Cirocchi, R., Farinella, E., Sciannameo, F., Abraha, I., Covering ileo- or colostomy in anterior resection for rectal carcinoma, Cochrane Database Syst Rev, 2010. p. CD006878., http://www.ncbi.nlm.nih.gov/pubmed/20464746

717. Lindgren, R., Hallbook, O., Rutegard, J., Sjodahl, R., Matthiessen, P., What is the risk for a permanent stoma after low anterior resection of the rectum for cancer? A six-year follow-up of a multicenter trial, Dis Colon Rectum, 2011. 54(1): p. 41-7., http://www.ncbi.nlm.nih.gov/pubmed/21160312

718. Klink, C. D., Willis, S., Neumann, U. P., Jansen, M., [Protective ileostoma versus protective transverse stoma. What evidence is available?], Chirurg, 2010. 81(11): p. 974-7., http://www.ncbi.nlm.nih.gov/pubmed/20959949

719. Rondelli, F., Reboldi, P., Rulli, A., Barberini, F., Guerrisi, A., Izzo, L., et.al. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis, Int J Colorectal Dis, 2009. 24(5): p. 479-88., http://www.ncbi.nlm.nih.gov/pubmed/19219439

720. Bass, E. M., Del Pino, A., Tan, A., Pearl, R. K., Orsay, C. P., Abcarian, H., Does preoperative stoma marking and education by the enterostomal therapist affect outcome?, Dis Colon Rectum, 1997. 40(4): p. 440-2., http://www.ncbi.nlm.nih.gov/pubmed/9106693

721. Millan, M., Tegido, M., Biondo, S., Garcia-Granero, E., Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units, Colorectal Dis, 2010. 12(7 Online): p. e88-92., http://www.ncbi.nlm.nih.gov/pubmed/19799617

722. Chaudhri, S., Brown, L., Hassan, I., Horgan, A. F., Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial, Dis Colon Rectum, 2005. 48(3): p. 504-9., http://www.ncbi.nlm.nih.gov/pubmed/15768181

723. Hermanek, P., G.P., Marzoli, Lokale Therapie des Rektumkarzinoms. Verfahren in kurativer Intention.Springer, 1994.

724. Winde, G., Nottberg, H., Keller, R., Schmid, K. W., Bunte, H., Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection, Dis Colon Rectum, 1996. 39(9): p. 969-76., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8797643

725. Sengupta, S., Tjandra, J. J., Local excision of rectal cancer: what is the evidence?, Dis Colon Rectum, 2001. 44(9): p. 1345-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11584215

726. Matzel, K. E., Merkel, S., Hohenberger, W., Lokale Therapieprinzipien beim Rektumkarzinom., Chirurg, 2003. 74(10): p. 897-904., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14605731, http://link.springer.com/article/10.1007%2Fs00104-003-0745-0

727. Ptok, H., Marusch, F., Meyer, F., Schubert, D., Koeckerling, F., Gastinger, I., et.al. Oncological outcome of local vs radical resection of low-risk pT1 rectal cancer, Arch Surg, 2007. 142(7): p. 649-55; discussion 656., http://www.ncbi.nlm.nih.gov/pubmed/17638803

728. You, Y. N., Baxter, N. N., Stewart, A., Nelson, H., Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database, Ann Surg, 2007. 245(5): p. 726-33., http://www.ncbi.nlm.nih.gov/pubmed/17457165

729. Moore, J. S., Cataldo, P. A., Osler, T., Hyman, N. H., Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses, Dis Colon Rectum, 2008. 51(7): p. 1026-30; discussion 1030-1., http://www.ncbi.nlm.nih.gov/pubmed/18481147

730. Sgourakis, G., Lanitis, S., Gockel, I., Kontovounisios, C., Karaliotas, C., Tsiftsi, K., et.al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes, Am Surg, 2011. 77(6): p. 761-72., http://www.ncbi.nlm.nih.gov/pubmed/21679648

731. Bach, S. P., Hill, J., Monson, J. R., Simson, J. N., Lane, L., Merrie, A., et.al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer, Br J Surg, 2009. 96(3): p. 280-90., http://www.ncbi.nlm.nih.gov/pubmed/19224520

732. Glimelius, B., Pahlman, L., Cervantes, A., Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010. 21 Suppl 5: p. v82-6., http://www.ncbi.nlm.nih.gov/pubmed/20555109

733. Suppiah, A., Maslekar, S., Alabi, A., Hartley, J. E., Monson, J. R., Transanal endoscopic microsurgery in early rectal cancer: time for a trial?, Colorectal Dis, 2008. 10(4): p. 314-27; discussion 327-9., http://www.ncbi.nlm.nih.gov/pubmed/18190614

734. Valentini, V., Aristei, C., Glimelius, B., Minsky, B. D., Beets-Tan, R., Borras, J. M., et.al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2), Radiother Oncol, 2009. 92(2): p. 148-63., http://www.ncbi.nlm.nih.gov/pubmed/19595467

735. Hahnloser, D., Wolff, B. G., Larson, D. W., Ping, J., Nivatvongs, S., Immediate radical resection after local excision of rectal cancer: an oncologic compromise?, Dis Colon Rectum, 2005. 48(3): p. 429-37., http://www.ncbi.nlm.nih.gov/pubmed/15747069

736. Schwenk, W., Haase, O., Neudecker, J., Muller, J. M., Short term benefits for laparoscopic colorectal resection, Cochrane Database Syst Rev, 2005. p. CD003145., http://www.ncbi.nlm.nih.gov/pubmed/16034888

737. Liang, Y., Li, G., Chen, P., Yu, J., Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence, Eur J Surg Oncol, 2008. 34(11): p. 1217-24., http://www.ncbi.nlm.nih.gov/pubmed/18155389

738. Kuhry, E., Schwenk, W. F., Gaupset, R., Romild, U., Bonjer, H. J., Long-term results of laparoscopic colorectal cancer resection, Cochrane Database Syst Rev, 2008. p. CD003432., http://www.ncbi.nlm.nih.gov/pubmed/18425886

739. Guillou, P. J., Quirke, P., Thorpe, H., Walker, J., Jayne, D. G., Smith, A. M., et.al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial, Lancet, 2005. 365(9472): p. 1718-26., http://www.ncbi.nlm.nih.gov/pubmed/15894098

740. Jayne, D. G., Thorpe, H. C., Copeland, J., Quirke, P., Brown, J. M., Guillou, P. J., Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer, Br J Surg, 2010. 97(11): p. 1638-45., http://www.ncbi.nlm.nih.gov/pubmed/20629110

741. Kwak, J. M., Kim, S. H., Kim, J., Son, D. N., Baek, S. J., Cho, J. S., Robotic vs laparoscopic resection of rectal cancer: short-term outcomes of a case-control study, Dis Colon Rectum, 2011. 54(2): p. 151-6., http://www.ncbi.nlm.nih.gov/pubmed/21228661

742. Pigazzi, A., Luca, F., Patriti, A., Valvo, M., Ceccarelli, G., Casciola, L., et.al. Multicentric study on robotic tumor-specific mesorectal excision for the treatment of rectal cancer, Ann Surg Oncol, 2010. 17(6): p. 1614-20., http://www.ncbi.nlm.nih.gov/pubmed/20087780

743. Jacquet, P., Sugarbaker, P. H., Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, Cancer Treat Res, 1996. 82: p. 359-74., http://www.ncbi.nlm.nih.gov/pubmed/8849962

744. Verwaal, V. J., van Ruth, S., de Bree, E., van Sloothen, G. W., van Tinteren, H., Boot, H., et.al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, J Clin Oncol, 2003. 21(20): p. 3737-43., http://www.ncbi.nlm.nih.gov/pubmed/14551293

745. Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., van Tinteren, H., 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Ann Surg Oncol, 2008. 15(9): p. 2426-32., http://link.springer.com/article/10.1245%2Fs10434-008-9966-2

746. Cao, C., Yan, T. D., Black, D., Morris, D. L., A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin, Ann Surg Oncol, 2009. 16(8): p. 2152-65., http://www.ncbi.nlm.nih.gov/pubmed/19434455

747. Stillwell, A. P., Buettner, P. G., Ho, Y. H., Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone, World J Surg, 2010. 34(4): p. 797-807., http://www.ncbi.nlm.nih.gov/pubmed/20054541

748. Poultsides, G. A., Servais, E. L., Saltz, L. B., Patil, S., Kemeny, N. E., Guillem, J. G., et.al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment, J Clin Oncol, 2009. 27(20): p. 3379-84., http://www.ncbi.nlm.nih.gov/pubmed/19487380

749. Wright, C. M., Dent, O. F., Barker, M., Newland, R. C., Chapuis, P. H., Bokey, E. L., et.al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer, Br J Surg, 2000. 87(9): p. 1197-202., http://www.ncbi.nlm.nih.gov/pubmed/10971428

750. Popat, S., Hubner, R., Houlston, R. S., Systematic review of microsatellite instability and colorectal cancer prognosis, J Clin Oncol, 2005. 23(3): p. 609-18., http://jco.ascopubs.org/content/23/3/609.long

751. Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., et.al. Microsatellite instability and colorectal cancer prognosis, Clin Cancer Res, 2005. 11(23): p. 8332-40., http://www.ncbi.nlm.nih.gov/pubmed/16322293

752. Malesci, A., Laghi, L., Bianchi, P., Delconte, G., Randolph, A., Torri, V., et.al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer, Clin Cancer Res, 2007. 13(13): p. 3831-9., http://www.ncbi.nlm.nih.gov/pubmed/17606714

753. Leopoldo, S., Lorena, B., Cinzia, A., Gabriella, D. C., Angela Luciana, B., Renato, C., et.al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features, Ann Surg Oncol, 2008. 15(5): p. 1429-39., http://www.ncbi.nlm.nih.gov/pubmed/18301950

754. Lanza, G., Gafa, R., Matteuzzi, M., Santini, A., Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival, J Clin Oncol, 1999. 17(8): p. 2429-38., http://www.ncbi.nlm.nih.gov/pubmed/10561306

755. Parc, Y., Gueroult, S., Mourra, N., Serfaty, L., Flejou, J. F., Tiret, E., et.al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer, Gut, 2004. 53(3): p. 371-5., http://www.ncbi.nlm.nih.gov/pubmed/14960518

756. Gafa, R., Maestri, I., Matteuzzi, M., Santini, A., Ferretti, S., Cavazzini, L., et.al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability, Cancer, 2000. 89(10): p. 2025-37., http://www.ncbi.nlm.nih.gov/pubmed/11066042

757. Lanza, G., Gafa, R., Maestri, I., Santini, A., Matteuzzi, M., Cavazzini, L., Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability, Mod Pathol, 2002. 15(7): p. 741-9., http://www.ncbi.nlm.nih.gov/pubmed/12118112

758. Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., Sargent, D. J., et.al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors, J Clin Oncol, 2002. 20(4): p. 1043-8., http://www.ncbi.nlm.nih.gov/pubmed/11844828

759. Overbeek, L. I., Ligtenberg, M. J., Willems, R. W., Hermens, R. P., Blokx, W. A., Dubois, S. V., et.al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting, Am J Surg Pathol, 2008. 32(8): p. 1246-51., http://www.ncbi.nlm.nih.gov/pubmed/18677806

760. Prandi, M., Lionetto, R., Bini, A., Francioni, G., Accarpio, G., Anfossi, A., et.al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial, Ann Surg, 2002. 235(4): p. 458-63., http://www.ncbi.nlm.nih.gov/pubmed/11923600

761. Ogino, S., Nosho, K., Irahara, N., Shima, K., Baba, Y., Kirkner, G. J., et.al. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction, Am J Gastroenterol, 2010. 105(2): p. 420-33., http://www.ncbi.nlm.nih.gov/pubmed/19809407

762. Swanson, R. S., Compton, C. C., Stewart, A. K., Bland, K. I., The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined, Ann Surg Oncol, 2003. 10(1): p. 65-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12513963

763. Carloss, H., Huang, B., Cohen, A., Carloss, E., Wyatt, S., Tucker, T., The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer, J Ky Med Assoc, 2004. 102(8): p. 345-7., http://www.ncbi.nlm.nih.gov/pubmed/15384384

764. Fazio, L., Cotterchio, M., Manno, M., McLaughlin, J., Gallinger, S., Association between colonic screening, subject characteristics, and stage of colorectal cancer, Am J Gastroenterol, 2005. 100(11): p. 2531-9., http://www.ncbi.nlm.nih.gov/pubmed/16279911

765. Wong, S. L., Ji, H., Hollenbeck, B. K., Morris, A. M., Baser, O., Birkmeyer, J. D., Hospital lymph node examination rates and survival after resection for colon cancer, JAMA, 2007. 298(18): p. 2149-54., http://www.ncbi.nlm.nih.gov/pubmed/18000198

766. Qiu, H. B., Zhang, L. Y., Li, Y. F., Zhou, Z. W., Keshari, R. P., Xu, R. H., Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with stage III colorectal cancer, Ann Surg Oncol, 2011. 18(6): p. 1568-74., http://www.ncbi.nlm.nih.gov/pubmed/21207155

767. Wang, J., Kulaylat, M., Rockette, H., Hassett, J., Rajput, A., Dunn, K. B., et.al. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?, Ann Surg, 2009. 249(4): p. 559-63., http://www.ncbi.nlm.nih.gov/pubmed/19300237

768. Chen, S. L., Steele, S. R., Eberhardt, J., Zhu, K., Bilchik, A., Stojadinovic, A., Lymph node ratio as a quality and prognostic indicator in stage III colon cancer, Ann Surg, 2011. 253(1): p. 82-7., http://www.ncbi.nlm.nih.gov/pubmed/21135690

769. Ha, Y. H., Jeong, S. Y., Lim, S. B., Choi, H. S., Hong, Y. S., Chang, H. J., et.al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer, Ann Surg, 2010. 252(2): p. 336-40., http://www.ncbi.nlm.nih.gov/pubmed/20647928

770. West, N. P., Hohenberger, W., Weber, K., Perrakis, A., Finan, P. J., Quirke, P., Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon, J Clin Oncol, 2010. 28(2): p. 272-8., http://www.ncbi.nlm.nih.gov/pubmed/19949013

771. West, N. P., Morris, E. J., Rotimi, O., Cairns, A., Finan, P. J., Quirke, P., Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study, Lancet Oncol, 2008. 9(9): p. 857-65., http://www.ncbi.nlm.nih.gov/pubmed/18667357

772. Quirke, P., Steele, R., Monson, J., Grieve, R., Khanna, S., Couture, J., et.al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial, Lancet, 2009. 373(9666): p. 821-8.

773. Tilney, H. S., Rasheed, S., Northover, J. M., Tekkis, P. P., The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery, Dis Colon Rectum, 2009. 52(10): p. 1723-9., http://www.ncbi.nlm.nih.gov/pubmed/19966604

774. Bernstein, T. E., Endreseth, B. H., Romundstad, P., Wibe, A., Circumferential resection margin as a prognostic factor in rectal cancer, Br J Surg, 2009. 96(11): p. 1348-57., http://www.ncbi.nlm.nih.gov/pubmed/19847867

775. Leite, J. S., Martins, S. C., Oliveira, J., Cunha, M. F., Castro-Sousa, F., Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer, Colorectal Dis, 2011. 13(4): p. 381-6., http://www.ncbi.nlm.nih.gov/pubmed/20002696

776. West, N. P., Finan, P. J., Anderin, C., Lindholm, J., Holm, T., Quirke, P., Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer, J Clin Oncol, 2008. 26(21): p. 3517-22., http://www.ncbi.nlm.nih.gov/pubmed/18541901

777. Hamilton, S. R., Aaltonen, L. A., Pathology and Genetics of Tumours of the Digestive SystemIARC Press, World Health Organization Classifecation of Tumours, 2000.

778. Hermanek, P., Guggenmoos-Holzmann, I., Gall, F. P., Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification, Dis Colon Rectum, 1989. 32(7): p. 593-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2737060

779. Hermanek, P., Hohenberger, W., The importance of volume in colorectal cancer surgery, Eur J Surg Oncol, 1996. 22(3): p. 213-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8654598

780. Compton, C. C., Pathology report in colon cancer: what is prognostically important?, Dig Dis, 1999. 17(2): p. 67-79., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10545712

781. Wong, J. H., Severino, R., Honnebier, M. B., Tom, P., Namiki, T. S., Number of nodes examined and staging accuracy in colorectal carcinoma, J Clin Oncol, 1999. 17(9): p. 2896-900., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10561368, http://jco.ascopubs.org/content/17/9/2896.long

782. Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., Fielding, L. P., American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group, Cancer, 2000. 88(7): p. 1739-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10738234

783. Compton, C. C., Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee, Arch Pathol Lab Med, 2000. 124(7): p. 1016-25., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10888778

784. Hermanek, P., Methodik der histopathologischen Untersuchung von Resektionen kolorektaler Karzinome., Chir Gastroenterol, 2000. 16: p. 255-59.

785. Hermanek, P., [Lymph nodes and malignant tumors], Zentralbl Chir, 2000. 125(10): p. 790-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11098570, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2000-10046

786. Junginger, T., P., Hermanek, Klimpfinger, M., Klassifikation maligner Tumoren des Gastrointestinaltraktes ISpringer Verlag, 2002.

787. Wittekind, C., Compton, C. C., Greene, F. L., Sobin, L. H., TNM residual tumor classification revisited, Cancer, 2002. 94(9): p. 2511-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12015777, http://onlinelibrary.wiley.com/store/10.1002/cncr.10492/asset/10492_ftp.pdf?v=1&t=ik57ng5n&s=8d9cd5078e68d5c41774fa588ea4acd7c168c193

788. Leibl, S., Tsybrovskyy, O., Denk, H., How many lymph nodes are necessary to stage early and advanced adenocarcinoma of the sigmoid colon and upper rectum?, Virchows Arch, 2003. 443(2): p. 133-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12844262, http://link.springer.com/article/10.1007%2Fs00428-003-0858-3

789. Sobin, L. H., TNM, sixth edition: new developments in general concepts and rules, Semin Surg Oncol, 2003. 21(1): p. 19-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12923912, http://onlinelibrary.wiley.com/doi/10.1002/ssu.10017/abstract

790. Dworak, O., Keilholz, L., Hoffmann, A., Pathological features of rectal cancer after preoperative radiochemotherapy, Int J Colorectal Dis, 1997. 12(1): p. 19-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9112145

791. Edwards, A. G., Hailey, S., Maxwell, M., Psychological interventions for women with metastatic breast cancer, Cochrane Database Syst Rev, 2004. p. CD004253., http://www.ncbi.nlm.nih.gov/pubmed/15106244

792. Sheard, T., Maguire, P., The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses, Br J Cancer, 1999. 80(11): p. 1770-80., http://www.ncbi.nlm.nih.gov/pubmed/10468295

793. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9., https://www.ncbi.nlm.nih.gov/pubmed/15277265

794. Sharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., et.al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs, Br J Cancer, 2004. 90(2): p. 314-20., http://www.ncbi.nlm.nih.gov/pubmed/14735170

795. Singer, S., Das-Munshi, J., Brahler, E., Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis, Ann Oncol, 2010. 21(5): p. 925-30., http://www.ncbi.nlm.nih.gov/pubmed/19887467

796. Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C., Piantadosi, S., The prevalence of psychological distress by cancer site, Psychooncology, 2001. 10(1): p. 19-28., http://www.ncbi.nlm.nih.gov/pubmed/11180574

797. Jansen, L., Herrmann, A., Stegmaier, C., Singer, S., Brenner, H., Arndt, V., Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study, J Clin Oncol, 2011. 29(24): p. 3263-9., http://www.ncbi.nlm.nih.gov/pubmed/21768465

798. Lynch, B. M., Steginga, S. K., Hawkes, A. L., Pakenham, K. I., Dunn, J., Describing and predicting psychological distress after colorectal cancer, Cancer, 2008. 112(6): p. 1363-70., http://www.ncbi.nlm.nih.gov/pubmed/18318044

799. Miovic, M., Block, S., Psychiatric disorders in advanced cancer, Cancer, 2007. 110(8): p. 1665-76., http://www.ncbi.nlm.nih.gov/pubmed/17847017

800. Ramsey, S. D., Andersen, M. R., Etzioni, R., Moinpour, C., Peacock, S., Potosky, A., et.al. Quality of life in survivors of colorectal carcinoma, Cancer, 2000. 88(6): p. 1294-303., http://www.ncbi.nlm.nih.gov/pubmed/10717609

801. Zettl, S, Hartlapp, J., Sexualstörungen durch Krankheit und Therapie, 1997. p. S. 59.

802. Fallowfield, L., Ratcliffe, D., Jenkins, V., Saul, J., Psychiatric morbidity and its recognition by doctors in patients with cancer, Br J Cancer, 2001. 84(8): p. 1011-5., http://www.ncbi.nlm.nih.gov/pubmed/11308246

803. Sollner, W., DeVries, A., Steixner, E., Lukas, P., Sprinzl, G., Rumpold, G., et.al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?, Br J Cancer, 2001. 84(2): p. 179-85., http://www.ncbi.nlm.nih.gov/pubmed/11161373

804. Ell, K., Xie, B., Quon, B., Quinn, D. I., Dwight-Johnson, M., Lee, P. J., Randomized controlled trial of collaborative care management of depression among low-income patients with cancer, J Clin Oncol, 2008. 26(27): p. 4488-96., http://www.ncbi.nlm.nih.gov/pubmed/18802161

805. Strong, V., Waters, R., Hibberd, C., Murray, G., Wall, L., Walker, J., et.al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial, Lancet, 2008. 372(9632): p. 40-8., http://www.ncbi.nlm.nih.gov/pubmed/18603157

806. Herschbach, P., Weis, J., Screeningverfahren in der PsychoonkologieDeutsche Krebsgesellschaft, 2008.

807. NHMRC, Clinical practice guidelines for the psychosocial care of adults with cancer, 2003. p. 1-237.

808. Turner, J., Zapart, S., Pedersen, K., Rankin, N., Luxford, K., Fletcher, J., Clinical practice guidelines for the psychosocial care of adults with cancer, Psychooncology, 2005. 14(3): p. 159-73., http://www.ncbi.nlm.nih.gov/pubmed/15669019

809. Weis, J., Schumacher, A., Blettner, G., Determann, M., Reinert, E., Rüffer, J.U., et.al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin., Onkologe, 2007. 13(2): p. 185-194.

810. Edwards, A. G., Hulbert-Williams, N., Neal, R. D., Psychological interventions for women with metastatic breast cancer, Cochrane Database Syst Rev, 2008. p. CD004253., http://www.ncbi.nlm.nih.gov/pubmed/18646104

811. Faller, H, ., Schuler, M., Richard, M., Heckl, U., Weis, J., Küffner, R., Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis, Nat J Cancer, in press.

812. Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Bleijenberg, G., Psychosocial interventions for reducing fatigue during cancer treatment in adults, Cochrane Database Syst Rev, 2009. p. CD006953., http://www.ncbi.nlm.nih.gov/pubmed/19160308

813. Jacobsen, P. B., Jim, H. S., Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges, CA Cancer J Clin, 2008. 58(4): p. 214-30., http://www.ncbi.nlm.nih.gov/pubmed/18558664

814. Luebbert, K., Dahme, B., Hasenbring, M., The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review, Psychooncology, 2001. 10(6): p. 490-502., http://www.ncbi.nlm.nih.gov/pubmed/11747061

815. Osborn, R. L., Demoncada, A. C., Feuerstein, M., Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses, Int J Psychiatry Med, 2006. 36(1): p. 13-34., http://www.ncbi.nlm.nih.gov/pubmed/16927576

816. Rehse, B., Pukrop, R., Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies, Patient Educ Couns, 2003. 50(2): p. 179-86., http://www.ncbi.nlm.nih.gov/pubmed/12781933

817. Uitterhoeve, R. J., Vernooy, M., Litjens, M., Potting, K., Bensing, J., De Mulder, P., et.al. Psychosocial interventions for patients with advanced cancer - a systematic review of the literature, Br J Cancer, 2004. 91(6): p. 1050-62., http://www.ncbi.nlm.nih.gov/pubmed/15316564

818. Williams, S., Dale, J., The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review, Br J Cancer, 2006. 94(3): p. 372-90., http://www.ncbi.nlm.nih.gov/pubmed/16465173

819. Merkel, S., Weber, K., Matzel, K. E., Agaimy, A., Gohl, J., Hohenberger, W., Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision, Br J Surg, 2016. 103(9): p. 1220-9., http://onlinelibrary.wiley.com/doi/10.1002/bjs.10183/abstract?systemMessage=Wiley+Online+Library+Journal+subscribe+and+renew+pages+for+some+journals+will+be+unavailable+on+Wednesday+11th+January+2017+from+06%3A00-12%3A00+GMT+%2F+01%3A00-07%3A00+EST+%2F+14%3A00-20%3A00+SGT+for+essential+maintenance.+Apologies+for+the+inconvenience

820. Booth, C. M., Nanji, S., Wei, X., Peng, Y., Biagi, J. J., Hanna, T. P., et.al. Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study, J Natl Compr Canc Netw, 2016. 14(1): p. 47-56., http://www.jnccn.org/content/14/1/47.long

821. Tournigand, C., Andre, T., Bonnetain, F., Chibaudel, B., Lledo, G., Hickish, T., et.al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial, J Clin Oncol, 2012. 30(27): p. 3353-60., http://jco.ascopubs.org/content/30/27/3353.full.pdf

822. Haller, D. G., O'Connell, M. J., Cartwright, T. H., Twelves, C. J., McKenna, E. F., Sun, W., et.al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials, Ann Oncol, 2015. 26(4): p. 715-24., http://annonc.oxfordjournals.org/content/26/4/715, http://annonc.oxfordjournals.org/content/26/4/715.long

823. Schmoll, H. J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., et.al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial, J Clin Oncol, 2015. 33(32): p. 3733-40., http://jco.ascopubs.org/content/33/32/3733.long

824. McCleary, N. J., Meyerhardt, J. A., Green, E., Yothers, G., de Gramont, A., Van Cutsem, E., et.al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database, J Clin Oncol, 2013. 31(20): p. 2600-6., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699725/pdf/zlj2600.pdf

825. Fata, F., Mirza, A., Craig, G., Nair, S., Law, A., Gallagher, J., et.al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center, Cancer, 2002. 94(7): p. 1931-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11932894, http://onlinelibrary.wiley.com/store/10.1002/cncr.10430/asset/10430_ftp.pdf?v=1&t=ik52ga69&s=9cc708acb03fae62cb8f1d2c6ead3a2e27b9e6fd

826. Biagi, J. J., Raphael, M. J., Mackillop, W. J., Kong, W., King, W. D., Booth, C. M., Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis, JAMA, 2011. 305(22): p. 2335-42., http://jama.jamanetwork.com/article.aspx?articleid=221033

827. Des Guetz, G., Nicolas, P., Perret, G. Y., Morere, J. F., Uzzan, B., Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis, Eur J Cancer, 2010. 46(6): p. 1049-55., http://www.ejcancer.com/article/S0959-8049(10)00039-0/abstract

828. Bos, A. C., van Erning, F. N., van Gestel, Y. R., Creemers, G. J., Punt, C. J., van Oijen, M. G., et.al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer, Eur J Cancer, 2015. 51(17): p. 2553-61., http://www.ejcancer.com/article/S0959-8049(15)00806-0/abstract

829. Bayraktar, U. D., Chen, E., Bayraktar, S., Sands, L. R., Marchetti, F., Montero, A. J., et.al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?, Cancer, 2011. 117(11): p. 2364-70., http://onlinelibrary.wiley.com/store/10.1002/cncr.25720/asset/25720_ftp.pdf?v=1&t=ik43xw36&s=f73ad5791582665da6a7110562e9135e2a2d2363

830. Lima, I. S., Yasui, Y., Scarfe, A., Winget, M., Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada, Cancer, 2011. 117(16): p. 3833-40., http://onlinelibrary.wiley.com/store/10.1002/cncr.25954/asset/25954_ftp.pdf?v=1&t=ik43yiqz&s=a63ed3883443dcf570d7242ed28b2dcd03a3acf2

831. Nachiappan, S., Askari, A., Mamidanna, R., Munasinghe, A., Currie, A., Stebbing, J., et.al. Initiation of adjuvant chemotherapy within 8 weeks of elective colorectal resection improves overall survival regardless of reoperation, Colorectal Dis, 2016. 18(11): p. 1041-1049., http://onlinelibrary.wiley.com/doi/10.1111/codi.13308/abstract?systemMessage=WOL+Usage+report+download+page+will+be+unavailable+on+Friday+27th+January+2017+at+23%3A00+GMT%2F+18%3A00+EST%2F+07%3A00+SGT+%28Saturday+28th+Jan+for+SGT%29++for+up+to+2+hours+due+to+essential+server+maintenance.+Apologies+for+the+inconvenience.

832. Dube, S., Heyen, F., Jenicek, M., Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis, Dis Colon Rectum, 1997. 40(1): p. 35-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9102259

833. Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., et.al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?, J Clin Oncol, 2004. 22(10): p. 1797-806., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15067028, http://jco.ascopubs.org/content/22/10/1797.full.pdf

834. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, Lancet, 1995. 345(8955): p. 939-44., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7715291, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)90696-7/abstract

835. Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., et.al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients, N Engl J Med, 2001. 345(15): p. 1091-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11596588, http://www.nejm.org/doi/pdf/10.1056/NEJMoa010957

836. Francini, G., Petrioli, R., Lorenzini, L., Mancini, S., Armenio, S., Tanzini, G., et.al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer, Gastroenterology, 1994. 106(4): p. 899-906., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8143995

837. O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., et.al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, J Clin Oncol, 1997. 15(1): p. 246-50., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8996149

838. Figueredo, A., Germond, C., Maroun, J., Browman, G., Walker-Dilks, C., Wong, S., Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group, Cancer Prev Control, 1997. 1(5): p. 379-92., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9765760

839. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators, J Clin Oncol, 1999. 17(5): p. 1356-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10334519, http://jco.ascopubs.org/content/17/5/1356.long

840. Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., et.al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04), J Clin Oncol, 1999. 17(5): p. 1349-55., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10334518, http://jco.ascopubs.org/content/17/5/1349.long

841. Benson, A. B., 3rd, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., et.al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer, J Clin Oncol, 2004. 22(16): p. 3408-19., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15199089, http://jco.ascopubs.org/content/22/16/3408.full.pdf

842. Quasar Collaborative, Group, Gray, R., Barnwell, J., McConkey, C., Hills, R. K., Williams, N. S., et.al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study, Lancet, 2007. 370(9604): p. 2020-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18083404, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61866-2/abstract

843. O'Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J. I., Heise, C. P., et.al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features, J Clin Oncol, 2011. 29(25): p. 3381-8., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164243/pdf/zlj3381.pdf

844. Andre, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., et.al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study, J Clin Oncol, 2015. 33(35): p. 4176-87., http://jco.ascopubs.org/content/33/35/4176.long

845. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., et.al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer, J Clin Oncol, 1995. 13(12): p. 2936-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8523058

846. Taal, B. G., Van Tinteren, H., Zoetmulder, F. A., Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III, Br J Cancer, 2001. 85(10): p. 1437-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11720425, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363941/pdf/85-6692117a.pdf

847. Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., Begg, C. B., Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer, J Clin Oncol, 2002. 20(19): p. 3999-4005., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12351597, http://jco.ascopubs.org/content/20/19/3999.long

848. Caplin, S., Cerottini, J. P., Bosman, F. T., Constanda, M. T., Givel, J. C., For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis, Cancer, 1998. 83(4): p. 666-72., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9708929

849. Merkel, S., Wein, A., Gunther, K., Papadopoulos, T., Hohenberger, W., Hermanek, P., High-risk groups of patients with Stage II colon carcinoma, Cancer, 2001. 92(6): p. 1435-43., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11745220

850. Petersen, V. C., Baxter, K. J., Love, S. B., Shepherd, N. A., Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer, Gut, 2002. 51(1): p. 65-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12077094, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773289/pdf/gut05100065.pdf

851. Morris, M., Platell, C., de Boer, B., McCaul, K., Iacopetta, B., Population-based study of prognostic factors in stage II colonic cancer, Br J Surg, 2006. 93(7): p. 866-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16622901, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5345/abstract

852. Burdy, G., Panis, Y., Alves, A., Nemeth, J., Lavergne-Slove, A., Valleur, P., Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence, Dis Colon Rectum, 2001. 44(11): p. 1682-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11711742

853. Jestin, P., Nilsson, J., Heurgren, M., Pahlman, L., Glimelius, B., Gunnarsson, U., Emergency surgery for colonic cancer in a defined population, Br J Surg, 2005. 92(1): p. 94-100., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15521083, http://onlinelibrary.wiley.com/doi/10.1002/bjs.4780/abstract

854. McArdle, C. S., McMillan, D. C., Hole, D. J., The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer, Br J Surg, 2006. 93(4): p. 483-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16555262, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5269/abstract

855. George, S., Primrose, J., Talbot, R., Smith, J., Mullee, M., Bailey, D., et.al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists, Br J Cancer, 2006. 95(7): p. 841-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16969342, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360535/pdf/95-6603352a.pdf

856. Chen, S. L., Bilchik, A. J., More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study, Ann Surg, 2006. 244(4): p. 602-10., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16998369, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856560/pdf/20061000s00015p602.pdf

857. Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., et.al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 2003. 349(3): p. 247-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12867608, http://www.nejm.org/doi/pdf/10.1056/NEJMoa022289

858. Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., et.al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 2010. 28(20): p. 3219-26., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903323/pdf/zlj3219.pdf

859. Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., et.al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut, 2006. 55(6): p. 848-55., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856227/pdf/848.pdf

860. Kim, J. E., Hong, Y. S., Kim, H. J., Kim, K. P., Lee, J. L., Park, S. J., et.al. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy, Ann Surg Oncol, 2015. 22 Suppl 3: p. 630-7., http://link.springer.com/article/10.1245%2Fs10434-015-4807-6

861. Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., et.al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 2004. 350(23): p. 2343-51., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15175436, http://www.nejm.org/doi/pdf/10.1056/NEJMoa032709

862. Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., et.al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, 2007. 25(16): p. 2198-204., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17470851, http://jco.ascopubs.org/content/25/16/2198.full.pdf

863. Kidwell, K. M., Yothers, G., Ganz, P. A., Land, S. R., Ko, C. Y., Cecchini, R. S., et.al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 2012. 118(22): p. 5614-22., http://onlinelibrary.wiley.com/store/10.1002/cncr.27593/asset/27593_ftp.pdf?v=1&t=j27898it&s=0b111b798a9bba319dae3050ad35f7c7e45c02a6

864. de Gramont A., C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingan, C. Lorenzato and T. André, Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 25, No 18S (June 20 Supplement), 2007: 4007, 2007.

865. Schmoll, H. J., Twelves, C., Sun, W., O'Connell, M. J., Cartwright, T., McKenna, E., et.al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials, Lancet Oncol, 2014. 15(13): p. 1481-92., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435787/pdf/nihms687271.pdf

866. Sanoff, H. K., Carpenter, W. R., Sturmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., et.al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years, J Clin Oncol, 2012. 30(21): p. 2624-34.

867. Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., et.al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J Clin Oncol, 2011. 29(28): p. 3768-74., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188282/pdf/zlj3768.pdf

868. Lund, C. M., Nielsen, D., Dehlendorff, C., Christiansen, A. B., Ronholt, F., Johansen, J. S., et.al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study, ESMO Open, 2016. 1(5): p. e000087., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115815/pdf/esmoopen-2016-000087.pdf

869. Kim, C. A., Spratlin, J. L., Armstrong, D. E., Ghosh, S., Mulder, K. E., Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience, Clin Colorectal Cancer, 2014. 13(3): p. 199-206.

870. Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et.al. Capecitabine as adjuvant treatment for stage III colon cancer, N Engl J Med, 2005. 352(26): p. 2696-704., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15987918, http://www.nejm.org/doi/pdf/10.1056/NEJMoa043116

871. Andre T., E. Quinaux, C. Louvet, E. Gamelin, O. Bouche, E. Achille, P. Piedbois, N. Tubiana-Mathieu, M. Buyse, A. de Gramont GERCOR, Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients, Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings., 2005.

872. Carrato A. , C. Köhne, L. Bedenne, I. Popov, O. Bouche, E. Gaspar, P. Rougier, U. Schubert, F. Biertz, H. Becker for AIO/CAO, FFCD, TTD, EORTC, Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 3563, 2006.

873. Andre, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., et.al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial, J Clin Oncol, 2003. 21(15): p. 2896-903., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12885807, http://jco.ascopubs.org/content/21/15/2896.long

874. Arkenau, H. T., Rettig, K., Porschen, R., Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion, Int J Colorectal Dis, 2005. 20(3): p. 258-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15549327, http://link.springer.com/article/10.1007%2Fs00384-004-0657-6

875. Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., et.al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer, Ann Oncol, 2005. 16(4): p. 549-57., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15695501, http://annonc.oxfordjournals.org/content/16/4/549.full.pdf

876. Lembersky, B. C., Wieand, H. S., Petrelli, N. J., O'Connell, M. J., Colangelo, L. H., Smith, R. E., et.al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06, J Clin Oncol, 2006. 24(13): p. 2059-64., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16648506, http://jco.ascopubs.org/content/24/13/2059.full.pdf

877. Sakamoto, J., Ohashi, Y., Hamada, C., Buyse, M., Burzykowski, T., Piedbois, P., Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials, J Clin Oncol, 2004. 22(3): p. 484-92., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14752071, http://jco.ascopubs.org/content/22/3/484.full.pdf

878. Poplin, E. A., Benedetti, J. K., Estes, N. C., Haller, D. G., Mayer, R. J., Goldberg, R. M., et.al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer, J Clin Oncol, 2005. 23(9): p. 1819-25., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15774775, http://jco.ascopubs.org/content/23/9/1819.full.pdf

879. O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Jr., Erlichman, C., Shepherd, L., et.al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer, J Clin Oncol, 1998. 16(1): p. 295-300., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9440756

880. Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., et.al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089, J Clin Oncol, 2005. 23(34): p. 8671-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16314627, http://jco.ascopubs.org/content/23/34/8671.full.pdf

881. Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., et.al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3, J Clin Oncol, 2009. 27(19): p. 3117-25., http://jco.ascopubs.org/content/27/19/3117.full.pdf

882. Ychou, M., Raoul, J. L., Douillard, J. Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., et.al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802), Ann Oncol, 2009. 20(4): p. 674-80., http://annonc.oxfordjournals.org/content/20/4/674.full.pdf

883. Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., et.al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 2007. 25(23): p. 3456-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17687149, http://jco.ascopubs.org/content/25/23/3456.full.pdf

884. Alberts, S. R., Sargent, D. J., Nair, S., Mahoney, M. R., Mooney, M., Thibodeau, S. N., et.al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, 2012. 307(13): p. 1383-93., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442260/pdf/nihms402124.pdf

885. Taieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J. L., et.al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial, Lancet Oncol, 2014. 15(8): p. 862-73., http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70227-X/abstract

886. Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H., et.al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial, J Clin Oncol, 2013. 31(3): p. 359-64., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732014/pdf/zlj359.pdf

887. de Gramont, A., Van Cutsem, E., Schmoll, H. J., Tabernero, J., Clarke, S., Moore, M. J., et.al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 2012. 13(12): p. 1225-33., http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70509-0/abstract

888. Kerr, R. S., Love, S., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., et.al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial, Lancet Oncol, 2016. 17(11): p. 1543-1557.

889. Amlani, A., Kumar, A., Ruan, J. Y., Cheung, W. Y., Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data, Cancer Med, 2016. 5(8): p. 1776-82., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884630/pdf/CAM4-5-1776.pdf

890. Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., et.al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer, N Engl J Med, 2018. 378(13): p. 1177-1188.

891. Andre, T., Vernerey, D., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., et.al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial, J Clin Oncol, 2018. 36(15): p. 1469-1477.

892. Sobrero, A., Lonardi, S., Rosati, G., Di Bartolomeo, M., Ronzoni, M., Pella, N., et.al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial, J Clin Oncol, 2018. 36(15): p. 1478-1485.

893. Iveson, T. J., Kerr, R. S., Saunders, M. P., Cassidy, J., Hollander, N. H., Tabernero, J., et.al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial, Lancet Oncol, 2018. 19(4): p. 562-578.

894. Shi, Qian, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, ... Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson, Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration., J Clin Oncol, 2017. 35: p. Suppl.

895. Andre T, et al., Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project., J Clin Oncol, 2017. 35((suppl; abstr 3500)):

896. Sobrero AF, et al., FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial., J Clin Oncol, 2017. 35((suppl; abstr 3501)):

897. Iveson T, et al., Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer., J Clin Oncol, 2017. 35((suppl; abstr 3502)):

898. Hwang IG, et al., Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance., J Clin Oncol, 2017. 35((suppl; abstr 3605)):

899. van Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M., Putter, H., Wiggers, T., et.al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial, Lancet Oncol, 2011. 12(6): p. 575-82.

900. Sebag-Montefiore, D., Stephens, R. J., Steele, R., Monson, J., Grieve, R., Khanna, S., et.al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial, Lancet, 2009. 373(9666): p. 811-20.

901. Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et.al. Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 2004. 351(17): p. 1731-40., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15496622, http://www.nejm.org/doi/pdf/10.1056/NEJMoa040694

902. Sauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., et.al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years, J Clin Oncol, 2012. 30(16): p. 1926-33.

903. Bosset, J. F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., et.al. Chemotherapy with preoperative radiotherapy in rectal cancer, N Engl J Med, 2006. 355(11): p. 1114-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16971718, http://www.nejm.org/doi/pdf/10.1056/NEJMoa060829

904. Bosset, J. F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R. J., et.al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study, Lancet Oncol, 2014. 15(2): p. 184-90.

905. Gerard, J. P., Conroy, T., Bonnetain, F., Bouche, O., Chapet, O., Closon-Dejardin, M. T., et.al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203, J Clin Oncol, 2006. 24(28): p. 4620-5., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17008704, http://jco.ascopubs.org/content/24/28/4620.full.pdf

906. Folkesson, J., Birgisson, H., Pahlman, L., Cedermark, B., Glimelius, B., Gunnarsson, U., Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate, J Clin Oncol, 2005. 23(24): p. 5644-50., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16110023, http://jco.ascopubs.org/content/23/24/5644.full.pdf

907. Marijnen, C. A., Organ preservation in rectal cancer: have all questions been answered?, Lancet Oncol, 2015. 16(1): p. e13-22.

908. Lezoche, E., Baldarelli, M., Lezoche, G., Paganini, A. M., Gesuita, R., Guerrieri, M., Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy, Br J Surg, 2012. 99(9): p. 1211-8., http://onlinelibrary.wiley.com/doi/10.1002/bjs.8821/abstract

909. Bujko, K., Richter, P., Smith, F. M., Polkowski, W., Szczepkowski, M., Rutkowski, A., et.al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study, Radiother Oncol, 2013. 106(2): p. 198-205.

910. Verseveld, M., de Graaf, E. J., Verhoef, C., van Meerten, E., Punt, C. J., de Hingh, I. H., et.al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study), Br J Surg, 2015. 102(7): p. 853-60., http://onlinelibrary.wiley.com/doi/10.1002/bjs.9809/abstract

911. Garcia-Aguilar, J., Renfro, L. A., Chow, O. S., Shi, Q., Carrero, X. W., Lynn, P. B., et.al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial, Lancet Oncol, 2015. 16(15): p. 1537-46., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984260/pdf/nihms-807702.pdf

912. Wong, R. K., Tandan, V., De Silva, S., Figueredo, A., Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma, Cochrane Database Syst Rev, 2007. p. Cd002102., http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002102.pub2/abstract

913. Fiorica, F., Cartei, F., Licata, A., Enea, M., Ursino, S., Colosimo, C., et.al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data, Cancer Treat Rev, 2010. 36(7): p. 539-49.

914. Ceelen, W. P., Van Nieuwenhove, Y., Fierens, K., Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer, Cochrane Database Syst Rev, 2009. p. Cd006041.

915. Camma, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., Cottone, M., Preoperative radiotherapy for resectable rectal cancer: A meta-analysis, Jama, 2000. 284(8): p. 1008-15., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10944647, http://jama.jamanetwork.com/article.aspx?articleid=193010

916. Mork, J., Lie, A. K., Glattre, E., Hallmans, G., Jellum, E., Koskela, P., et.al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck, N Engl J Med, 2001. 344(15): p. 1125-31., https://www.ncbi.nlm.nih.gov/pubmed/11297703

917. FL, Greene, CC, Compton, AG, Fritz, J, Shah, DP, Winchester, AJCC Cancer Staging Atlas. New York, Springer, 2006.

918. Rodel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., et.al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 2015. 16(8): p. 979-89.

919. Kreis, M. E., Ruppert, R., Ptok, H., Strassburg, J., Brosi, P., Lewin, A., et.al. Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649), J Gastrointest Surg, 2016. 20(1): p. 25-32; discussion 32-3., http://link.springer.com/article/10.1007%2Fs11605-015-3011-0

920. Bonnetain, F., Bosset, J. F., Gerard, J. P., Calais, G., Conroy, T., Mineur, L., et.al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?, Eur J Cancer, 2012. 48(12): p. 1781-90., http://www.ejcancer.com/article/S0959-8049(12)00279-1/pdf

921. Wiltink, L. M., Chen, T. Y., Nout, R. A., Kranenbarg, E. M., Fiocco, M., Laurberg, S., et.al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial, Eur J Cancer, 2014. 50(14): p. 2390-8., http://www.ejcancer.com/article/S0959-8049(14)00785-0/pdf

922. Birgisson, H., Pahlman, L., Gunnarsson, U., Glimelius, B., Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial, J Clin Oncol, 2005. 23(34): p. 8697-705.

923. Chen, T. Y., Wiltink, L. M., Nout, R. A., Meershoek-Klein Kranenbarg, E., Laurberg, S., Marijnen, C. A., et.al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial, Clin Colorectal Cancer, 2015. 14(2): p. 106-14.

924. Wiltink, L. M., Marijnen, C. A., Meershoek-Klein Kranenbarg, E., van de Velde, C. J., Nout, R. A., A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial, Acta Oncol, 2016. 55(4): p. 502-8.

925. Li, X. T., Sun, Y. S., Tang, L., Cao, K., Zhang, X. Y., Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis, Colorectal Dis, 2015. 17(6): p. O129-35., http://onlinelibrary.wiley.com/doi/10.1111/codi.12909/abstract

926. Merkel, S., Weber, K., Schellerer, V., Gohl, J., Fietkau, R., Agaimy, A., et.al. Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria, Br J Surg, 2014. 101(5): p. 566-72., http://onlinelibrary.wiley.com/doi/10.1002/bjs.9419/abstract

927. Taylor, F. G., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., et.al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study, Ann Surg, 2011. 253(4): p. 711-9.

928. Taylor, F. G., Quirke, P., Heald, R. J., Moran, B. J., Blomqvist, L., Swift, I. R., et.al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study, J Clin Oncol, 2014. 32(1): p. 34-43.

929. Peeters, K. C., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., et.al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma, Ann Surg, 2007. 246(5): p. 693-701., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17968156

930. Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., et.al. Effective surgical adjuvant therapy for high-risk rectal carcinoma, N Engl J Med, 1991. 324(11): p. 709-15., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1997835, http://www.nejm.org/doi/pdf/10.1056/NEJM199103143241101

931. Smalley, S. R., Benedetti, J. K., Williamson, S. K., Robertson, J. M., Estes, N. C., Maher, T., et.al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144, J Clin Oncol, 2006. 24(22): p. 3542-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16877719, http://jco.ascopubs.org/content/24/22/3542.full.pdf

932. Ngan, S. Y., Burmeister, B., Fisher, R. J., Solomon, M., Goldstein, D., Joseph, D., et.al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04, J Clin Oncol, 2012. 30(31): p. 3827-33.

933. Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., Pudelko, M., et.al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy, Radiother Oncol, 2004. 72(1): p. 15-24., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15236870, http://www.thegreenjournal.com/article/S0167-8140(04)00004-0/abstract

934. Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., Kryj, M., Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer, Br J Surg, 2006. 93(10): p. 1215-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16983741, http://onlinelibrary.wiley.com/doi/10.1002/bjs.5506/abstract

935. Pietrzak, L., Bujko, K., Nowacki, M. P., Kepka, L., Oledzki, J., Rutkowski, A., et.al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial, Radiother Oncol, 2007. 84(3): p. 217-25.

936. McLachlan, S. A., Fisher, R. J., Zalcberg, J., Solomon, M., Burmeister, B., Goldstein, D., et.al. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04), Eur J Cancer, 2016. 55: p. 15-26., http://www.ejcancer.com/article/S0959-8049(15)01017-5/fulltext

937. Pettersson, D., Cedermark, B., Holm, T., Radu, C., Pahlman, L., Glimelius, B., et.al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer, Br J Surg, 2010. 97(4): p. 580-7., http://onlinelibrary.wiley.com/doi/10.1002/bjs.6914/abstract

938. Pettersson, D., Lorinc, E., Holm, T., Iversen, H., Cedermark, B., Glimelius, B., et.al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer, Br J Surg, 2015. 102(8): p. 972-8; discussion 978., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744683/pdf/BJS-102-972.pdf

939. Bujko, K., Wyrwicz, L., Rutkowski, A., Malinowska, M., Pietrzak, L., Krynski, J., et.al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study, Ann Oncol, 2016. 27(5): p. 834-42., http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/27/5/10.1093_annonc_mdw062/2/mdw062.pdf?Expires=1485006686&Signature=cfCjfK8XeyDW-e5t2oqIGOAXm8cfSgEh2rIHY8tPq1uv1xQPiC9Y9d-dYOGByjwbqo29X-kNOh0LLqhB2lcobi81HiLpbD4CePuz~EWbzp-e4r1VIN69xWT~XNVJa7qatLxyC8rfCI8WzpQHdeUAXi4iNpt9kee6EeGECzxF6-SbN2URWcYgq48EAQyO4HhuWO8IgRNUrQ-Wx6SbY92ijXVe153xDPEnEKeK9~liClk3WV5EzCuG4nNYPjSF2QO9x6UILt1MoEn18sLuCuYiv6b~BYaoghQJVyaof3jPenPdPK7dDmZ1YXAqyWHEGhvimZlIovnlAJCtg9Soe97MxA__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

940. O'Connell, M. J., Colangelo, L. H., Beart, R. W., Petrelli, N. J., Allegra, C. J., Sharif, S., et.al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04, J Clin Oncol, 2014. 32(18): p. 1927-34., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050205/pdf/zlj1927.pdf

941. Hofheinz, R. D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., et.al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial, Lancet Oncol, 2012. 13(6): p. 579-88.

942. Lefevre, J. H., Mineur, L., Kotti, S., Rullier, E., Rouanet, P., de Chaisemartin, C., et.al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6), J Clin Oncol, 2016.

943. Wang, X. J., Zheng, Z. R., Chi, P., Lin, H. M., Lu, X. R., Huang, Y., Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis, Gastroenterol Res Pract, 2016. 2016: p. 6756859., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829714/pdf/GRP2016-6756859.pdf

944. Petrelli, F., Sgroi, G., Sarti, E., Barni, S., Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies, Ann Surg, 2016. 263(3): p. 458-64.

945. Foster, J. D., Jones, E. L., Falk, S., Cooper, E. J., Francis, N. K., Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature, Dis Colon Rectum, 2013. 56(7): p. 921-30.

946. van den Broek, C. B., Vermeer, T. A., Bastiaannet, E., Rutten, H. J., van de Velde, C. J., Marijnen, C. A., Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients, Eur J Cancer, 2013. 49(15): p. 3131-9.

947. Fernandez-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., et.al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study, J Clin Oncol, 2010. 28(5): p. 859-65.

948. Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., et.al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger, Ann Oncol, 2015. 26(8): p. 1722-8.

949. Garcia-Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G., et.al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial, Lancet Oncol, 2015. 16(8): p. 957-66.

950. Smith, J. J., Chow, O. S., Gollub, M. J., Nash, G. M., Temple, L. K., Weiser, M. R., et.al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management, BMC Cancer, 2015. 15: p. 767., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619249/pdf/12885_2015_Article_1632.pdf

951. Schrag, D., Weiser, M. R., Goodman, K. A., Gonen, M., Hollywood, E., Cercek, A., et.al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial, J Clin Oncol, 2014. 32(6): p. 513-8.

952. Fernandez-Martos, C., Brown, G., Estevan, R., Salud, A., Montagut, C., Maurel, J., et.al. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial, Oncologist, 2014. 19(10): p. 1042-3., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201001/pdf/theoncologist_14233.pdf

953. Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., et.al. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial, J Clin Oncol, 2016. 34(27): p. 3300-7.

954. van Dijk, T. H., Tamas, K., Beukema, J. C., Beets, G. L., Gelderblom, A. J., de Jong, K. P., et.al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer, Ann Oncol, 2013. 24(7): p. 1762-9., http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/24/7/10.1093/annonc/mdt124/2/mdt124.pdf?Expires=1485006873&Signature=fmbpyyXYXahCAMR-TsjbsffyK9HA~w2lK4QnWfVlrpzfAVCP3vzHsaJNgbGJ0zOsMGLglMRnPOWKN5OePa5hjVwYPRVd13DJuGczHQoG4ISlRRF5sG8yu~~cjjONwgHd9oGg3ivZxaEzbSFEYpNozX7xVKTbL2ZIzRyP9ut0pYbRZrb0xQr08c3KVWpAaqHM~D4hknMTTaCfwKGQ7iZ18kuYyhBBvdDxi-WWP-4QqS~ki8MaNa1dbQyOoxg07vxqjmDDpPlnchazhnseZ5GZa7rIWaYonriUhDJRoVi55NXmiOPiwqlufDcwdTFlyRujw7sQnhaYNdDx7JvjZs19GQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

955. Rodel, C., Sauer, R., Radiotherapy and concurrent radiochemotherapy for rectal cancer, Surg Oncol, 2004. 13(2-3): p. 93-101.

956. Gunderson, L. L., Sargent, D. J., Tepper, J. E., Wolmark, N., O'Connell, M. J., Begovic, M., et.al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis, J Clin Oncol, 2004. 22(10): p. 1785-96.

957. Valentini, V., Glimelius, B., Haustermans, K., Marijnen, C. A., Rodel, C., Gambacorta, M. A., et.al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review, Radiother Oncol, 2014. 110(1): p. 195-8.

958. Sainato, A., Cernusco Luna Nunzia, V., Valentini, V., De Paoli, A., Maurizi, E. R., Lupattelli, M., et.al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT), Radiother Oncol, 2014. 113(2): p. 223-9.

959. Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., et.al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control, Ann Oncol, 2014. 25(7): p. 1356-62., http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/25/7/10.1093_annonc_mdu147/2/mdu147.pdf?Expires=1485006737&Signature=Z8AqmRC~0XoTiNpHYNhgP5xKVOG0n91PcNAdo-WXylYEcwinrCHej-YeyQmRPjHWe71kg1ql2fW5BZcToKQjkaQp7N~kb2TbcZH6VfbBuAYSAsu3EybWKDYibgYASYVlAlg0xrdG2Ps9grmxF3iePAfSlbBR6pU7ikFfZ0DwAdxAagTHngQk~v5U7z4vqK31CURQ6l6BThcsUs4jtmtqTSE0gxqlc2XxT4ou-BtTo0SzN0iQSXPMBZqUyiJ~RxoX8I3sayKzha-~SxwGDWciOioKFR31zEN5RxmD8hkJN2gWxl26z0fTxC32e8tGxYbZcA0RfxGOICilQ6I3k46Gtw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

960. Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, A., van den Broek, C. B., Fokstuen, T., et.al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial, Ann Oncol, 2015. 26(4): p. 696-701., http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/26/4/10.1093/annonc/mdu560/3/mdu560.pdf?Expires=1485006669&Signature=OrppxAEq5Sl3MeFefM5aCLPJILOhwDs~pyoUSIyN7F8YNmHKOVXwLbnhYTsdxw6RVmlOk44dO-765ZsKj7qJwNixxF81jTzb8T02rwQQHxgB7JOwf3VLykUSqKhmD~mVLxspjdTJo129RVWJ-HfSZIdqXNWQsjTVbGQMvh4pQo94gLcgPWgrAXKBTSlr94liU-WPZ86jEpt8YHt0nTbcKyLF01QALXYvapL0GBrRcDonKSA5knWxB5Ns9xdOotL2HJqM1g6RnDYaVHQWhLmXSST37rJWQDDYtfQ~6nuahIA1I70tCa8ErdqWhoFLHeou-b7dh2YDB~gUtBGKwDPPzg__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

961. Breugom, A. J., Swets, M., Bosset, J. F., Collette, L., Sainato, A., Cionini, L., et.al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 2015. 16(2): p. 200-7.

962. Petrelli, F., Coinu, A., Lonati, V., Barni, S., A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer, Int J Colorectal Dis, 2015. 30(4): p. 447-57., http://link.springer.com/article/10.1007%2Fs00384-014-2082-9

963. Maas, M., Nelemans, P. J., Valentini, V., Crane, C. H., Capirci, C., Rodel, C., et.al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients, Int J Cancer, 2015. 137(1): p. 212-20., http://onlinelibrary.wiley.com/doi/10.1002/ijc.29355/abstract

964. Hong, Y. S., Nam, B. H., Kim, K. P., Kim, J. E., Park, S. J., Park, Y. S., et.al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial, Lancet Oncol, 2014. 15(11): p. 1245-53.

965. Schmoll, HJ, Haustermanns, K., Rice, TJ, al., et, Preoperative chemoradiotherapy and postoperative chemothrapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survial at interim analysis, Proc Am Soc Clin Oncol, 2014. 32(abstract 3501):

966. Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., et.al. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer, J Clin Oncol, 2015. 33(32): p. 3718-26.

967. Abrams, T. A., Meyer, G., Schrag, D., Meyerhardt, J. A., Moloney, J., Fuchs, C. S., Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer, J Natl Cancer Inst, 2014. 106(2): p. djt371.

968. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., et.al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 2016. 27(8): p. 1386-422.

969. Knijn, N., Mekenkamp, L. J., Klomp, M., Vink-Borger, M. E., Tol, J., Teerenstra, S., et.al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients, Br J Cancer, 2011. 104(6): p. 1020-6.

970. Loes, I. M., Immervoll, H., Sorbye, H., Angelsen, J. H., Horn, A., Knappskog, S., et.al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases, Int J Cancer, 2016. 139(3): p. 647-56., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071774/pdf/IJC-139-647.pdf

971. Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 2015. 26(1): p. 13-21.

972. Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z. Q., Lieu, C. H., et.al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 2011. 117(20): p. 4623-32.

973. Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., et.al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study, J Clin Oncol, 2012. 30(15): p. 1755-62.

974. Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., et.al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis, Eur J Cancer, 2015. 51(5): p. 587-94.

975. Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., et.al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies, Clin Cancer Res, 2014. 20(20): p. 5322-30.

976. Domingo, E., Niessen, R. C., Oliveira, C., Alhopuro, P., Moutinho, C., Espin, E., et.al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, 2005. 24(24): p. 3995-8.

977. Cremolini, C., Di Bartolomeo, M., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., et.al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, Ann Oncol, 2015. 26(10): p. 2092-7.

978. Liu, X., Cheng, D., Kuang, Q., Liu, G., Xu, W., Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians, Pharmacogenomics J, 2014. 14(2): p. 120-9.

979. Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., et.al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis, J Clin Oncol, 2016. 34(3): p. 227-34.

980. Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., et.al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 2015. 16(16): p. 1639-50.

981. Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., et.al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Mod Pathol, 2015. 28(11): p. 1481-91.

982. Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., et.al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, Cancer Discov, 2011. 1(6): p. 508-23.

983. Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., et.al. The genomic landscape of response to EGFR blockade in colorectal cancer, Nature, 2015. 526(7572): p. 263-7.

984. Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., et.al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 2016. 17(6): p. 738-46.

985. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH, Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases., Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21., 1999.

986. Nigri, G., Neoadjuvant chemotherapy for resectable colorectal liver metastases: What ist the evidence? Results of a systematic review of comparative studies, The Surgeon, 2014. 13/2015: p. 83 - 90.

987. Ono, T., Ishida, H., Kumamoto, K., Okada, N., Ishibashi, K., Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy, Oncol Lett, 2012. 4(5): p. 905-909., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499558/pdf/ol-04-05-0905.pdf

988. Ferrero, A., Langella, S., Russolillo, N., Vigano, L., Lo Tesoriere, R., Capussotti, L., Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease, J Gastrointest Surg, 2012. 16(4): p. 806-14., http://link.springer.com/article/10.1007%2Fs11605-011-1810-5

989. van Vledder, M. G., de Jong, M. C., Pawlik, T. M., Schulick, R. D., Diaz, L. A., Choti, M. A., Disappearing colorectal liver metastases after chemotherapy: should we be concerned?, J Gastrointest Surg, 2010. 14(11): p. 1691-700., http://link.springer.com/article/10.1007%2Fs11605-010-1348-y

990. Auer, R. C., White, R. R., Kemeny, N. E., Schwartz, L. H., Shia, J., Blumgart, L. H., et.al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy, Cancer, 2010. 116(6): p. 1502-9., http://onlinelibrary.wiley.com/store/10.1002/cncr.24912/asset/24912_ftp.pdf?v=1&t=ioto21bz&s=51d896a80529f5cdfe274ed7c85b981d75b97eb7

991. Tanaka, K., Takakura, H., Takeda, K., Matsuo, K., Nagano, Y., Endo, I., Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases, Ann Surg, 2009. 250(6): p. 935-42.

992. Fiorentini, G., Del Conte, A., De Simone, M., Guadagni, S., Mambrini, A., D'Alessandro, M., et.al. Complete response of colorectal liver metastases after intra-arterial chemotherapy, Tumori, 2008. 94(4): p. 489-92.

993. Elias, D., Goere, D., Boige, V., Kohneh-Sharhi, N., Malka, D., Tomasic, G., et.al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin, Ann Surg Oncol, 2007. 14(11): p. 3188-94., http://link.springer.com/article/10.1245%2Fs10434-007-9482-9

994. Benoist, S., Brouquet, A., Penna, C., Julie, C., El Hajjam, M., Chagnon, S., et.al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?, J Clin Oncol, 2006. 24(24): p. 3939-45., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16921046, http://jco.ascopubs.org/content/24/24/3939.full.pdf

995. Elias, D., Youssef, O., Sideris, L., Dromain, C., Baton, O., Boige, V., et.al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy, J Surg Oncol, 2004. 86(1): p. 4-9., http://onlinelibrary.wiley.com/doi/10.1002/jso.20039/abstract

996. Ciliberto, D., Role of systemic chemothreapy in the management of rsected or resectable colorectal liver metastases: A systematic review and meta-analysis of randomized controlled trials, Oncology Reports, 2012. 27: p. 1849 - 1856.

997. Zhu, Gui-Qi, Systematic Review with network Meta-Analysis, Medicine (Baltimore), 2015. 94:

998. Mitry, E., Adjuvant Chemotherapy after potentially curative Resection of metastases from colorectal cancer: A pooled analysis of two randomized trials, Journal of clinical oncology, 2008. 26(30):

999. Heinemann, V., Rivera, F., O'Neil, B. H., Stintzing, S., Koukakis, R., Terwey, J. H., et.al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer, Eur J Cancer, 2016. 67: p. 11-20.

1000. Yamauchi, M., Morikawa, T., Kuchiba, A., Imamura, Y., Qian, Z. R., Nishihara, R., et.al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum, Gut, 2012. 61(6): p. 847-54., http://gut.bmj.com/content/gutjnl/61/6/847.full.pdf

1001. von Einem, J. C., Heinemann, V., von Weikersthal, L. F., Vehling-Kaiser, U., Stauch, M., Hass, H. G., et.al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial, J Cancer Res Clin Oncol, 2014. 140(9): p. 1607-14., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131148/pdf/432_2014_Article_1678.pdf

1002. Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., et.al. Primary tumor location as a prognostic factor in metastatic colorectal cancer, J Natl Cancer Inst, 2015. 107(3):

1003. Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., et.al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features, Ann Oncol, 2014. 25(10): p. 1995-2001., https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/25/10/10.1093_annonc_mdu275/2/mdu275.pdf?Expires=1488707601&Signature=VmhLosArcwiBFqkO91ZhWFqB29bE4zQmyUTN8cGLhc~kVOJuniGp0NIOYs1uvhmMPQ5N~lCIm3L-Fd2GTcpcS-TQvP-O74rMjWLmuz1C1INJPTIvsfIuXEnVO-rLah3cYoEnfWsOWG-6Uqn0SN0FftZ-9OMkP9YVxmD9qceUJiNYMPtVANTg2rR~Dg4K4JbGsMqDTm1atMTlN8wMPgAQXRiOPAhLkw9Gh6LiTdyRsgo3R7Y-h6Vdq7loM9y1yThwvfJBhRaoCiHL-FufU9ffzwJ1AFmB6dG9jLe0YVTmKMK4o~5IkO~0Ee9dLZpEMSmrdF9mmQ7is~UvoqC8bzkqgw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

1004. Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., et.al. The consensus molecular subtypes of colorectal cancer, Nat Med, 2015. 21(11): p. 1350-6., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636487/pdf/nihms722223.pdf

1005. Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., et.al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials, JAMA Oncol, 2016.

1006. Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., Heinemann, V., The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials, Eur J Cancer, 2017. 70: p. 87-98.

1007. Arnold, D., Lueza, B., Douillard, J. Y., Peeters, M., Lenz, H. J., Venook, A., et.al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials, Ann Oncol, 2017.

1008. Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., et.al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, 2015. 16(13): p. 1306-15.

1009. Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., et.al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer, Eur J Cancer, 2014. 50(1): p. 57-63., http://www.ejcancer.com/article/S0959-8049(13)00840-X/pdf

1010. The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer, Nature, 2012. 487(7407): p. 330-7.

1011. Young, J., Simms, L. A., Biden, K. G., Wynter, C., Whitehall, V., Karamatic, R., et.al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis, Am J Pathol, 2001. 159(6): p. 2107-16., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850604/pdf/2927.pdf

1012. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et.al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, 2015. 372(26): p. 2509-20.

1013. Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., et.al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial, J Clin Oncol, 2005. 23(16): p. 3697-705., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15738537, http://jco.ascopubs.org/content/23/16/3697.full.pdf

1014. Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., et.al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, Lancet Oncol, 2013. 14(11): p. 1077-85.

1015. Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., et.al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 2014. 371(17): p. 1609-18., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1403108

1016. Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A., et.al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG), Br J Cancer, 2006. 94(6): p. 798-805., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16508637, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361370/pdf/94-6603011a.pdf

1017. Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., et.al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, 2007. 25(13): p. 1670-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17470860, http://jco.ascopubs.org/content/25/13/1670.full.pdf

1018. Montagnani, F., A systematic review of FOLFOXIRI chemotherapy for the firstline treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity, Colorectal Disease, 2011. 13: p. 846 - 854.

1019. Gruenberger, T., Bridgewater, J., Chau, I., Garcia Alfonso, P., Rivoire, M., Mudan, S., et.al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial, Ann Oncol, 2015. 26(4): p. 702-8.

1020. Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et.al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 2013. 369(11): p. 1023-34., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305275

1021. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et.al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 2004. 350(23): p. 2335-42., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15175435, http://www.nejm.org/doi/pdf/10.1056/NEJMoa032691

1022. Stathopoulos, G. P., Batziou, C., Trafalis, D., Koutantos, J., Batzios, S., Stathopoulos, J., et.al. Treatment of colorectal cancer with and without bevacizumab: a phase III study, Oncology, 2010. 78(5-6): p. 376-81.

1023. Guan, Z. Z., Xu, J. M., Luo, R. C., Feng, F. Y., Wang, L. W., Shen, L., et.al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial, Chin J Cancer, 2011. 30(10): p. 682-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012268/pdf/cjc-30-10-682.pdf

1024. Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et.al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, J Clin Oncol, 2008. 26(12): p. 2013-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18421054, http://jco.ascopubs.org/content/26/12/2013.full.pdf

1025. Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., et.al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial, Ann Oncol, 2015. 26(6): p. 1201-7.

1026. Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., et.al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 2003. 21(1): p. 60-5.

1027. Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., et.al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study, J Clin Oncol, 2010. 28(19): p. 3191-8.

1028. Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J., Schrama, J. G., et.al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 2009. 360(6): p. 563-72.

1029. Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., et.al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer, J Clin Oncol, 2009. 27(5): p. 672-80.

1030. Saltz, L., Badarinath, S., Dakhil, S., Bienvenu, B., Harker, W. G., Birchfield, G., et.al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer, Clin Colorectal Cancer, 2012. 11(2): p. 101-11.

1031. Hegewisch-Becker, S., Graeven, U., Lerchenmuller, C. A., Killing, B., Depenbusch, R., Steffens, C. C., et.al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial, Lancet Oncol, 2015. 16(13): p. 1355-69.

1032. Zhao, L., Wang, J., Li, H., Che, J., Cao, B., Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer, Oncotarget, 2016., http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=8644&path%5B%5D=25858

1033. Pereira, A. A., Rego, J. F., Munhoz, R. R., Hoff, P. M., Sasse, A. D., Riechelmann, R. P., The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials, Acta Oncol, 2015. 54(10): p. 1737-46., http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2015.1044022

1034. Berry, S. R., Cosby, R., Asmis, T., Chan, K., Hammad, N., Krzyzanowska, M. K., Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis, Ann Oncol, 2015. 26(3): p. 477-85., http://annonc.oxfordjournals.org/content/26/3/477.full.pdf

1035. Esin, E., Yalcin, S., Maintenance strategy in metastatic colorectal cancer: A systematic review, Cancer Treat Rev, 2016. 42: p. 82-90.

1036. Simkens, L. H., van Tinteren, H., May, A., ten Tije, A. J., Creemers, G. J., Loosveld, O. J., et.al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group, Lancet, 2015. 385(9980): p. 1843-52.

1037. Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., et.al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial, J Clin Oncol, 2003. 21(11): p. 2059-69., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12775730, http://jco.ascopubs.org/content/21/11/2059.long

1038. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., et.al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, Lancet, 1998. 352(9138): p. 1407-12., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9807986, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)03085-2/abstract

1039. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., et.al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet, 1998. 352(9138): p. 1413-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9807987, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)02309-5/abstract

1040. Tournigand, C., Andre, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et.al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 2004. 22(2): p. 229-37., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14657227, http://jco.ascopubs.org/content/22/2/229.full.pdf

1041. Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausova, J., Macarulla, T., et.al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 2012. 30(28): p. 3499-506.

1042. Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., et.al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study, Lancet Oncol, 2015. 16(5): p. 499-508.

1043. Sobrero AF, Fehrenbacher L, Rivera F, et al., Phase III trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer, J Clin Oncol 26: 2311-2319, 2008.

1044. Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et.al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J Clin Oncol, 2010. 28(31): p. 4706-13.

1045. Bennouna, J., Sastre, J., Arnold, D., Osterlund, P., Greil, R., Van Cutsem, E., et.al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 2013. 14(1): p. 29-37.

1046. Derangere, V., Fumet, J. D., Boidot, R., Bengrine, L., Limagne, E., Chevriaux, A., et.al. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?, Oncotarget, 2016. 7(8): p. 9309-21., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891042/pdf/oncotarget-07-9309.pdf

1047. Wainberg, Z. A., Drakaki, A., The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors, Expert Opin Biol Ther, 2015. 15(8): p. 1205-20.

1048. Zaniboni, A., Formica, V., The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside, Cancer Chemother Pharmacol, 2016. 78(2): p. 233-44., http://link.springer.com/article/10.1007%2Fs00280-016-3032-8

1049. Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J. L., Hecht, J. R., et.al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer, J Clin Oncol, 2014. 32(21): p. 2240-7.

1050. Hecht JR, Cohn AL, Dakhil SR, et al., SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)., Journal of Clinical Oncology, 2013. 31: p. 4_suppl, 454 - 454.

1051. Hiret S, Borg C, Bertaut A, et al., Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI)., J Clin Oncol, 2016. 34: p. suppl; abstr 3514.

1052. Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et.al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer, Clin Cancer Res, 2015. 21(24): p. 5469-79.

1053. Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., et.al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer, N Engl J Med, 2015. 372(20): p. 1909-19.

1054. Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., et.al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial, Lancet Oncol, 2012. 13(10): p. 993-1001.

1055. Li, J., Qin, S., Xu, R., Yau, T. C., Ma, B., Pan, H., et.al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 2015. 16(6): p. 619-29.

1056. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et.al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 2013. 381(9863): p. 303-12.

1057. Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., et.al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?, Ann Oncol, 2012. 23(9): p. 2313-8.

1058. Petersen, C. Gauer, T., Möglichkeiten der lokal-ablativen Bestrahlung (SBRT) bei metastasiertem kolorektalem Karzinom, Der Onkologe, 2016. 22: p. 115 - 120.

1059. Herfarth, K. K., Debus, J., Wannenmacher, M., Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial, Front Radiat Ther Oncol, 2004. 38: p. 100-5.

1060. van der Pool, A. E., Mendez Romero, A., Wunderink, W., Heijmen, B. J., Levendag, P. C., Verhoef, C., et.al. Stereotactic body radiation therapy for colorectal liver metastases, Br J Surg, 2010. 97(3): p. 377-82., http://onlinelibrary.wiley.com/doi/10.1002/bjs.6895/abstract

1061. Wybranski, C. Gazis, A. Ricke, J., Hepatisch metastasiertes kolorektales Karzinom, Der Onkologe, 2015. 21(1): p. 69 - 82.

1062. Ricke, J., Mohnike, K., Pech, M., Seidensticker, M., Ruhl, R., Wieners, G., et.al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, 2010. 78(2): p. 479-85., http://www.redjournal.org/article/S0360-3016(09)03222-2/abstract

1063. de Baere, T., Auperin, A., Deschamps, F., Chevallier, P., Gaubert, Y., Boige, V., et.al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases, Ann Oncol, 2015. 26(5): p. 987-91., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405279/pdf/mdv037.pdf

1064. Vogl, T. J., Eckert, R., Naguib, N. N., Beeres, M., Gruber-Rouh, T., Nour-Eldin, N. A., Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation, AJR Am J Roentgenol, 2016. 207(6): p. 1340-1349.

1065. Agcaoglu, O., Aliyev, S., Karabulut, K., El-Gazzaz, G., Aucejo, F., Pelley, R., et.al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients, World J Surg, 2013. 37(6): p. 1333-9., http://link.springer.com/article/10.1007%2Fs00268-013-1981-1

1066. Sasaki, K., Margonis, G. A., Andreatos, N., Kim, Y., Wilson, A., Gani, F., et.al. Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes, J Surg Res, 2016. 206(1): p. 182-189.

1067. van Amerongen, M. J., van der Stok, E. P., Futterer, J. J., Jenniskens, S. F., Moelker, A., Grunhagen, D. J., et.al. Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation, Eur J Surg Oncol, 2016. 42(4): p. 523-30.

1068. Ruers, T., Van Coevorden, F., Punt, C. J., Pierie, J. E., Borel-Rinkes, I., Ledermann, J. A., et.al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial, J Natl Cancer Inst, 2017. 109(9):

1069. Hendlisz, A., Van den Eynde, M., Peeters, M., Maleux, G., Lambert, B., Vannoote, J., et.al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy, J Clin Oncol, 2010. 28(23): p. 3687-94.

1070. Turaga, K., Levine, E., Barone, R., Sticca, R., Petrelli, N., Lambert, L., et.al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States, Ann Surg Oncol, 2014. 21(5): p. 1501-5., http://link.springer.com/article/10.1245%2Fs10434-013-3061-z

1071. Elias, D., Mariani, A., Cloutier, A. S., Blot, F., Goere, D., Dumont, F., et.al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin, Eur J Surg Oncol, 2014. 40(11): p. 1467-73.

1072. van Oudheusden, T. R., Nienhuijs, S. W., Luyer, M. D., Nieuwenhuijzen, G. A., Lemmens, V. E., Rutten, H. J., et.al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review, Eur J Surg Oncol, 2015. 41(10): p. 1269-77.

1073. Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., Maspero, F., et.al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, 2013. 12(3): p. 145-51.

1074. Wulaningsih, W., Wardhana, A., Watkins, J., Yoshuantari, N., Repana, D., Van Hemelrijck, M., Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer, Cochrane Database Syst Rev, 2016. 2: p. CD008593., http://onlinelibrary.wiley.com/store/10.1002/14651858.CD008593.pub3/asset/CD008593.pdf?v=1&t=j0maaji6&s=553a2f80e8a09119c2103129080b458f2fe4ca3a

1075. Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., et.al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis, J Clin Oncol, 2014. 32(10): p. 1031-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879695/pdf/zlj1031.pdf

1076. Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., et.al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, J Clin Oncol, 2016. 34(6): p. 557-65., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872028/pdf/JCO630830.pdf

1077. Molassiotis, A., Brearley, S., Saunders, M., Craven, O., Wardley, A., Farrell, C., et.al. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial, J Clin Oncol, 2009. 27(36): p. 6191-8.

1078. Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W. Y., et.al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly, J Clin Oncol, 2006. 24(15): p. 2368-75.

1079. de Raaf, P. J., de Klerk, C., Timman, R., Busschbach, J. J., Oldenmenger, W. H., van der Rijt, C. C., Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial, J Clin Oncol, 2013. 31(6): p. 716-23.

1080. Enblad, P., Adami, H. O., Glimelius, B., Krusemo, U., Pahlman, L., The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study, Cancer, 1990. 65(9): p. 2091-100., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2372775, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19900501)65:9<2091::AID-CNCR2820650934>3.0.CO;2-M/asset/2820650934_ftp.pdf?v=1&t=ik52ejkz&s=e5b7636f3aea1b07e5826f3d32f047b644ccd162

1081. Cali, R. L., Pitsch, R. M., Thorson, A. G., Watson, P., Tapia, P., Blatchford, G. J., et.al. Cumulative incidence of metachronous colorectal cancer, Dis Colon Rectum, 1993. 36(4): p. 388-93., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8458267

1082. Hermanek, P., Jr., Wiebelt, H., Riedl, S., Staimmer, D., Hermanek, P., [Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group], Chirurg, 1994. 65(4): p. 287-97., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8020349

1083. Yamazaki, T., Takii, Y., Okamoto, H., Sakai, Y., Hatakeyama, K., What is the risk factor for metachronous colorectal carcinoma?, Dis Colon Rectum, 1997. 40(8): p. 935-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9269810

1084. Hemminki, K., Li, X., Dong, C., Second primary cancers after sporadic and familial colorectal cancer, Cancer Epidemiol Biomarkers Prev, 2001. 10(7): p. 793-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11440965, http://cebp.aacrjournals.org/content/10/7/793.full.pdf

1085. Green, R. J., Metlay, J. P., Propert, K., Catalano, P. J., Macdonald, J. S., Mayer, R. J., et.al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089, Ann Intern Med, 2002. 136(4): p. 261-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11848723, http://annals.org/article.aspx?articleid=715127

1086. Harris, G. J., Church, J. M., Senagore, A. J., Lavery, I. C., Hull, T. L., Strong, S. A., et.al. Factors affecting local recurrence of colonic adenocarcinoma, Dis Colon Rectum, 2002. 45(8): p. 1029-34., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12195186

1087. Merkel, S., Meyer, T., Gohl, J., Hohenberger, W., Late locoregional recurrence in rectal carcinoma, Eur J Surg Oncol, 2002. 28(7): p. 716-22., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12431468, http://www.ejso.com/article/S0748-7983(02)91305-3/abstract

1088. Poulin, E. C., Schlachta, C. M., Gregoire, R., Seshadri, P., Cadeddu, M. O., Mamazza, J., Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma, Surg Endosc, 2002. 16(6): p. 989-95., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12163970, http://link.springer.com/article/10.1007%2Fs004640080182

1089. Bulow, S., Christensen, I. J., Harling, H., Kronborg, O., Fenger, C., Nielsen, H. J., Recurrence and survival after mesorectal excision for rectal cancer, Br J Surg, 2003. 90(8): p. 974-80., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12905551, http://onlinelibrary.wiley.com/doi/10.1002/bjs.4137/abstract

1090. Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Campora, E., Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis, Hepatogastroenterology, 1997. 44(16): p. 1057-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9261599

1091. Pietra, N., Sarli, L., Thenasseril, B. J., Costi, R., Sansebastiano, G., Peracchia, A., Risk factors of local recurrence of colorectal cancer: a multivariate study, Hepatogastroenterology, 1998. 45(23): p. 1573-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9840107

1092. Scholmerich, J., [Sense and nonsense in after-care of colorectal carcinoma], Med Klin (Munich), 1996. 91(6): p. 420-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8767320

1093. Kievit, J., Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness, Eur J Surg Oncol, 2000. 26(4): p. 322-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10873350, http://www.ejso.com/article/S0748-7983(99)90893-4/abstract

1094. Kievit, J., Follow-up of patients with colorectal cancer: numbers needed to test and treat, Eur J Cancer, 2002. 38(7): p. 986-99., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11978524, http://www.ejcancer.com/article/S0959-8049(02)00061-8/abstract

1095. Wichmann, M. W., Muller, C., Hornung, H. M., Lau-Werner, U., Schildberg, F. W., Results of long-term follow-up after curative resection of Dukes A colorectal cancer, World J Surg, 2002. 26(6): p. 732-6., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12053228, http://link.springer.com/article/10.1007%2Fs00268-002-6221-z

1096. Yamamoto, S., Akasu, T., Fujita, S., Moriya, Y., Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified?, Hepatogastroenterology, 2005. 52(62): p. 444-9., http://www.ncbi.nlm.nih.gov/pubmed/15816454

1097. Talbot, I. C., Ritchie, S., Leighton, M. H., Hughes, A. O., Bussey, H. J., Morson, B. C., The clinical significance of invasion of veins by rectal cancer, Br J Surg, 1980. 67(6): p. 439-42., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7388345, http://onlinelibrary.wiley.com/doi/10.1002/bjs.1800670619/abstract

1098. Minsky, B. D., Mies, C., Recht, A., Rich, T. A., Chaffey, J. T., Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion, Cancer, 1988. 61(7): p. 1417-24., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3345494, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19880401)61:7<1417::AID-CNCR2820610723>3.0.CO;2-9/asset/2820610723_ftp.pdf?v=1&t=ik55od6b&s=6b41122e17f2f27a7c0a39ff3a1032584452e97c

1099. Krasna, M. J., Flancbaum, L., Cody, R. P., Shneibaum, S., Ben Ari, G., Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance, Cancer, 1988. 61(5): p. 1018-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3338045, http://onlinelibrary.wiley.com/store/10.1002/1097-0142(19880301)61:5<1018::AID-CNCR2820610527>3.0.CO;2-H/asset/2820610527_ftp.pdf?v=1&t=ik556bu5&s=3b0e9f21f819e7ae177562fa8fd320337def98fa

1100. Inoue, T., Mori, M., Shimono, R., Kuwano, H., Sugimachi, K., Vascular invasion of colorectal carcinoma readily visible with certain stains, Dis Colon Rectum, 1992. 35(1): p. 34-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1370777

1101. Bruinvels, D. J., Stiggelbout, A. M., Kievit, J., van Houwelingen, H. C., Habbema, J. D., van de Velde, C. J., Follow-up of patients with colorectal cancer. A meta-analysis, Ann Surg, 1994. 219(2): p. 174-82., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8129488, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243119/pdf/annsurg00060-0076.pdf

1102. Rosen, M., Chan, L., Beart, R. W., Jr., Vukasin, P., Anthone, G., Follow-up of colorectal cancer: a meta-analysis, Dis Colon Rectum, 1998. 41(9): p. 1116-26., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9749495

1103. Jeffery, G. M., Hickey, B. E., Hider, P., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database Syst Rev, 2002. p. CD002200., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11869629, http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002200/abstract

1104. Renehan, A. G., Egger, M., Saunders, M. P., O'Dwyer, S. T., Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials, Bmj, 2002. 324(7341): p. 813., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11934773, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC100789/pdf/813.pdf

1105. Makela, J. T., Laitinen, S. O., Kairaluoma, M. I., Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial, Arch Surg, 1995. 130(10): p. 1062-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7575117, http://archsurg.jamanetwork.com/article.aspx?articleid=596341

1106. Ohlsson, B., Breland, U., Ekberg, H., Graffner, H., Tranberg, K. G., Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up, Dis Colon Rectum, 1995. 38(6): p. 619-26., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7774474

1107. Kjeldsen, B. J., Kronborg, O., Fenger, C., Jorgensen, O. D., A prospective randomized study of follow-up after radical surgery for colorectal cancer, Br J Surg, 1997. 84(5): p. 666-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9171758, http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1997.02733.x/abstract

1108. Pietra, N., Sarli, L., Costi, R., Ouchemi, C., Grattarola, M., Peracchia, A., Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study, Dis Colon Rectum, 1998. 41(9): p. 1127-33., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9749496

1109. Schoemaker, D., Black, R., Giles, L., Toouli, J., Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients, Gastroenterology, 1998. 114(1): p. 7-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9428212

1110. Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Ravera, G., et.al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial, Eur J Surg Oncol, 2002. 28(4): p. 418-23., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12099653, http://www.ejso.com/article/S0748-7983(01)91250-8/abstract

1111. Wattchow, D. A., Weller, D. P., Esterman, A., Pilotto, L. S., McGorm, K., Hammett, Z., et.al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial, Br J Cancer, 2006. 94(8): p. 1116-21., http://www.ncbi.nlm.nih.gov/pubmed/16622437

1112. Rodriguez-Moranta, F., Salo, J., Arcusa, A., Boadas, J., Pinol, V., Bessa, X., et.al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial, J Clin Oncol, 2006. 24(3): p. 386-93., http://www.ncbi.nlm.nih.gov/pubmed/16365182

1113. Laubert, T., Bader, F. G., Oevermann, E., Jungbluth, T., Unger, L., Roblick, U. J., et.al. Intensified surveillance after surgery for colorectal cancer significantly improves survival, Eur J Med Res, 2010. 15(1): p. 25-30., http://www.ncbi.nlm.nih.gov/pubmed/20159668

1114. Papagrigoriadis, S., Heyman, B., Patients' views on follow up of colorectal cancer: implications for risk communication and decision making, Postgrad Med J, 2003. 79(933): p. 403-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12897220, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1742752/pdf/v079p00403.pdf

1115. Cooper, G. S., Kou, T. D., Reynolds, H. L., Jr., Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis, Cancer, 2008. 113(8): p. 2029-37., http://www.ncbi.nlm.nih.gov/pubmed/18780338

1116. Rocklin, M. S., Slomski, C. A., Watne, A. L., Postoperative surveillance of patients with carcinoma of the colon and rectum, Am Surg, 1990. 56(1): p. 22-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2294807

1117. Benson, A. B., 3rd, Desch, C. E., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., et.al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines, J Clin Oncol, 2000. 18(20): p. 3586-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11032600, http://jco.ascopubs.org/content/18/20/3586.full.pdf

1118. Berman, J. M., Cheung, R. J., Weinberg, D. S., Surveillance after colorectal cancer resection, Lancet, 2000. 355(9201): p. 395-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10665570, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)06552-6/abstract

1119. Macdonald, J. S., Carcinoembryonic antigen screening: pros and cons, Semin Oncol, 1999. 26(5): p. 556-60., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10528904

1120. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., et.al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines, Eur J Cancer, 2003. 39(6): p. 718-27., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12651195, http://www.ejcancer.com/article/S0959-8049(02)00811-0/abstract

1121. Desch, C. E., Benson, A. B., 3rd, Smith, T. J., Flynn, P. J., Krause, C., Loprinzi, C. L., et.al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology, J Clin Oncol, 1999. 17(4): p. 1312., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10561194, http://jco.ascopubs.org/content/17/4/1312.full.pdf

1122. Safi, F., Beyer, H. G., The value of follow-up after curative surgery of colorectal carcinoma, Cancer Detect Prev, 1993. 17(3): p. 417-24., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8402729

1123. Ahlquist, D. A., Wieand, H. S., Moertel, C. G., McGill, D. B., Loprinzi, C. L., O'Connell, M. J., et.al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests, Jama, 1993. 269(10): p. 1262-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8437303, http://jama.jamanetwork.com/article.aspx?articleid=404157

1124. Hunerbein, M., Totkas, S., Moesta, K. T., Ulmer, C., Handke, T., Schlag, P. M., The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer, Surgery, 2001. 129(2): p. 164-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11174709, http://www.surgjournal.com/article/S0039-6060(01)16661-4/abstract

1125. Mitry, E., Guiu, B., Cosconea, S., Jooste, V., Faivre, J., Bouvier, A. M., Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study, Gut, 2010. 59(10): p. 1383-8., http://www.ncbi.nlm.nih.gov/pubmed/20732912

1126. Jeffery, M., Hickey, B. E., Hider, P. N., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database Syst Rev, 2007. p. CD002200., http://www.ncbi.nlm.nih.gov/pubmed/17253476

1127. Desch, C. E., Benson, A. B., 3rd, Somerfield, M. R., Flynn, P. J., Krause, C., Loprinzi, C. L., et.al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 2005. 23(33): p. 8512-9., http://www.ncbi.nlm.nih.gov/pubmed/16260687

1128. Chau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E., et.al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer, J Clin Oncol, 2004. 22(8): p. 1420-9., http://www.ncbi.nlm.nih.gov/pubmed/15007086

1129. Sugarbaker, P. H., Gianola, F. J., Dwyer, A., Neuman, N. R., A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results, Surgery, 1987. 102(1): p. 79-87., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3589978

1130. Wang, T., Cui, Y., Huang, W. S., Deng, Y. H., Gong, W., Li, C. J., et.al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study, Gastrointest Endosc, 2009. 69(3 Pt 2): p. 609-15., http://www.ncbi.nlm.nih.gov/pubmed/19136105

1131. Rulyak, S. J., Lieberman, D. A., Wagner, E. H., Mandelson, M. T., Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients, Clin Gastroenterol Hepatol, 2007. 5(4): p. 470-6; quiz 407., http://www.ncbi.nlm.nih.gov/pubmed/17270502

1132. Rex, D. K., Kahi, C. J., Levin, B., Smith, R. A., Bond, J. H., Brooks, D., et.al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, 2006. 130(6): p. 1865-71., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16697749, http://www.gastrojournal.org/article/S0016-5085(06)00562-2/pdf

1133. Bouvier, A. M., Latournerie, M., Jooste, V., Lepage, C., Cottet, V., Faivre, J., The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up, Eur J Cancer, 2008. 44(4): p. 522-7., http://www.ncbi.nlm.nih.gov/pubmed/18255278

1134. Sobhani, I., Tiret, E., Lebtahi, R., Aparicio, T., Itti, E., Montravers, F., et.al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer, Br J Cancer, 2008. 98(5): p. 875-80., http://www.ncbi.nlm.nih.gov/pubmed/18301402

1135. Selvaggi, F., Cuocolo, A., Sciaudone, G., Maurea, S., Giuliani, A., Mainolfi, C., FGD-PET in the follow-up of recurrent colorectal cancer, Colorectal Dis, 2003. 5(5): p. 496-500., http://www.ncbi.nlm.nih.gov/pubmed/12925088

1136. Eckardt, V.F., Bernhard, G., Nachsorge beim kolorektalen Karzinom. Eine Analyse von Effektivität und Kosten., Deutsches Ärzteblatt, 1997. 94: p. A456-62.

1137. Schwibbe, G., [Changes in quality of life in oncological patients in the course of an inpatient after-care program], Rehabilitation (Stuttg), 1991. 30(2): p. 55-62., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1651548

1138. Gartner, U., Braun, G. D., Held, K., Friedrich, H., Reimers, H. J., Schmidt, J., et.al. [Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation], Med Klin (Munich), 1996. 91(8): p. 501-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8965748

1139. Meyerhardt, J. A., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Nelson, H., et.al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803, J Clin Oncol, 2008. 26(25): p. 4109-15., http://www.ncbi.nlm.nih.gov/pubmed/18757324

1140. Meyerhardt, J. A., Giovannucci, E. L., Holmes, M. D., Chan, A. T., Chan, J. A., Colditz, G. A., et.al. Physical activity and survival after colorectal cancer diagnosis, J Clin Oncol, 2006. 24(22): p. 3527-34., http://www.ncbi.nlm.nih.gov/pubmed/16822844

1141. Meyerhardt, J. A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., et.al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803, J Clin Oncol, 2006. 24(22): p. 3535-41., http://www.ncbi.nlm.nih.gov/pubmed/16822843

1142. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Köhler, al., Ollenschläger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

1143. Hoensch, H., Groh, B., Edler, L., Kirch, W., Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence, World J Gastroenterol, 2008. 14(14): p. 2187-93., http://www.ncbi.nlm.nih.gov/pubmed/18407592

1144. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.0. 2017., 2017., http://leitlinienprogramm-onkologie.de/Informationen-zur-Methodik.53.0.html